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Abstract
Chronic degenerative radiculomyelopathy (CDRM) is a well-recognised 
neurodegenerative disease of unknown aetiology which affected large breed dogs, 
primarily the German shepherd dog (GSD). Previous studies had identified the 
major clinical signs of pelvic limb ataxia and weakness resulting from degeneration 
of tracts in spinal cord white matter. This clinical entity has been recognised since 
1973, most reports concentrated on the clinical aspects of the disease and the 
pathology of the spinal cord. This project is the first to study a large number of 
affected dogs repeatedly throughout the course of disease. The previously reported 
clinical signs have been confirmed and the relationship between age of onset and 
rate of deterioration has been addressed for which no definite correlation was found.
Clinical and pathological similarities between CDRM and neurodegenerative 
disorders due to vitamin E deficiency in horses and humans had implicated vitamin 
E as a potential factor in the aetiology of CDRM. This stimulated a study of serum 
vitamin E concentrations. Data presented in this thesis suggests that affected GSDs 
do not have significantly lower serum vitamin E concentrations than other breeds of 
dog. In contrast, GSDs with CDRM appear to have elevated levels of serum 
vitamin E in comparison with the general canine population.
The pathology of the spinal cord is consistent with previously-described spinal cord 
pathology. However detailed examination of the brains of affected dogs revealed 
novel pathological changes in specific brain nuclei. Such changes included
neurones with eccentric nuclei, chromatolytic neurones and neuronal loss often with 
an associated gliosis. These changes affected the red nucleus, lateral vestibular 
nucleus and lateral (dentate) nucleus to varying extents. Such changes were found 
consistently in CDRM dogs but only rarely in dogs with focal spinal cord lesions. 
Furthermore, gliosis in the red nucleus was found only in the dogs with CDRM.
Due to the unusually high incidence of CDRM in one breed of dog and the 
discovery of at least two pairs o f affected littermates, the investigation of a possible 
genetic factor was indicated. Following a literature search for diseases in other 
species with clinical and pathological similarities to CDRM, a working hypothesis 
was established: CDRM is caused by a CAG trinucleotide repeat expansion in an 
unknown gene. A number of molecular biological techniques were employed to test 
this theory, including the Repeat Expansion Detection (RED) technique. This work 
is still in progress but there is some evidence, still inconclusive, that CDRM may be 
the result of a trinucleotide repeat expansion.
To my parents
and
In m emory o f Douglas H odges, whose generosity allowed this w ork to be
carried out.
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Introduction
1.1 Background Information
1.1.1 Establishment of the nomenclature
The occurrence of a progressive pelvic limb ataxia and paresis in the older German 
shepherd dog (GSD) had been recognised for many years. Originally the clinical 
signs were attributed to the presence of ossified plaques in the dura mater which 
commonly developed at the cervical and lumbar enlargements, usually on the 
ventral and ventrolateral aspects of the spinal cord. In extreme cases a bony tube 
formed around the cord (Morgan, 1968). This ossification, which was relatively 
common in older dogs, was called chronic ossifying pachymeningitis or spinal dural 
ossification.
These plaques could not have accounted for the clinical signs seen in chronic 
degenerative radiculomyelopathy (CDRM). Morgan (1968) showed that dural 
ossification was a relatively common finding in middle to old age dogs of large 
breeds but occurrence did not necessarily coincide with signs o f pelvic limb ataxia 
or weakness. In his study, approximately two thirds of all dogs over two years of 
age had evidence of dural ossification. Of the 52 cases which showed dural 
ossification only 12 had clinical signs of abnormal gait or hindquarter weakness; a 
further three dogs had clinical signs but no evidence of dural ossification. The 
position of the majority of plaques at the cervical and lumbar enlargements would 
have resulted in a lower motor neurone lesion (LMN) whereas CDRM involved an 
upper motor neurone lesion (UMN) (Griffiths and Duncan, 1975a). In addition, the 
occurrence of plaques at the cervical enlargement should have caused concurrent 
thoracic limb and pelvic limb dysfunction, which did not occur.
The condition was first described as degenerative myelopathy by Averill (1973). 
When they found degenerating fibres in the lumbar dorsal nerve roots of a number 
of affected dogs, Griffiths and Duncan (1975a) proposed the name chronic 
degenerative radiculomyelopathy (CDRM). German shepherd dog myelopathy was 
another term used to describe the condition. In this account the disease will be 
referred to as CDRM.
1.1.2 Occurrence
This disease had been described in a number of large breeds and large breed crosses 
such as German shepherd dog (GSD), Irish setter, Collie cross (Averill, 1973), 
Rough collie, Rhodesian ridgeback and Labrador cross (Griffiths and Duncan, 
1975a). Most cases reported had been in the GSD. Of the studies completed to 
date, the percentage of affected dogs which were GSD ranged from 56% (9/16)
2
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(Griffiths and Duncan, 1975a) to 82% (18/22) (Averill, 1973). These relatively 
small studies did not give an accurate picture of the actual occurrence within breeds 
and precise information regarding incidence was difficult to obtain. Experts in the 
field (Griffiths, personal communication, 1995) suggested that about 90% of 
affected dogs are GSDs. In addition, anecdotal evidence (GSD breeders, personal 
communication, 1996) suggested that up to 20% of the total GSD population may 
develop clinical signs suggestive o f CDRM at some stage in their lives.
1.1.3 Aetiology
Prior to 1973 the clinical signs were ascribed to the presence of dural bone plaques 
or multiple small intervertebral disc protrusions (Morgan, 1968). Averill (1973) 
mentioned the similarity with vitamin B j2 deficiency in man, noting that in man the 
disease initially involved only the thoracic cord, affected all funiculi and was slowly 
progressive unless appropriately treated. There was however a fundamental 
difference between humans and dogs in that the human disease initially exhibited a 
perivenular pattern and was usually multifocal, whereas CDRM in the dog was 
topographically continuous. Levels of methylmalonic acid in affected dogs showed 
no abnormalities, which suggested that normal vitamin B j2 metabolism was 
occurring. Williams et a l (, 1984) also investigated the possible involvement of 
vitamin Bi2- They found that all six affected dogs tested had bacterial overgrowth 
in their duodenal juice. This abnormality was not associated with any histological 
changes in jejunal biopsies. These dogs, however, had marked biochemical 
abnormalities which included the following changes to brush border enzymes: 
leucyl-2-naphthylamidase was decreased, y-glutamyl transferase was increased. 
Marked increases in activities of an endoplasmic reticular enzyme, tris-resistant a -  
glucosidase and the lysosomal enzymes N-acetyl-p-glucosaminidase and acid 
phosphatase were also seen. The significance of these changes must be questioned 
as this study did not include a control population of unaffected dogs. Vitamin Bj2 
levels were subnormal in only three of the six dogs.
The above findings suggested that CDRM may occur due to the abnormal 
absorption of some other nutrient(s) or that the biochemical abnormalities occurred 
secondary to the neurologic dysfunction. A consideration of nutritional factors 
which may be involved in CDRM must include vitamin E. Williams et al. (, 1985) 
investigated the serum tocopherol concentrations in a group of seven GSDs with 
CDRM and concluded that serum tocopherol concentrations were slightly lower in 
affected dogs (0.5-8.6mg/l) compared to healthy controls (4.4-29.4mg/l). These 
authors suggested that the enteropathy they saw, and the associated reduction in 
serum tocopherol levels, may have arisen secondary to CDRM. Alternatively, the
3
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enteropathy may have been the primary lesion responsible for malabsorption of 
tocopherol and subsequent development o f CDRM. It had been shown that 
deficiency of vitamin E caused neuropathology in other species; for example, 
degenerative myelopathy/myeloencephalopathy in the horse and ataxia with vitamin 
E deficiency (AVED) in man. AVED patients were known to respond to the 
administration of high doses of vitamin E (DiDonato, 1995). In addition, loss of 
axons and myelin sheaths, especially in the dorsal columns (Pentschew and 
Schwarz, 1962; Nelson et a l, 1981; Southam et al., 1991), had been associated with 
chronic vitamin E deficiency in rats and rhesus monkeys. As vitamin E was known 
to work as a free radical scavenger, therefore protecting neuronal cell membranes 
from peroxidation, its absence could lead to increased membrane fragility and 
ultimately neuronal cell death.
Several familial neuronal degenerations such as Freidriech's ataxia, hereditary 
spastic ataxia and hereditary spastic paraplegia existed in man. These were the 
result of neuronal atrophy or abiotrophy in which the cell body and proximal nerve 
fibre remained intact whilst the distal axon degenerated. Although the actual 
mechanisms were poorly understood, Averill mentioned a possible similarity to 
CDRM in 1973, suggesting that this process should be considered in CDRM. If 
correct, he suggested, neuronal loss or atrophy in several important locations such as 
the spinal ganglia (SpG), red nucleus, rostral colliculus and vestibular nucleus 
should be present (Averill, 1973).
Griffiths and Duncan (1975a) considered the neuropathology indicative o f a “dying 
back”, or distal axonopathy, phenomenon such as occurred in various human 
neurodegenerative conditions and experimental neurological diseases. Central 
“dying back” processes had been implicated in conditions such as amyotrophic 
lateral sclerosis and some of the spinocerebellar disorders (Griffiths and Duncan, 
1975a). Griffiths and Duncan considered that no proof of a hereditary factor had 
been put forward but explained the greater occurrence in large breed dogs to be the 
result o f differential susceptibility due to the longer nerve fibres present compared 
with small dogs. This did not, however, explain the particular breed predilection 
seen in CDRM. In studies on equine laryngeal hemiplegia Duncan et al. (1974) 
showed a positive correlation between nerve fibre length and susceptibility to 
degeneration. Braund (1978) argued that the distribution of lesions in CDRM did 
not fit the expected pattern of a “dying back” disease. The severity of lesions in the 
thoracic segments which suggested selective vulnerability of thoracic cord (Averill, 
1973; Braund and Vandevelde, 1978) in CDRM remained unexplained despite 
having been found in viral, nutritional and idiopathic disorders in other species.
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Waxman et al. (1980b) considered the pathology of CDRM to be indicative of a 
chronic demyelinating disease rather than an acute inflammatory response. As the 
immune system was known to play an important role in chronic demyelinating 
diseases in other species such as multiple sclerosis (MS) in man and experimental 
allergic encephalomyelitis (EAE) in rats (Bernard and Kerlero de Rosbo, 1992; 
Hartung and Rieckmann, 1997) the authors investigated the response to thymus- 
dependent mitogens in seven normal and six CDRM affected dogs. An abnormal T 
cell function was found in the peripheral blood cells of affected dogs, leucocytes 
displayed an impaired response to the T cell mitogens concanavalin A (Con A) and 
phytohaemagglutinin P (PHA). Serum or plasma obtained from dogs with CDRM 
was not suppressive for normal cells and neither was normal proliferative function 
restored when peripheral blood cells from affected dogs were cultured in normal 
serum or plasma, which suggested that any abnormal function of T cells was not due 
to the presence of serum inhibitory factors. Whether or not this was related to the 
disease process of CDRM was not known. The results of this study did not explain 
why depressed lymphocyte responsiveness occurred in dogs with CDRM, nor did it 
explain why the immunological deficit was seen only in the peripheral blood 
leucocyte compartment. It was suggested that an autoimmune lymphocyte 
population may have been activated during the course o f CDRM.
In a follow-up study Waxman et a l (1980a) showed that CDRM dogs had 
circulating suppressor cells associated with the impaired peripheral blood response. 
These findings had not been linked directly to the disease process but they could 
have indicated either an immunodeficiency problem where depressed T cell function 
allowed an infectious agent to enter the central nervous system (CNS) or where the 
suppressor cell population was activated secondarily by the host to regulate an 
autoimmune event. Barclay and Haines (1994a) studied a small group of dogs (five 
affected and one unaffected) and suggested that an immune-mediated spinal cord 
destruction may be occurring, because they found immunohistochemical evidence 
of immunoglobulin and a component o f complement in the spinal cords o f affected 
dogs which was not present in the normal dog. Clemmons (1992) suggested that, 
despite the lack of direct evidence for CDRM being caused by an infectious agent, it 
was possible that the disease was the result o f a combination of genetic 
predisposition and exposure to an infectious agent. He reported in 1992 that 
workers were investigating whether a canine retrovirus infection or “scrapie-like” 
prion organism was involved, however, neither of these possibilities had been 
proven (no references were cited on the Clemmons paper).
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Undoubtedly, CDRM has a complex aetiology which probably involves several 
different factors but most authors agreed there was almost certainly a genetic factor 
due to the very high incidence of the disease in one breed.
1.1.4 Age of Onset
All accounts to date conceded that there was great variation in age of onset, the 
youngest reported case was five years old, the eldest 14 years while the majority 
were about nine years old at first presentation.
1.1.5 Clinical Signs
Clinical signs of CDRM had been well documented (Averill, 1973; Griffiths and 
Duncan, 1975a; Braund and Vandevelde, 1978; Clemmons, 1989; Clemmons, 
1992). The dogs showed a slowly progressive pelvic limb ataxia and paresis with 
loss of proprioception. Initially they scuffed the middle two toes of one or both hind 
feet. Subsequently they developed problems with circling and with stairs, especially 
going down, they often scuffed, misjudged distances and showed hypermetria 
(ataxia in which intended movements overreach the intended goal). The dogs were 
often affected asymmetrically although both pelvic limbs were usually involved. 
Disuse muscle atrophy developed over the trunk and hindquarters several months 
after disease onset. With time, prolonged scuffing resulted in excoriation and 
ulceration of the feet. Eventually the disease resulted in marked paraparesis, the 
dogs could not rise without assistance and would pull themselves along with their 
thoracic limbs. A degree of faecal and urinary incontinence would often develop 
late in the disease. Dogs maintained beyond this stage could show thoracic limb 
signs. It had been reported that brain stem involvement eventually occurred 
(Clemmons, 1992) which could result in a number o f signs including asymmetrical 
tetraparesis, cranial nerve abnormalities and altered mental status. The clinical 
course was very variable ranging over six to 12 months (Clemmons, 1992) from 
onset of the disease to complete pelvic limb paraparesis. The clinical signs were 
inexorably progressive and whilst they may have stabilised for short periods of time 
improvement did not occur.
On neurological examination conscious proprioception as evidenced by paw 
position sense, reflex stepping and sway test was severely affected either uni- or 
bilaterally which depended, to some extent, on the duration of disease. Pedal reflex 
was usually unaffected while the patellar reflex varied in response to the disease. 
Hyperreflexia o f the patellar reflex, with or without clonus, had been reported 
(Averill, 1973; Waxman et al., 1980b; Clemmons, 1992). Hyporeflexia and loss of
6
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the patellar reflex had also been reported (Griffiths and Duncan, 1975a). The 
panniculus reflex remained intact, as did the perineal reflex, until late in the disease.
1.1.6 Diagnosis
It was not possible to diagnose CDRM definitively in life. A presumptive diagnosis 
could be made based on typical history and clinical signs. Other differential 
diagnoses such as disc disease, lumbosacral disease or neoplasia could be ruled out 
by further investigations which included haematology, serum chemistry profiles, 
urinalysis, CSF analysis, spinal radiographs and myelography. Some authors had 
reported an unspecified increase in CSF protein and abnormality in electrophoretic 
pattern (Clemmons, 1992; Clemmons et al., 1995) in dogs with CDRM. Further 
diagnostic procedures such as electrophysiology, epidurography, discography, 
computed tomography (CT) and magnetic resonance imaging (MRI) were indicated 
in specific cases. The results from all these tests were negative in CDRM as 
definitive diagnosis could be achieved only by histological examination of the 
spinal cord.
Clemmons (1992) suggested, on the basis that he considered dogs with CDRM to 
have three to 10 times more circulating immune complexes than normal dogs, that it 
may be possible to develop serum markers for the specific diagnosis o f CDRM. 
From preliminary work, he suggested the presence of an 85kDa antigen in dogs with 
CDRM but not in those with other neurological disorders. However, to date, no 
other authors have mentioned such a possibility.
1.1.7 Treatment
The emphasis in CDRM research over the last 25 years had been to map accurately 
the neuropathology and investigate the possible aetiologies involved. It had been 
considered an untreatable disease (Braund, 1987). Clemmons (1989) was the first 
author to suggest a therapy which may slow down the rate o f deterioration in 
affected dogs. Glucocorticoids, used for the treatment of inflammatory processes or 
to suppress supposed immune responses, had been used by veterinary surgeons but 
without any success. Clemmons suggested the use of other immunosuppressive 
drugs, initially he tried cyclophosphamide and azothiaprine without success. 
Immunostimulants such as levamisole were also tried but appeared to speed up the 
rate o f progression of the disease. The use o f intravenous dimethylsulphoxide 
(DMSO), which has a number of unproven possible activities including the 
scavenging of free radicals, and intramuscular cobra venom, had also been tried 
unsuccessfully.
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High doses of vitamin E (2000IU/day), high potency B vitamin complex and epsilon 
aminocaproic acid (EACA) had all been used as treatments (Clemmons, 1989; 
Clemmons, 1992) although their efficacy appeared questionable. EACA has anti­
protease activity, Clemmons considered that it would therefore be helpful in CDRM 
as it would block the final step in the inflammatory pathway thus helping to prevent 
tissue destruction. All authors agreed that maintenance of regular exercise and 
optimal body weight seemed beneficial to affected dogs.
There was no further evidence which suggested that any of the therapies suggested 
by Clemmons were beneficial in the treatment o f CDRM which was still considered 
untreatable.
1.1.8 Pathology
The pathology was initially described by Averill (1973) and subsequently by others, 
all o f whom agreed that the lesion involved mainly the spinal cord white matter and 
affected both the axon and myelin sheath. As previously discussed, before 1973 it 
was thought that the clinical signs seen in CDRM were attributable to the 
occurrence of spinal dural ossification. Averill reported irregular oval plaques 
formed from thin cancellous bone which contained normal bone marrow on the 
ventral aspect o f the dura mater. These did not impinge on the intervertebral space 
and from their position could not have resulted in the upper motor neurone (UMN) 
lesions seen in CDRM. Averill also found varying amounts o f spondylosis, these 
varied from small bony spurs on the vertebral bodies to large, hard, wedge-shaped 
structures which extended underneath the intervertebral space. The incidence of 
spondylosis was not significantly different between the affected and control groups 
of dogs and in addition the sites did not correspond with the spinal cord pathology. 
The spinal cord changes were consistent for all affected dogs. On gross 
examination of the cord the leptomeninges were slightly thickened, histologically 
they exhibited slight fibrosis. The white matter ascending and descending tracts 
were affected to varying degrees throughout the cervical, thoracic and lumbar 
segments (mid to caudal thoracic segments were the most severely affected). Only 
the fasciculus proprius appeared to be unaffected. Averill considered these areas to 
consist of loss of axons and myelin sheaths with an associated astrocytic 
hypertrophy and hyperplasia. The only grey matter changes noted were a possible 
loss of ventral horn neurones and an occasional mild perivascular fibrosis of the 
arterioles in this region. He noted that none of the degenerative changes appeared to 
extend into either the brain or the peripheral nerves. There were no consistent 
visceral lesions present in affected dogs.
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The pathology was described in more detail by Griffiths and Duncan (1975a). 
Again they described the presence of degenerative lesions in the spinal cords of all 
dogs examined but with variations in distribution and severity, these lesions were 
considered to be typical of Wallerian-type degeneration and affected both the axon 
and myelin sheath. They noted that any observed clinical asymmetry correlated 
with the pathological asymmetry. Loss of axons and myelin sheaths was seen in the 
dorsal funiculi, specifically in the fasciculus gracilis, o f cervical and cranial thoracic 
segments. Occasional axon and myelin sheath loss was also noted in the dorsal 
funiculi o f lumbar and sacral cord segments. In the lateral funiculus the most 
consistently affected area was the corticospinal tract which was most severely 
affected in the caudal thoracic segments. Any other fibre loss was scattered and not 
severe enough to constitute an actual tract involvement. The only grey matter 
change reported was the presence of increased numbers of astrocytes in the lateral 
and dorsal horns of grey matter in the lumbar and caudal thoracic segments. Some 
affected dogs had an occasional SpG neurone which exhibited central 
chromatolysis. No changes were seen in peripheral nerves or muscles o f affected 
dogs. There was no indication in this paper that the brains had been examined. As 
the present study identified significant brain pathology this illustrated the necessity 
for carrying out a complete neuropathological examination.
The report by Braund and Vandevelde (1978) confirmed most of the previous 
findings, however these authors did not observe any pathological changes in the 
SpG. They concluded that this may have been due to the clinical and pathological 
variations in the dogs studied. In addition to previous findings they reported marked 
axon and myelin loss in the white matter which surrounded the ventromedian 
fissure. Again they noted that the thoracic cord was the most severely affected 
region, although both cervical and lumbar segments were also involved.
Clemmons (1989) reported widespread demyelination and axon loss in affected 
areas of the spinal cord white matter with an associated increase in astrocyte 
numbers and increase in density of small vascular elements. In the thoracic cord he 
saw vacuolation in all funiculi, with swollen axons and eosinophilic globules, which 
represented degenerate and regenerate axons. A number of the vacuoles seen 
contained macrophages and astrocytes. Clemmons reported finding similar lesions, 
very occasionally, throughout the white matter areas of the brain (1989).
1.2 Other degenerative myelopathies of dogs
A number of diseases which had clinical and pathological similarities with CDRM 
had been recognised in other dog breeds. They were all characterised clinically by a
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progressive pelvic limb ataxia and paresis. On post mortem examination the spinal 
cord white matter exhibited degeneration of both axons and myelin sheaths, often 
with an associated gliosis. The age of onset amongst this group of diseases was, 
however, very variable.
In 1973 an ataxia with an autosomal recessive mode of inheritance was reported in 
Jack Russell terriers (Hartley and Palmer, 1973) in Britain and in Sweden. A 
progressive pelvic limb incoordination and dysmetria with over-protraction of the 
thoracic limbs commenced at three to six months o f age. Affected dogs showed a 
characteristic “dancing” gait. On pathological examination the two populations 
varied, although both had focal symmetrical loss of myelinated fibres in the 
peripheral dorsolateral white matter. In the more severely affected English cases a 
widespread Wallerian-type degeneration was noted throughout the CNS with 
degenerative changes in the central auditory pathway and peripheral nerves. It had 
been suggested that the differences may be due to the different time spans of 
disease.
A number of authors have reported a condition in a variety of hounds which had 
been variously named hound ataxia (Palmer and Medd, 1981; Palmer et al., 1984; 
Palmer and Medd, 1988) or spinal myelinopathy (Sheahan et al., 1991). This 
condition occurred in the adult animal, two to seven years old, with affected animals 
exhibiting pelvic limb weakness and incoordination. Most cases had a restricted 
panniculus localising to mid-thoracic to cranial lumbar segments. Conscious pain 
sensation remained intact. On pathological examination of the CNS vacuolar 
degeneration was present in lateral and ventral funiculi throughout the length of the 
spinal cord. Astrocytic proliferation and myelin debris were common. Changes in 
the spinal cord grey matter were uncommon, but chromatolysis was observed in the 
lateral vestibular nucleus and in thoracic neurones in segments T7 and T8 in two 
cases out of sixteen (Palmer et al., 1984). In all other cases the pathology observed 
in the brain stem was indicative of tract degeneration. The changes suggested a 
primary myelinopathy, unlike CDRM which appeared to have simultaneous 
degeneration of both the axon and myelin sheath. The occurrence of this disorder 
amongst foxhounds coincided with a change in diet to include a high proportion o f 
ruminant stomachs (tripe). Subsequent alteration to include a much higher 
proportion of meat had resulted in decreased incidence of the disease. Thus, a clear 
association had been established between the occurrence of hound ataxia and the 
feeding of ruminant stomachs which possibly resulted in decreased methionine 
levels and increased methionine synthetase activity in serum. It had been previously 
suggested that neurological deficits in subacute combined degeneration in man 
could have resulted from a methyl group deficiency associated with decreased levels
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of methionine and a concomitant decrease in levels o f S-adenosylmethionine. The 
suggestions for the aetiology of hound ataxia have never been confirmed, although 
the incidence had reduced dramatically since the diet was altered to include more 
meat.
Bichsel and Vandevelde (1983) described three related Siberian huskies with a late- 
onset progressive pelvic limb ataxia. In the two cases which could be examined 
muscle tone and flexor reflexes in the pelvic limbs were weak, whereas patellar 
reflexes were exaggerated. Pain sensation remained intact but proprioceptive 
positioning of the pelvic limbs was slow. These dogs all developed urinary 
incontinence as the disease progressed. At post mortem all three dogs had similar 
changes which comprised of disseminated vacuolation of the white matter, 
sometimes associated with axonal swelling and necrosis. These changes were found 
at all levels of the cord, especially in the ventral and lateral columns. Minimal 
gliosis was observed and there was no evidence of inflammation. The thoracic 
segments were the most severely affected, particularly in the peripheral white 
matter. The changes were asymmetrical and were not attributable to specific tracts. 
The affected dogs were closely related, two littermates and their mother, which 
suggested a possible hereditary basis to the disease.
A progressive pelvic limb ataxia had been reported in a five month old Pyrenean 
mountain dog (Wright and Brownlie, 1985). Diffuse axonal degeneration was noted 
in the dorsolateral, lateral and ventral white matter extending from the medulla to 
the fifth lumbar segment. The most severely affected segments were C8 to L2. The 
degenerative changes involved both the axon and myelin sheath. The SpG and the 
spinal cord grey matter were unaffected. Changes found in the brain included 
axonal swelling and degeneration in the spinocerebellar tracts, caudal and middle 
cerebellar peduncles and the cerebellar folia. No attempt had been made to 
determine the underlying cause of this disease.
In 1995 a degenerative myelopathy was reported in a ten year old Miniature poodle 
(Matthews and de Lahunta, 1985). A progressive pelvic limb ataxia and paresis 
developed with loss of proprioception, which initially affected only one pelvic limb. 
As the disease progressed hypertonia and hyperreflexia became evident in both 
pelvic limbs. Post mortem examination of the spinal cord revealed extensive diffuse 
degeneration of the white matter in all funiculi at all levels, which involved both 
axons and myelin. Again, the thoracic cord was the most severely affected. The 
spinal nerve roots were unaffected in this case. No cause was established.
A progressive neurological disorder had been reported in a young adult Ibizan 
hound (Summers et al., 1995). The ataxia was obvious in the pelvic limbs from the
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time of ambulation and progressed to involve the thoracic limbs. The gait was 
spastic and dysmetric with overflexion and abduction which led to a distinctive 
bobbing, bouncing type of gait. Patellar reflexes were absent. On microscopic 
examination of the spinal cord there was symmetrical degeneration of ascending and 
descending tracts in all funiculi and at all levels o f the spinal cord although the 
thoracic cord was most severely affected. Unlike CDRM, the pathology extended 
into specific peripheral nerves where there were dilated myelin sheaths which 
contained intact axons. This condition essentially represented a diffuse nervous 
system degeneration with myelopathy and neuropathy which mainly affected axons. 
Pedigree analysis supported an autosomal recessive pattern of inheritance for this 
condition.
A degenerative myelopathy with some resemblance to CDRM had recently been 
reported in the young GSD (Longhofer et al., 1990). The two affected animals were 
six and seven months of age. They exhibited a progressive pelvic limb ataxia and 
weakness. These dogs had very poor muscling of their hindquarters and normal 
conscious proprioception which distinguished them from dogs with CDRM. Pedal 
and patellar reflexes were intact but one dog had clonus of the patellar reflex. The 
pathological findings were similar in both dogs and involved symmetrical diffuse 
degeneration of axons and myelin with mild gliosis. These changes occurred 
predominantly in the lateral and ventral funiculi. The thoracic cord was most 
severely affected. Axonal degeneration was a prominent feature in this disease with 
many axonal spheroids and macrophages in affected areas of white matter. The 
only changes seen in the brain involved occasional degenerating axons in cerebellar 
white matter. The SpG and spinal nerve roots were all normal. Due to the 
significant differences between this condition and CDRM it was suggested that the 
pathogenesis may be unrelated. In addition, since the dogs were both thin and 
poorly muscled, a possible hereditary metabolic disorder was postulated.
There were other progressive neurodegenerative conditions which had been reported 
in a number of different dog breeds. These conditions were too dissimilar to CDRM 
to warrant discussion in this thesis. Examples of these were hereditary myelopathy 
in the Afghan hound (Cockrell et al., 1973; Cummings and de Lahunta, 1978), 
leukoencephalomyelopathy in the Rottweiler (Gamble and Chrisman, 1984) and 
progressive axonopathy in the Boxer (Griffiths, 1989).
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1.3 Anatomy of the spinal cord structures involved in 
CDRM
In this section the structure of the spinal cord with the emphasis on areas which are 
o f relevance to CDRM will be considered. Figure 1 (page 15) illustrates the spinal 
cord tracts o f interest in CDRM. Most of the work done to date had been in the cat.
1.3.1 White matter
The white matter is divided into bilaterally symmetrical areas or funiculi in which 
most fibres are arranged in functional units or tracts. The long ascending tracts are 
essentially sensory while the long descending tracts contain the axons of the UMNs. 
The long descending tracts were previously referred to as the “motor” system, but 
this would be inaccurate as among other things they regulate the transmission of 
sensory impulses in the ascending tracts. White matter tracts are often represented 
as being well circumscribed and functionally discrete, but even in man this is not the 
case. In addition it is not appropriate to directly transfer detailed knowledge of 
human anatomy to other species.
1.3.2 Dorsal funiculus
The dorsal funiculus extends from the dorsal median sulcus to the entrance of the 
dorsal spinal nerve roots in the dorsolateral sulcus, it is made up of two large 
ascending fibre tracts, the fasciculus gracilis and fasciculus cuneatus. The 
fasciculus cuneatus is present only in the cervical and parts of the thoracic cord. 
These tracts are associated with conscious proprioception and contain fibres which 
enter the dorsolateral sulcus, pass over the dorsal horn and ascend in the ipsilateral 
dorsal funiculus. The fibres of these tracts are the longest in the body, they are large 
and heavily myelinated with high metabolic requirements.
1.3.2.1 Fasciculus gracilis
The fasciculus gracilis is the medial tract which borders the dorsal median sulcus 
and extends the whole length of the cord. This tract is mainly composed o f axons 
from the cell bodies in the SpG of the nerves which innervate the pelvic limbs and 
caudal trunk. The arrangement of fibres is such that those fibres which enter the 
cord caudally lie medially within the cord, while fibres added as far forward as the 
mid-thoracic level lie laterally.
1.3.2.2 Fasciculus cuneatus
The fasciculus cuneatus lies lateral to the fasciculus gracilis and transmits impulses 
from the thoracic limb, cranial trunk and neck. Similarly to the fasciculus gracilis,
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this tract is made up of axons from cell bodies in the SpG which enter the dorsal 
funiculus directly i.e. without synapses. Again the arrangement of fibres is such that 
the longer fibres, this time from the mid-thoracic levels, lie medial to the shorter 
ones from the thoracic limb and cervical regions.
Both of these tracts convey impulses to the brain, the first neurone terminating in 
the respective nucleus (nucleus gracilis and nucleus cuneatus) in the medulla 
oblongata.
1.3.3 Lateral funiculus
The lateral funiculus lies between the dorsal and ventral spinal nerve roots and 
contains both ascending and descending tracts.
1.3.3.1 Ascending tracts
The ascending tracts usually lie around the peripheral margin of each spinal cord 
segment.
1.3.3.2 Dorsal spinocerebellar tract
The dorsal spinocerebellar tract (DSCT), also called Flechsig's fasciculus, is 
composed of heavily myelinated fibres whose cell bodies are within the thoracic 
nucleus (dorsal nucleus of Clarke). In the cat this extends from the cranial thoracic 
segments as far caudally as the fourth lumbar segment (Hubbard and Oscarsson, 
1962). The axons pass ipsilaterally from this nucleus to lie at the periphery of the 
cord between the dorsal root entrance and the lateral corticospinal tract. Caudally 
the tract begins at segments L3 or L4 and increases in size as it passes cranially 
throughout the levels of the thoracic nuclear column (this region has been accurately 
defined in the cat as extending from L3 to T3). The DSCT enters the cerebellum via 
the caudal cerebellar peduncle. Verhaart and van Beusekom (1958) reported that 
this tract contained a mixture of fibres from the pyramidal and other tracts. They 
also reported that not all fibres reach the cerebellum, some terminating in the lateral 
cervical nucleus of the cord, others in the medullary nuclei. The DSCT is involved 
with the unconscious subdivision of proprioception transmitting impulses from 
neuromuscular spindles, Golgi tendon organs, touch and pressure receptors in the 
skin of the pelvic limbs and caudal trunk to the cerebellum. The cerebellum then 
exerts its tonic and synergising influence on the motor pathways. Although the 
proprioceptive neurones are sensory (general somatic afferent) their dysfunction is 
recognised clinically by assessing motor performance. The important sign 
associated with damage to these tracts is ataxia (dyssynergia).
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1.3.3.3 Ventral spinocerebellar tract
The ventral spinocerebellar tract lies at the periphery of the lateral funiculus ventral 
to the DSCT and is bordered medially by the lateral spinothalamic tract. The origin 
is diffuse, although in the cat the majority of the cells of origin lie in the lateral base 
and neck of the dorsal horn in the lumbar segments, with a few in adjacent parts of 
the ventral horn and the head of the dorsal horn (Hubbard and Oscarsson, 1962). 
This tract transmits only impulses which arise in the pelvic limbs and caudal trunk. 
Some axons remain ipsilateral while others decussate then decussate back again at 
the level of the cerebellum. In the cat the position of this tract varies as it passes 
cranially; moving dorsally from the lumbosacral through the thoracic and caudal 
cervical segments, then ventrally in the cranial cervical segments (Grant, 1962). 
Ultimately this tract ascends through the brain stem to the peripheral margin of the 
rostral cerebellar peduncle which it follows into the cerebellum. The fibres transmit 
impulses generated from large receptive fields of Golgi tendon organs and flexor 
reflex afferents (Noback and Demarest, 1986). The ultimate projection of the 
ventral spinocerebellar tract is ipsilateral.
1.3.3.4 Descending tracts
The descending tracts lie between the grey matter and the ascending tracts. These 
are upper motor neurones (UMNs) which terminate by entering the grey matter to 
synapse with an intemeuron, thus indirectly synapsing with the cell body of lower 
motor neurones (LMNs).
1.3.3.5 Corticospinal tracts
Fibres o f the lateral corticospinal tract originate throughout the cerebral cortex and 
descend through the ipsilateral brain stem to the spinomedullary junction. This is 
the major pathway by which the cerebral motor cortex connects directly to the 
spinal cord (Buxton and Goodman, 1967). At the level of the spinomedullary 
junction many of the fibres, 75-85%, cross in the pyramidal decussation and 
descend as far caudally as the lumbar segments in the dog. The remaining 
uncrossed fibres, 15-25%, descend in the ipsilateral ventral funiculus as the ventral 
corticospinal tract. In veterinary neuroanatomy the lateral corticospinal tract is 
functionally insignificant, in contrast to its great importance in man. Dysfunction of 
this tract in man, which commonly occurs following strokes, causes a severe spastic 
hemiparesis. The location of terminal fibre synapses is the factor which determines 
to what extent the corticospinal tract directly influences movement. In man the 
fibres synapse directly on LMNs, so directly influence movement. In animals the
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corticospinal pathways terminate in the dorsal horns and synapse on intemeurons 
thus indirectly influencing the action of the LMNs. Damage to these tracts in the 
dog would result in hypotonia, hypokinesia and dysmetria on the contralateral side. 
These functional deficits would be more severe in the hindlimbs than the thoracic 
limbs.
1.3.3.6 Rubrospinal tract
The rubrospinal tract, also called von Monakow's bundle, arises from cells 
throughout the red nucleus (for details see page 20) which lies in the midbrain 
tegmentum. Much work has been done on the possible somatotopic arrangement of 
this nucleus in the cat (Pompeiano and Brodal, 1958; Nyberg-Hansen and Brodal, 
1964a). Fibres serving the lumbosacral cord originate in the ventral and 
ventrolateral regions of the nucleus, those serving the thoracic cord originate in the 
intermediate portion and those destined for the cervical cord arise in the dorsal and 
dorsomedial portions of the nucleus. On leaving the red nucleus, fibres immediately 
cross the median raphe as the ventral tegmental decussation and descend in the 
lateral brain stem tegmentum then continue in the lateral funiculus o f the spinal 
cord. Due to their location, the rubrospinal fibres partly intermingle with the 
descending fibres of the lateral corticospinal tract, although the majority lie 
ventrolateral to this tract. In the dog the rubrospinal tract has been traced 
throughout its length, as far caudally as the lumbar segments whereas in the cat a 
few fibres extend to the sacral segments (Hinman and Carpenter, 1959; Staal and 
Verhaart, 1963). It has been reported that most of the fibres are received by the 
cervical cord segments, with the remainder going to the thoracic and lumbar 
segments (Pompeiano and Brodal, 1958). The rubrospinal fibres enter the spinal 
cord grey matter at the level of the lateral horn terminating in the fifth, sixth and 
seventh laminae (Nyberg-Hansen and Brodal, 1964a). The actual termination points 
for these fibres are subject to some controversy for two reasons; firstly, most 
experimenters used the Marchi technique which does not demonstrate terminal 
ramifications of fibres and secondly, the terminology used to describe the different 
grey matter zones is vague and confusing. The majority o f the rubrospinal fibres 
terminate in the intermediate grey matter (de LaHunta, 1977). This tract is of vital 
importance in animals, more so than in man, because it is concerned with 
coordination and possibly also locomotion. The rubrospinal tract exerts a number of 
influences on the spinal cord. Through intemeurons it excites alpha and also 
gamma motoneurons of the contralateral flexor muscles. At the same time, it 
inhibits the alpha fibres and the static fusimotor fibres of the contralateral extensor 
muscles. It also facilitates a set of inhibitory and excitatory spinal reflexes by direct 
action on relevant intemeurons. The rubrospinal tract is responsible for the
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facilitation of the cells of origin of the ventral spinocerebellar tract and, by means of 
presynaptic inhibition, controls activity in the primary afferents as these enter the 
spinal cord.
1.3.4 Ventral funiculus
The ventral funiculus lies between the emerging ventral spinal nerves and the 
ventral median fissure and contains mainly descending tracts. The tracts in this 
region are generally smaller and more dispersed, tending to overlap more than in 
other funiculi.
1.3.4.1 Descending tracts
1.3.4.2 Tectospinal tract
The tectospinal tract arises mainly from the rostral colliculus of the midbrain 
tectum. The fibres cross over and descend in the ventral funiculus bordering the 
ventral median fissure. Most o f the fibres terminate in the upper four cervical 
segments by synapsing with intemuncial neurones to the LMNs. Specific functions 
for this tract are difficult to define but, in combination with interstitiospinal fibres 
and the medial vestibulospinal tract, it is involved in reflex postural movements of 
the eyes, head and body.
1.3.4.3 Ventral corticospinal tract
The ventral corticospinal tract has been considered with the lateral corticospinal 
tract see 1.3.3.5 Corticospinal tracts (page 16).
1.3.4.4 Lateral vestibulospinal tract
The lateral vestibulospinal tract in the cat contains descending fibres from the 
ipsilateral lateral vestibular nucleus (Nyberg-Hansen and Mascitti, 1964b). In the 
dog the pathway extends to the lumbosacral cord with the cervical and lumbar 
enlargements receiving more fibres than the grey matter o f the thoracic segments. A 
somatotopic organisation has been recognised in the vestibulospinal projection, such 
that the pelvic limb region of the cord is served by the dorsocaudal region of the 
lateral nucleus (Nyberg-Hansen and Mascitti, 1964b). The lateral vestibulospinal 
tract functions to maintain equilibrium and is of great importance in all carnivores. 
The medial vestibulospinal tract arises from the medial vestibular nucleus and 
descends bilaterally, but mainly ipsilaterally, within the medial area of the ventral 
funiculus. This tract is much less important than its lateral counterpart and extends 
only as far as the mid-thoracic spinal cord segments.
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1.3.4.5 Medial longitudinal fasciculus (MLF)
The medial longitudinal fasciculus (MLF) which consists of both ascending and 
descending fibres, extends from the level o f the rostral midbrain caudally 
throughout the brain stem then continues into the spinal cord ventral funiculus. In 
the dog this tract passes caudally to lumbar levels. Functionally, the MLF acts as a 
connector between vestibular and motor nuclei o f cranial nerves III, IV and VI 
accounting for vestibular reflexes involving eye movements. Due to the large size 
of this tract and its ventral position in domestic animals, it is prone to injury.
1.3.4.6 Ventral reticulospinal tract
The ventral reticulospinal tract is less often involved in cases of CDRM than the 
previously described, lateral vestibulospinal tract. The reticulospinal fibre system is 
complex and is described differently by various authors. The ventral reticulospinal 
tract is thought to arise from the caudal pontine reticular area, the fibres then 
descend almost exclusively on the same side within the ventral funiculus. They 
continue as far caudally as the lumbosacral segments (Nyberg-Hansen, 1966). This 
pontine (as opposed to medullary) reticulospinal tract, along with the lateral 
vestibulospinal tract, facilitates extensor motoneurones. Unlike the rubrospinal and 
corticospinal tracts there is no evidence for somatotopic organisation in this tract.
1.3.5 Grey matter
The grey matter is made up mainly of neurone cell bodies, myelinated and non­
myelinated fibres, glial cells and capillaries. The supporting neuropil is formed 
from neuronal dendrites and axons plus a fine meshwork of glial processes. Rexed 
(1952; 1954) has subdivided the grey matter of the cat into ten distinct laminae, 
based on differential cytoarchitectonics. This system provides a precise criterion for 
localization of specific axon terminations and origins. Romanes (1951) correlated 
specific cell bodies in the ventral horn of the grey matter of the cat spinal cord with 
innervation of individual muscles in the pelvic limb. This level of knowledge is still 
not available for the dog. Essentially, the grey matter is considered to consist of 
several regions; the main ones being dorsal horn, lateral horn, ventral horn and 
Clarke's column. The region o f particular interest in CDRM is the area of grey 
matter level with the central canal and lying between the dorsal and ventral horns. 
The classification system used in this thesis is that of de Lahunta (1977) who 
designated this area the intermediate grey horn.
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1.3.5.1 Dorsal horn (column)
This region of the grey matter is infrequently involved in CDRM. It is made up of a 
number of nuclear groups, namely the substantia gelatinosa, nucleus proprius, 
secondary visceral nucleus, thoracic nucleus and lateral cervical nucleus. The 
thoracic nucleus lies dorsolateral to the central canal in the thoracic and cranial 
lumbar portions of the cord. This nucleus is the origin of the dorsal spinocerebellar 
tract.
1.3.5.2 Intermediate horn (column)
This is the region of grey matter most often affected in CDRM. The general 
somatic afferent and general proprioception neurones are located in this region with 
the general somatic efferent neurones.
1.3.5.3 Lateral horn (column)
A small evagination of grey matter which is visible from T1 caudally, lying just 
lateral to the level of the central canal. This region indicates the stratum of cell 
bodies which are the nucleus of origin for the general visceral efferent sympathetic 
neurones.
1.3.5.4 Ventral horn (column)
This area contains the large multipolar cell bodies of the alpha motor neurones. In 
addition, the ventral horn also contains the smaller cell bodies of the gamma efferent 
neurones which transmit impulses to motor endings of the intrafusal muscle fibres in 
the neuromuscular spindles. These are both examples of LMNs. These LMN cell 
bodies are found throughout the entire length of the spinal cord.
1.4 Anatomy of the brain nuclei involved in CDRM
Again, most of the anatomical and physiological investigations have been carried 
out in the cat.
1.4.1 Red nucleus
This nucleus lies in the tegmentum at the level of the rostral colliculus, embedded 
within the reticular formation and ventral to the oculomotor nucleus. It can be seen 
on gross examination of the sectioned brain due to its distinct red colour which is 
thought to be due to the high level of vascularisation within the nucleus. 
Identification is also aided by the presence of a distinct “capsule” formed by the
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fibres of the rostral cerebellar peduncle (brachium conjunctivum) (Hinman and 
Carpenter, 1959).
At a cellular level, the red nucleus is composed of a number o f large, medium and 
small cells. In man these can easily be separated into a caudal magnocellular and a 
rostral parvocellular population. However, this distinction in cell sizes is much less 
well defined for carnivores than other mammals. All the efferents from the 
magnocellular part of the red nucleus are crossed. The main efferent pathway is the 
rubrospinal tract (for details see page 17), other efferents pass to the bulbar lateral 
reticular nucleus, the facial nucleus and the cerebellar nucleus interpositus. The 
cells within this tract are somatotopically arranged, the pelvic limb being served by 
the ventrolateral region while the thoracic limb is served by the dorsomedial region. 
A similar topographic arrangement is found among the corticorubral and 
cerebellorubral projections. The parvocellular region of the red nucleus contains 
mainly small and medium sized cells and, in carnivores only, a small number of 
large cells. Efferent connections to this part of the nucleus are ipsilateral, consisting 
of rubrothalamic and rubro-olivary fibres. Most of the afferent fibres originate from 
the contralateral nucleus interpositus.
The red nucleus contains colonies of neurones which ultimately activate the 
motoneurone pools of individual muscles. These effects are mediated by particular 
intemeurones in the dorsolateral intemeuronal cell groups of the spinal cord. There 
is considerable overlap of individual rubral efferent colonies. Microstimulation 
within the red nucleus is capable of eliciting contraction of both flexor and extensor 
muscles of the contralateral limb (Ghez, 1975).
1.4.1.1 Origin of afferent fibres
Afferent fibres arise in the opposite side of the cerebellum via the rostral cerebellar 
peduncle which enters the tegmentum and crosses caudal to the red nucleus as the 
decussation of the brachium conjunctivum. Most o f these cerebellorubral fibres 
originate in the nucleus interpositus with a small number of fibres originating in the 
lateral nucleus. Fibres from the most rostral part of the nucleus interpositus pass to 
the caudal two thirds of the red nucleus which in turn sends fibres to the 
contralateral pelvic limb. Projections from the caudal part of the nucleus 
interpositus end in the area of the red nucleus which influences the thoracic limb. 
Afferent fibres also arise from the cerebrum and corpus striatum (Jenkins, 1978).
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1.4.1.2 Projections
Unlike other nuclei in the reticular formation, efferent fibres of the red nucleus 
project into spinal segments more caudal than the thoracic segments and in addition, 
parts of the nucleus project large fibre bundles to brain stem nuclei, the cerebellum 
and the diencephalon.
The principal efferent pathway is the rubrospinal pathway which has been discussed 
on page 17. A number o f other efferent pathways exist. The rubrocerebellar tract 
(Massion, 1967) has been recognised in both rodents and carnivores. Fibres 
originate mainly from the large neurones in the caudal third of the contralateral red 
nucleus with most fibres ending in the nucleus interpositus. The presence of the 
rubro-olivary tract whose ipsilateral fibres originate in the rostral red nucleus and 
terminate in the dorsal lamina of the principle olive has also been confirmed 
(Hinman and Carpenter, 1959). Other efferent connections have been described, 
ipsilateral rubropallidal and rubrosubthalamic fibres have been identified in a 
number of species, including the cat. Both direct and crossed rubrotegmental fibres 
have been described by von Monakow, Weisschedel (both in German) and Rioch 
(1929). Rubrobulbar fibres fall into two categories; the first being the uncrossed 
fibres which pass to the dorsal lamellae of the principal inferior olivary nucleus; the 
second being crossed fibres passing to specific portions of the lateral reticular 
nucleus of the medulla which arise from the caudal two thirds o f the contralateral 
red nucleus.
Finally, rubrorubral connections passing via the caudal commissure and a tract 
connecting the red nucleus to the contralateral hypothalamus have been reported.
1.4.2 Vestibular nuclei
The vestibular system consists o f a group of four nuclei i.e. lateral, medial, rostral 
and caudal, on each side of the midline in the floor of the fourth ventricle at the 
level of the upper medullary-pons junction. The lateral vestibular nucleus (LVN) or 
nucleus of Deiters is the one most commonly affected in CDRM. This nucleus lies 
immediately rostral to the spinal nucleus and is medial to the caudal cerebellar 
peduncle and dorsomedial to the spinal tract and nucleus of the trigeminal nerve. 
The LVN is generally defined as the part of the vestibular complex containing giant 
cells of Deiters, although it also contains a number of medium and small sized cells 
(Nyberg-Hansen and Mascitti, 1964b). The giant cells are generally present in 
greater numbers in the dorsocaudal part of the nucleus, while the medium and small 
cells tend to be in the rostral part. The axons of all these cells pass to the spinal cord 
in the vestibulospinal tract. The medial (Schwalbe's) vestibular nucleus lies medial 
to the LVN and dorsolateral to the MLF.
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1.4.2.1 Origin of afferent fibres
Direct primary vestibular axons from the vestibular (Scarpa's) ganglion enter all 
four nuclei via the vestibular nerve. Cerebellovestibular fibres from the cerebellar 
cortex and fastigial nucleus provide a feedback mechanism between the vestibular 
nuclei and the cerebellum. The general proprioceptive impulses from the neck 
muscles, tendons and joints permit head movements and position to direct the 
orientation of the body in space as the primary basic principle in the vestibular 
righting reflex.
1.4.2.2 Projections
Fibre connections from the vestibular nuclei can be separated into two main 
pathways. In the first of these, descending axons from the lateral vestibular nucleus 
project ipsilaterally as the lateral vestibulospinal tract (the tract is exclusively 
uncrossed) to the ventral funiculus of the lumbosacral spinal cord in the dog 
(Nyberg-Hansen and Mascitti, 1964b). The vestibulospinal projection has a 
somatotopic organisation, the pelvic limb being served by the dorsocaudal region. 
In the second pathway axons originating from all four vestibular nuclei pass 
medially to enter the MLF. In addition, a group of secondary vestibulocerebellar 
axons are relayed from the various nuclei to the cerebellar cortex.
1.4.2.3 Functions
The LVN, by way of the vestibulospinal tract (Pompeiano and Brodal, 1957), exerts 
a facilitatory effect on spinal reflexes which control muscle tone, especially to 
maintain appropriate posture or strength of supporting and balancing movements. 
Maintenance of equilibrium is largely reflex activity governed primarily by general 
proprioceptive impulses from muscles, tendons and joints in the trunk and limbs and 
special proprioceptive nerve endings in the labyrinth which initiate impulses 
conveyed via the vestibular nerve to the vestibular nuclei. The vestibulospinal tracts 
(along with the reticulospinal tracts) have a facilitatory effect on the spinal cord 
LMNs especially those supplying the antigravity {i.e. the postural and extensor) 
muscles. A failure in the normal activity o f the vestibular system due to 
labyrinthine overstimulation, disease, irritative or destructive lesions may cause 
disequilibrium, staggering, postural changes, falling or rolling to the same side, 
nystagmus, deviation of the eyes, nausea, vomiting and vasomotor reactions.
1.4.3 Lateral (dentate) nucleus
The lateral nucleus is one of the three cerebellar nuclei which are embedded in the 
white matter dorsal to the fourth ventricle, the other two being the fastigial nucleus
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and the nucleus interpositus. The lateral nucleus is the most lateral of the three but 
is difficult to differentiate anatomically from the neighbouring nucleus interpositus. 
This nucleus has a dorsal and a ventral eminence protruding laterally to give a tooth­
like shape which is less pronounced in the dog than in other species.
1.4.3.1 Origin of afferent fibres
Afferent fibres originate from the rostral and caudal lobes of the cerebellum via the 
axons of the Purkinje cells.
1.4.3.2 Projections
Fibres project to the red nucleus, the reticular formation, the pallidum and the 
ventrolateral nucleus of the thalamus through the rostral cerebellar peduncle.
1.4.3.3 Function
The lateral nucleus is concerned with regulation of skilled, spatially organised 
movements o f the limbs, but has no direct regulatory function on posture or tone 
(Holliday, 1979). In addition, recent medical research using MRI has suggested that 
the lateral nucleus may be active during motor, perceptual and cognitive 
performances due to the requirement to process sensory data (Nyberg-Hansen, 
1966; Barinaga, 1996).
1.5 Comparable Diseases In Other Species
1.5.1 Feline
Degenerative myelopathy had occurred very infrequently in the cat, being reported 
only in two cats infected with Feline leukaemia virus (FeLV) (Mesfin et a l , 1980). 
The pathology of the one case available was dissimilar to CDRM.
1.5.2 Equine
Equine degenerative myeloencephalopathy (EDM) had occurred not only in 
domesticated horse breeds such as Appaloosas, Arabians, Quarter horses, 
Thoroughbreds, Standardbreds and Morgan horses, but also in the Prezwalski horse 
and the zebra (Dill et a l , 1989; Dill et a l , 1990; Blythe and Craig, 1992a; Blythe 
and Craig, 1992b) and was characterised clinically by ataxia, especially of the pelvic 
limbs, and a wide-based stance and gait. A number of affected animals also had 
laryngeal adductor, cervicofacial, local cervical and cutaneous trunci hyporeflexia 
(Mayhew et a l,  1987). Clinical signs usually developed within the first twelve
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months of life. This condition was most common in the northeast United States but 
had been seen in other parts of North America, the United Kingdom (Whitwell, 
1980) and in two Haflinger fillies in Germany (Baumgartner et a l , 1990). There 
was no obvious sex predisposition. On histopathological examination of the spinal 
cord there was diffuse degeneration of both axons and myelin sheaths, the 
ventromedial and dorsolateral funiculi were the most consistently affected. Changes 
included the presence of spheroids (axonal swellings), neuronal atrophy, astrogliosis 
and accumulation o f lipofiiscin-like pigment in neurones. Grey matter changes were 
seen in the nucleus o f the spinocerebellar tracts in the thoracic region and in several 
nuclei of the lateral horn. These grey matter changes were reported in detail by 
Mayhew (1977; 1987). Brain changes involved neuroaxonal dystrophy in brain 
stem nuclei, especially the medial and lateral cuneate nuclei and the nucleus gracilis. 
Neuroaxonal dystrophy was characterised by the presence of disseminated axonal 
swellings (spheroids) in preterminal portions of axons and in synaptic terminals.
A condition called degenerative myelopathy had been reported in a small group of 
Prezwalski horses (Liu et al., 1983), a Welsh pony and a donkey (Scarratt et al., 
1985). The clinical signs and spinal cord pathology had marked similarities to 
EDM. The brain was not examined at post mortem in these cases. The available 
evidence would suggest that these cases all represented the same condition.
The pathogenesis for this condition(s) was not understood but there was a body of 
evidence which suggested that vitamin E may have been involved. Firstly, 
experimentally induced vitamin E deficiency in rats (Southam et al., 1991) and 
rhesus monkeys (Nelson et al., 1981) often caused a neuroaxonal dystrophy with 
lipofuscin-like pigment accumulation, as had been noted in the aforementioned 
equine cases. Secondly, a naturally occurring vitamin E deficiency in humans 
resulted in neuroaxonal dystrophy with the same pigment accumulation. In 
addition, inadequate serum or plasma oc-tocopherol concentrations had been 
reported in several studies on EDM. However, unaffected horses from different 
lines had equally low concentrations of serum a-tocopherol. Prophylactic 
administration of d ,l oc-tocopherol, at a level of 1000 to 2000IU/day, to foals from 
sires known to produce EDM-affected offspring led to a decrease in disease 
incidence. In the first year the incidence dropped from 40% to 10% (Mayhew et al., 
1987) and subsequently from 10% to 1% over the next three years. In one study 
(Blythe and Craig, 1992b) affected horses were treated with 6000IU/day of d,l-oc- 
tocopherol acetate for several years. The neurological scores improved in all cases.
The pathology seen in these equine diseases had similarities to CDRM, both in the 
distribution of the lesions within the spinal cord i.e. predominantly the dorsolateral
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and ventromedian regions of the white matter and in the nature of the changes seen 
i.e. degeneration of both axons and myelin sheaths. However, degeneration in the 
grey matter was much more marked than in CDRM which suggested that underlying 
pathogenetic mechanisms were unlikely to be exactly the same.
1.5.3 Bovine
A number of neurologic disorders with some similarities to CDRM had been 
reported in several breeds o f cattle. Bovine progressive degenerative 
myeloencephalopathy (BPDME) had been seen in Brown Swiss cattle in Canada, 
Denmark, Germany, Switzerland and the United States of America (Leipold et al., 
1973; Stuart and Leipold, 1983; Stuart and Leipold, 1985; Baird et al., 1988; Oyster 
et al., 1991a; Oyster et al., 1991b). This condition was characterised clinically by a 
progressive pelvic limb weakness and ataxia which usually began at five to eight 
months of age and resulted in permanent recumbency over a 12 to 18 month period. 
On microscopic examination of the CNS the spinal cord white matter was the most 
consistently and severely affected area. Active axonal degeneration, loss of axons 
and myelin, status spongiosus and very large axonal swellings were visible at all 
levels of the cord. The degenerate axons were present in both ascending and 
descending tracts of the white matter and were considered to be the primary lesions 
of BPDME. The thoracic region and the ventral funiculi were the most severely 
affected regions in all cases. No significant changes were found in the grey matter, 
spinal motor neurones or SpG at any level.
In the brain, spheroids and pyknotic glial cells were seen in the subcortical white 
matter of the cerebrum, cerebellum and medullary pyramids. Lesions in the grey 
matter of the brain were found in the olivary nucleus of the medulla oblongata and 
consisted of degenerative changes which ranged from neuronal vacuolar 
degeneration to chromatolysis, accompanied by mild, reactive astrocytosis. In 
addition, oligodendroglia numbers were reduced. Although the pathogenesis was 
not understood, BPDME was considered to be a degenerative spinocerebellar 
disease with familial predisposition.
A progressive spinal myelinopathy had been seen in Murray grey cattle in Western 
Australia (Richards and Edwards, 1986). The age o f onset was most commonly 
within the first six months of life. This condition was characterised clinically by 
spinal ataxia manifest as pelvic limb incoordination and a lateral swaying of the 
hindquarters when standing. These animals also exhibited an increased muscle tone 
in the pelvic limbs. At post mortem, microscopic lesions were found in the spinal 
cord white matter of all cases but only the ventral and lateral funiculi were 
consistently affected. The lesions were bilaterally symmetrical, present throughout
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the length of the cord and generally affected all segments equally. Peripheral white 
matter tracts were usually severely, but diffusely, affected with relative sparing of 
the propriospinal tract. Several cases had shown dorsal funicular lesions which 
affected both the fasciculus gracilis and fasciculus cuneatus. The pathology 
consisted o f numerous dilated myelin sheaths, many of which still contained axons 
o f normal diameter. Swollen axons were present in a small proportion of these 
fibres while some sheaths contained mononuclear macrophages (gitter cells). 
Occasionally, “digestion chambers” were seen, made up of macrophages and cell 
debris, which were typical of Wallerian degeneration. Glial cell (cell type not 
specified) density was slightly increased within the spinal lesions. Spinal nerve 
roots were unaffected. A few chromatolytic neurones were present in all spinal cord 
segments, usually in the grey matter of the ventral horn but occasionally in the 
thoracic nucleus. There did not appear to be an overt neuronal dropout in the spinal 
cord grey matter.
In the brains o f most affected calves, white matter degeneration in the 
spinocerebellar and tectospinal tracts and the MLF was noted. These lesions 
resembled the spinal cord white matter changes. Chromatolytic neurones were often 
present in the red nucleus of the midbrain, LVN, medial portion of the reticular 
formation (brain region not specified) and occasionally in the cerebellar nuclei. 
This chromatolysis was usually diffuse and involved some swelling of the cell body, 
however no cellular necrosis was observed.
Both these conditions in cattle show many clinical and pathological similarities to 
CDRM although one marked difference is the early age of onset in the affected 
cattle.
1.5.4 Other herbivores
Ataxia associated with spinal cord degeneration had been seen in a number of other 
species such as llama, wildebeeste and camel (Palmer et a l , 1980). There have 
been several reports of a pelvic limb ataxia and paresis occurring in the llama 
(Palmer et al., 1980; Morin et al., 1994). Clinically, the affected llamas showed a 
variety of different pictures which varied from a unilateral pelvic limb ataxia and 
paresis (Palmer et al., 1980) through to sudden onset recumbency (Morin et al., 
1994). No gross lesions were found in any of the affected animals and on 
microscopic examination of the CNS very similar patterns of degeneration were 
seen in all affected animals. In the cord, bilateral axonal degeneration was found 
throughout all spinal cord segments, this was particularly severe in the thoracic 
cord. The tracts most severely affected were the dorsal and dorsolateral sensory 
tracts, only minimal degeneration was visible in the cervical cord. The changes
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consisted of myelin sheaths which contained cellular debris and gitter cells, the 
latter often contained lipofuscin granules. Grey matter changes were minimal and 
confined to the ventral horn, they consisted of a few distended eosinophilic 
structures which were interpreted to be swollen, dystrophic axons (spheroids). In 
some brain stem nuclei small numbers of hyperchromatic and slightly shrunken 
degenerate neurones, often containing lipoftiscin were observed. No evidence of 
inflammatory change or specific pathogens was observed.
There had been one isolated case of ataxia reported in a one year old camel (Palmer 
et al., 1980), in which degenerative changes resembled those seen in the llamas. 
Ataxic wildebeeste have been examined post mortem (Palmer et al., 1980) and 
Wallerian degeneration of ventral and lateral funiculi, especially spinocerebellar 
tracts was noted. The degeneration was traced up into the caudal cerebellar 
peduncle.
To date a number of conditions with some similarities to CDRM have been reported 
in several other species but minimal attempt had been made to study the 
aetiopathogenesis. The obvious exception to this were the human 
neurodegenerative disorders. A number of diseases with clinical and pathological 
similarities to CDRM occurred in this species. O f particular interest were a group 
of late onset, progressive neurodegenerative diseases which resulted in selective loss 
of neurone populations. These were the result of CAG trinucleotide repeat 
expansions. Several of these conditions have recently been investigated such that 
the actual gene defect has been characterised. These conditions are considered in 
detail in 6 An investigation towards the identification of a possible molecular lesion 
associated with CDRM (page 159).
1.6 Aims of the thesis
Since 1973 a progressive, neurodegenerative disease had been recognised in large 
breed dogs with a higher incidence in the GSD than other breeds. A number of 
aetiological factors had been suggested, including various vitamin deficiencies, or 
immune-mediated disease, but none had been proven to be the cause of CDRM. 
Most authors considered a genetic factor likely due to the high incidence of the 
disease in one breed. The clinical signs occurred in older GSDs and involved a 
progressive pelvic limb ataxia and paresis. Local spinal reflexes in the pelvic limbs 
were commonly intact, although the patellar reflex varied in response to the disease. 
The perineal and panniculus reflexes were unaffected. Clinical signs progressed 
over a six to 12 month period before the dogs lost useful pelvic limb function. 
There was no diagnostic test available for use in the live animal. Diagnosis was
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dependent on pathological examination of the spinal cord. Only one author had 
suggested an effective treatment regime which included vitamin E, vitamin B and 
EACA, this was not confirmed by other workers in the field. CDRM was still an 
untreatable disease.
The pathology in the spinal cord had been described in detail by a number of 
authors. Most agreed that the white matter areas of the spinal cord were the most 
consistently affected, with degeneration which involved both axons and myelin, 
often with an associated gliosis. The caudal thoracic segments were consistently the 
most severely affected. The grey matter changes reported varied from loss of 
neurones in the ventral horn (Averill, 1973) to increased astrocyte numbers in the 
dorsal and lateral horns (Griffiths and Duncan, 1975a). Only one author suggested 
that there was evidence of axonal regeneration in the spinal cord (Clemmons, 1989), 
the same author mentioned the possibility of changes occurring in unspecified white 
matter areas of the brain. A number of comparable conditions characterised by 
progressive pelvic limb ataxia and paresis, both in other breeds o f dog and in other 
species had been described. As a general rule the pathology had been described in 
detail for most of these conditions but the aetiology was still unknown. There were 
obvious exceptions to this, most importantly in many of the human ataxias, where 
the underlying lesion was known to be genetic while in some the actual gene defect 
had been characterised.
This project aimed to examine clinically and pathologically a large number of GSDs 
affected by CDRM. Clinically, we wished to confirm the previously reported 
clinical signs, and look for any that may not have been reported. We proposed to 
follow the dogs through the clinical course of the disease, re-examining on a regular 
basis to establish whether the rate of degeneration was constant or variable. If 
variable, were there a number o f recognisable patterns which might suggest we were 
dealing with a syndrome rather than a single disease ? In addition, we wished to 
confirm whether or not GSDs with CDRM had lower serum vitamin E 
concentrations than other dogs, since this vitamin had been associated with a 
number of neurodegenerative diseases in other species. The initial aim of the 
pathology investigation was to carefully examine the spinal cord using 
immunocytochemistry and electron microscopy, as well as classical techniques, to 
confirm the pathology previously reported and to look for new clues to the 
pathogenesis and aetiology using the more modem techniques. The next step was to 
carefully search through the brain, in particular those structures which, on the basis 
of the clinical signs, were most likely to be involved in CDRM. This search 
resulted in the discovery that specific brain nuclei and areas of white matter were 
altered in dogs with CDRM. These findings suggested marked clinical and
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pathological similarities between CDRM and a group of late onset progressive 
human neurodegenerative conditions which were the result of CAG trinucleotide 
expansions. This led into an investigation of the hypothesis that “CDRM is the 
result of a CAG trinucleotide repeat expansion”.
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2.1 COLLECTION OF CLINICAL MATERIAL
2.2 Case Selection
A full case history was obtained from the owner and referring veterinary surgeon 
and the relevant details were recorded. All cases underwent full systemic 
examination with only significant abnormal findings being recorded.
All cases received a complete neurological examination as detailed by Oliver and 
Mayhew (1987). Mentation and posture were noted and the owners questioned 
about any change in behaviour or attitude. The gait was evaluated for lameness, 
coordination and weakness. Conscious proprioception and motor function were 
assessed by paw position, reflex stepping, hip sway test and wheelbarrowing. The 
reflex step is a test of proprioception and is not a true reflex, this test can also be 
referred to as the "piece of paper test". The hip sway test was carried out by holding 
the dog either side of the midline in the flank region and gently moving the dog over 
to one side then the other, a dog with normal proprioception will immediately move 
the relevant foot such that the body is properly supported (Griffiths and Duncan, 
1975a). Local spinal reflexes were assessed in each limb with the dog in lateral 
recumbency. Muscle tone was assessed by passive flexion and extension of the 
limb. The patellar reflex was assessed, but myotactic reflexes were not routinely 
carried out in the thoracic limbs as these were known to be inconsistent, even in 
animals with normal thoracic limb function (Dr C.E. Thomson, personal 
communication, 1995). The pedal reflex was tested to evaluate flexor muscle group 
strength and to assess cutaneous sensory fields in the distal limb. The presence or 
absence of conscious pain perception was noted. Muscle bulk and symmetry were 
assessed by palpation and the joints were examined for the presence of 
musculoskeletal disease. The panniculus reflex was tested on each side. Bladder 
and bowel function was evaluated by questioning the owner and examination of the 
perineal reflex.
Based on these findings an attempt was made to localise the lesion to the T3-L3 
region of the spinal cord.
A complete list of all dogs included in the project, both CDRM cases and controls is 
given in Table 1, pages 33-44.
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A B C D E F G H I J
No. Case ID Breed Age
in
years
Sex CDRM
status:
G or R 
+ or -
3 4 5 6
1 129202 GSDX 10 FN G+ + + + +
2 126438 GSD 12 FN G+ + + + +
3 126586 GSD 7 FN G+ + + + +
4 126496 GSD 8 M G+ + - + +
5 125636 GSD 9 M G+ + + + +
6 129449 GSD 9 M G+ + - - +
7 126403 GSD 12 F G+ + + + +
8 126063 GSD 9 M G+ - - - +
9 126126 GSD 8 FN G+ + - - +
10 125880 GSD 10 F G+ - - - +
11 129769 GSD 10 F G+ + + + +
12 127432 GSD 8 M G+ + + - +
13 114803 GSD 8 FN G+ + + - +
14 129800 GSD 9 M G+ + + + +
15 129450 GSD 9 FN G+ + - - +
16 129527 GSD 9 F G+ + + +
Table la. Signalment for all dogs included in this project. (For key see page
44).
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A B C D E F G H I J
No. Case ID Breed Age
in
years
Sex CDRM
status:
G or R 
+ or -
3 4 5 6
17 126750 GSD 7 FN G+ + - - +
18 127398 GSD 8 M G+ + - - +
19 128951 GSD 9 M G+ + - + +
20 126497 GSD 9 M G+ + - - +
21 CDRM3 GSD 10 M G+ + - - +
22 129965 GSD 9 M G+ + + - +
23 CDRM4 GSD 9 M R+ - - - +
24 CDRM5 GSD 8 M R+ - - - +
25 CDRM6 GSD 7 F R+ - - - +
26 CDRM7 GSD 10 M R+ - - - +
27 CDRM8 GSD 9 F R+ - - - +
28 127996 GSD 11 M G+ + - - +
29 129644 GSD 9 M G+ + + - +
30 130538 GSD 8 M G+ + + - +
31 129966 GSD 9 M G+ + + + +
32 CDRM9 GSD 12 M R+ - - - +
33 130541 GSD 8 F G+ + + + +
Table lb. Signalment for all dogs included in this project. (For key see page
44).
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A B C D E F G H I J
No. Case ID Breed Age
in
years
Sex CDRM
status:
G or R  
+ or -
3 4 5 6
34 CDRM 10 GSD 10 MN R+ - 4- - +
35 CDRM 11 GSD 8 M R+ - - - +
36 127994 GSD 12 M G+ + - - +
37 CDRM 12 GSD 10 M G+ - - - +
38 CDRM 13 GSD 8 F R+ - - - +
39 129625 GSD 9 FN G+ + + - +
40 131739 GSD 12 FN G+ + + - +
41 132560 GSD 8 M G+ + 4- + +
42 CDRM 14 GSD 10 M R+ - - - +
43 132090 GSD 12 FN G+ + 4- - +
44 CDRM 15 GSD 12 M R+ - - - +
45 CDRM 16 GSD 8 F R+ - - - +
46 CDRM 17 GSD 6 M G+ - 4- + +
47 132913 GSD 8 M G+ + + + +
48 CDRM 18 GSD 8 F R+ - - - +
49 128291 GSDX 8 FN G+ + + + +
50 129057 GSDX 12 M G+ + - + +
51 130839 GSDX 8 M G+ + + - +
Table
44).
c. Signalment for a 1 dogs included in this project. (For key see page
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A B C D E F G H I J
No. Case ID Breed Age
in
years
Sex CDRM
status:
G or R  
+ or -
3 4 5 6
52 126755 GSD 9 M G+ - - - +
53 131613 GSD 8 M G+ + - + +
54 CDRM 19 GSD 8 M R+ - - - +
55 126541 GSDX 9 F G+ + - + +
56 CDRM20 GSD 8 M R+ - - - +
57 CDRM21 GSD 8 M R+ - - - +
58 129238 GSD 8 M G- - - - +
59 129237 GSD 8 M G- - - - +
60 GSD1 GSD 3 F G- - + - +
61 GSD2 GSD 3 FN G- - + - +
62 GSD3 GSD 12 F R- - - - +
63 128935 GSD 3 M G- - + - +
64 GSD4 GSD 9 M G- - + - +
65 GSD5 GSD 9 M G- - - - +
66 GSD6 GSD 13 FN G- - + - +
67 GSD7 GSD 9 F G- - + - +
68 GSD8 GSD 10 M R- - - - +
Table Id. Signalment for all dogs included in this project. (For key see page
44).
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A B C D E F G H I J
No. Case ID Breed Age
in
years
Sex CDRM
status:
G or R  
+ or -
3 4 5 6
69 GSD9 GSD 12 F R- - - - +
70 GSD 10 GSD 10 F R- - - - +
71 GSD 11 GSD 9 FN R- - - - +
72 GSD 12 GSD 9 FN G- - - - +
73 131707 GSD 11 M G- - + - +
74 GSD 13 GSD 9 MN G- - - - +
75 GSD14 GSD 10 MN G- - + - +
76 GSD 15 GSD 10 F R- - - - +
77 GSD 16 GSD 8 F R- - - - +
78 GSDX1 GSDX 8 FN G- - - - +
79 GSDX2 GSDX 12 M G- - + - +
80 GSD17 GSD 8 M G- - + - +
81 125920 GSDX 9 FN G- - + - +
82 GSD 18 GSD 11 F G- - - - +
83 Bob Lab. 9 M G- - + - +
84 Gean Lab. 3 FN G- - + - +
85 Zulu Lab. 10 M G- - + - +
Table le. Signalment for a 
44).
1 dogs included in this project. (For key see page
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A B C D E F G H I J
No. Case ID Breed Age
in
years
Sex CDRM
status:
G or R  
+ or -
3 4 5 6
86 Lewis Lab. 1 F G- - - - +
87 Aoifa DH 6 FN G- - - - +
88 Jack JR 10 M G- - + - +
89 Fanny JR 10 FN G- - + - +
90 Daz JR 2 M G- - + - +
91 Tanya BC 15 . FN G- - + - +
92 Megan BC 8 FN G- - - - +
93 Jenny Collie X 1 FN G- - - - +
94 Rudi Collie X 8 FN G- - + - +
95 Blackie Collie X 8 M G- - - - +
96 Bronwyn FCR 7 F G- - + - +
97 Rosco Lurcher 7 M G- - - - +
98 Brin Collie X 6 M G- - - - +
99 Brecon Sp Span 6 FN G- - + - +
100 Frankie Dob. 9 FN G- - - - +
101 Bengie Collie X 8 FN G- - + - +
102 Tess Collie X 3 FN G- + - +
Table If. Signalment for all dogs included in this project. (For key see page
44).
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A B C D E F G H I J
No. Case ID Breed Age
in
years
Sex CDRM
status:
G or R  
+ or -
3 4 5 6
103 Butch JRX 10 M G- - + - +
104 Sparky BeagleX 6 MN G- - + - +
105 Steffie Lab. 7 FN G- - + - +
106 Cassidy JRX 8 M G- - + - +
107 130595 Collie X 7 M G- - + - +
108 Smudge Collie X 8 FN G- - + - +
109 129528 Dob. 7 M G- - + - +
1 1 0 130650 CKCS 2 F G- - - - +
111 130660 Ger. P. 4.5 M G- - - + +
1 1 2 130686 Collie X 2 M G- - + - +
113 130623 Sp Span 0 . 6 M G- - + - +
114 130675 DH 2 F G- - + - +
115 129709 Newf. 5 M G- - - - +
116 129675 GSD 5 M G- - + - +
117 130601 Cl. Span 6 M G- - + - +
118 131992 Collie X 11 FN G- - - + +
119 131910 GSD 6 F G- - + - +
Table lg . Signalment for a 
44).
1 dogs included in this project. (For key see page
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A B C D E F G H I J
No. Case ID Breed Age
in
years
Sex CDRM
status:
G or R 
+ or -
3 4 5 6
1 2 0 131737 Lurcher 6 M G- - - - +
121 CDRM22 GSD 7 M G+ - + - -
1 2 2 CDRM23 GSD 8 M G+ + + + -
123 131870 GSD 10 M G+ + + - -
124 CDRM24 GSD 7 M G+ - + - -
125 133198 GSD 8 M G+ - + - -
126 CDRM25 GSD 10 M R+ - + - -
127 130884 GSD 10 M G+ - + - -
128 130417 GSD 11 M G+ + + - -
129 131167 GSD 7 M G+ + + + -
130 119643 G. Ret. 7 M G- - + - -
131 Roz GSDX 2 FN G- - + - -
132 Iris Sp.
Span
2 FN G-
'
+
133 GSD19 GSD 8 M G- - + - -
134 GSD20 GSD 3 M G- - + - -
135 Fergus GSD 4.5 M G- - + -
Table lh. Signalment for all dogs included in this project. (For key see page
44).
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A B C D E F G H I J
No. Case ID Breed Age
in
years
Sex CDRM
status:
G or R 
+ or -
3 4 5 6
136 GSD22 GSD 3 M G- - + - -
137 GSD23 GSD 3 M G- - + - -
138 Hamish GSD 7.5 M G- - + - -
139 Spot GSD 4.5 F G- - + - -
140 126400 GSD 7.5 M G- - + - -
141 Fudge Lab. 8 FN G- - + - -
142 Jake Collie X 9 MN G- - + - -
143 120407 GSD 8 M G+ + - - -
144 124705 GSD 7 F G+ + - + -
145 129203 GSD 12 F G+ + - - -
146 CDRM1 GSD 10 M G+ + - + -
147 CDRM2 GSD 10 M G+ + - + -
148 127660 GSD 8 M G+ + - - -
149 129305 GSD 9 FN G+ + - - -
150 129415 GSD 12 F G+ + - - -
151 132623 GSD 10 M G+ + - - -
152 126583 GSD 9 M G+ + - - -
Table li. Signalment for all dogs included in this project. (For key see page
44).
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A B C D E F G H I J
No. Case ID Breed Age
in
years
Sex CDRM
status:
G or R 
+ or -
3 4 5 6
153 125737 GSD 10 M G+ + - - -
154 125157 GSD 9 F G+ + - - -
155 124365 GSD 8 M G+ + - - -
156 125462 GSD 8 M G+ + - - -
157 132146 GSD 10 FN G+ + - - -
158 125110 GSD 9 M G+ + - - -
159 125777 GSD 9 F G+ + - - -
160 124625 GSD 10 FN G+ + ' - + -
161 123913 GSD 13 M G+ + - - -
162 128040 GSD 12 M G+ + - - -
163 125570 GSD 9 MN G+ + - + -
164 126131 GSD 7 M G+ + - + -
165 127470 GSDX 9 FN G+ + - - -
166 126348 GSD 9 M G+ + - - -
167 127150 GSDX 10 MN G+ + - + -
168 125545 GSD 7 FN G+ + - - -
169 129664 GSD 7 FN G- - - +
•
Table lj. Signalment for al
44).
dogs included in this project. (For key see page
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A B C D E F G H I J
No. Case ID Breed Age
in
years
Sex CDRM
status:
G or R  
+ or -
3 4 5 6
170 125731 Lab. 7 M G- - - + -
171 130383 A. Kar. 8 F G- - - + -
172 130122 Gt Dane 0.58 F G- - - + -
173 130401 Scot Ter 2 M G- - - + -
174 129178 B. Terr. 6 M G- - - + -
175 129950 Eng. P. 5 M G- - - + -
176 130095 Lab. 9.5 M G- - - + -
177 129428 B. Coll. 5 M G- - - + -
178 129790 Gt Dane 0 . 6 6 F G- - - + -
179 129454 DobX 7 FN G- - - + -
180 129481 GSD 9 F G+ - - + -
181 129611 GSD 8 F G- - + - -
182 127761 GSD 3 M G- - - + -
183 128904 BMD 6.5 F G- - - + -
184 129039 Dob. 9 M G- - - + -
Table lk. Signalment for all dogs included in this project. (For key see page 
44).
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A B C D E F G H I J
No. Case ID Breed Age
in
years
Sex CDRM
status:
G or R 
+ or -
3 4 5 6
185 129329 FCR 8 FN G- - - + -
186 129365 Lab. 9 M G- - - + -
187 116796 GSD 5.5 M G- - - + -
Table 11. Signalment for all dogs included in this project. CDRM status is 
given in column F as follows: “G” indicates diagnosis made a t GUVS, “R ” 
indicates diagnosis made in referral practice by G ary Clayton-Jones following 
fu rther investigations as appropriate (e.g. survey radiography of the spine, 
myelography, EMG) “+” dog has CDRM and dog has no evidence of 
CDRM. Columns G, H, I and J  list the dogs included in results chapters 3, 4, 5 
and 6  respectively. In column C the following abbreviations were used: 
Germ an shepherd dog (GSD), L abrador (Lab.), Deer hound (DH), Jack  Russell 
te rrie r (JR), Border collie (BC), Flat coat retriever (FCR), Springer spaniel (Sp 
Span), Doberman pinscher (Dob.), Cavalier King Charles spaniel (CKCS), 
Germ an pointer (Ger. P.), Newfoundland (Newf.), C lum ber spaniel (Cl. Span), 
Golden retriever (G. Ret.), Anatolian karabash (A. Kar.), G reat Dane (Gt 
Dane), Bernese mountain dog (BMD), Scottish terrier (Scot. Ter). The suffix X 
denotes a crossbreed.
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2.2.1 Ancillary investigations
In many cases the owners were unwilling to permit further investigations in order to 
rule out other differential diagnoses. In these cases, a typical history and clinical 
signs suggestive of CDRM in association with multiple re-examinations were 
necessary before the dogs were included in the study.
In several cases where it was thought likely that CDRM was not the problem, 
further diagnostic procedures were performed.
Routine biochemical and haematological evaluations were performed on thirty cases 
to investigate the possibility of systemic disease or to evaluate general health prior 
to anaesthesia. Plasma concentrations of urea, creatinine, sodium, potassium, 
chloride, calcium, phosphate, glucose, cholesterol, bilirubin, alkaline phosphatase, 
alanine transferase (ALT), aspartate transferase (AST), total protein, creatine kinase, 
albumin and globulin were analysed. Red blood cell count, haematocrit, 
haemoglobin concentration, mean corpuscular volume, mean cell haemoglobin, 
platelet count and total and differential white blood cell count were determined. 
Results of these tests were compared with reference ranges for University of 
Glasgow Veterinary School (GUVS) laboratories.
Radiographic, myelographic and electromyographic (EMG) examinations as well as 
cerebrospinal fluid (CSF) sampling were carried out under general inhalation 
anaesthesia. The precise anaesthetic regime depended on the procedure and 
individual patient requirements.
Survey radiography of the thoracolumbar spine and hips was performed as 
appropriate. Myelography was carried out in eight cases and involved injection of 
0.3 ml/kg Iopamidol (Niopalm 300mg iodine/ml, Merck Pharmaceuticals) into the 
cistema magna using the same protocol as described for CSF sampling. CSF 
samples were obtained from either the cerebellomedullary or lumbar cistern or both. 
The relevant collection site was clipped up and aseptically prepared. Cistema 
magna samples were collected using a 21 gauge 1.5 inch hypodermic needle. The 
technique used is described by Evans [Method 1] (1995). Lumbar samples, where 
appropriate, were obtained via the L5/L6 interarcuate space as described by Lewis 
(1991) using a 20 guage 3.5 inch spinal needle (Monoject 220 Spinal Needle, 
Sherwood Medical Industries, St. Louis, U.S.A.). Samples were examined for 
colour, consistency and turbidity. The cell count and total protein concentration 
were determined and compared to reference values given by Bailey and Higgins 
(1985). In cases where the count exceeded five cells/pl in the cisterna magna or 
eight cells/p.1 in the lumbar cistern, a differential count was determined following
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cytospin. A number of cases underwent electrophysiological examination using a 
Neuromatic 2000M electromyograph (Dantec Electronic, Denmark) and recordings 
of spontaneous and evoked muscle action potentials were made. Dogs were laid in 
lateral recumbency following general anaesthesia. EMG was performed using a 
concentric bipolar needle electrode as described by Bowen (1987). Pelvic limb 
muscles, in particular those demonstrating muscle atrophy or decreased muscle tone, 
were assessed for any abnormal electrical activity. EMG studies were carried out in 
seven cases.
From the history, clinical findings and lack of abnormalities found at further 
investigation, a tentative diagnosis of CDRM was made. Cases were monitored on 
a regular basis throughout the course of their disease and, with the owners’ 
permission, a post mortem examination was performed following euthanasia.
2.2.2 Gait scoring system
A scoring system was devised to allow a more objective assessment o f the 
progression of disease. This involved assessment of gait analysis at each 
examination.
Analysis of Gait
Gait Score Gait Analysis
0 Normal
1 Occasionally scuff hind feet when 
circling or on stairs
2 Scuff dorsi (hind feet) at slow pace and 
on stairs. Cross pelvic limbs on circling.
3 Circling very difficult, may fall over.
4 Collapse to one side when moving in a 
straight line.
5 Loss of useful pelvic limb function, able 
to pull along with thoracic limbs.
6 Loss of useful pelvic limb and thoracic 
limb function
Table 2. Gait scoring analysis.
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2.2.3 Collection of samples
Affected dogs were examined in the GUYS clinic every two to three months. At 
each visit a number of blood samples were collected. On the first visit to the clinic, 
routine haematology and biochemistry screens were carried out, in 30 of the dogs, to 
check for any intercurrent diseases. These were processed by the relevant 
laboratories at GUVS and compared with normal values for these laboratories. A 
2 0 ml jugular sample was collected; five ml was collected into a plain tube, and 
allowed to clot at room temperature for 30 to 60 minutes before undergoing a 1400g 
spin in a Beckman GP centrifuge for 15 minutes at room temperature. The serum 
was carefully removed using a one ml pipetteman and divided and stored in 1.5 ml 
eppendorf vials at -70°C. This was used to measure serum vitamin E levels, see
2.2.3.1 Measurement of serum vitamin E (page 47).
A further 10ml was collected into EDTA(K2), and stored at either 4°C for genomic 
DNA (gDNA) extraction within five days, otherwise at -20°C. The procedure used 
for routine gDNA extraction was influenced by the potential downstream 
application of Southern analysis and the Repeat Expansion Detection (RED) 
technique, with their requirements for reproducibility and high quality. A number 
of commercially available kits were assessed. These kits are marketed primarily as 
offering high quality gDNA from procedures with reduced manipulations (saving on 
time) and increased safety by removing the need for phenol-chloroform extraction. 
The various kits selected were based on different principles. In all cases 
contaminating RNA was removed with RNAse A treatment (see 8.5.1 RNase A, 
page 215) the details of which varied between protocols. The Nucleon II kit 
(Scotlab) was chosen as being the most suitable for the purposes of this project.
2.2.3.1 M easurem ent of serum vitamin E
Samples were sent to the Scottish Agricultural College (SAC) at Auchincruive 
where the serum vitamin E levels were measured using the serum a-tocopherol 
High Performance Liquid Chromatography (HPLC) method. Vitamin E standard 
(Kodak Chemical Co. Liverpool) 2(ig/ml in 0.5ml ethanol and internal standard 
(100fj.l o f 2.5(xg/ml tocol in ethanol) were diluted with 0.5ml distilled water. 0.5ml 
serum samples and internal standard (as above) were precipitated with 0.5ml 
ethanol. The vitamin E was extracted from samples and standards into 2.5ml 
hexane by vigorous mixing followed by centrifugation at 1500rpm for 5 minutes. 
As much as possible of the hexane layer was taken off and dried on a Dri-block 
heater under oxygen free nitrogen (BOC gases) at 50°C and then redissolved in 
300p.l methanol (BDH) before transfer to autosampler vials for vitamin E 
determination. Separation of the end products was achieved by HPLC, using a
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15cm by 4mm i.d. Superspher 4|im RP18 column with a Lichrocart 4-4 guard 
column. Degassed methanol .water 98:2 was used as eluent, flowing at 1.5ml/min 
from a Spectra Physics SP8770 isocratic pump. A Gilson 232 Bio autosampler was 
used to inject 1 IO jlx I through the 20pl loop the contents of which were then flushed 
onto the column. Detection was achieved using a Jasco 821-FP fluorimeter with 
296nm excitation and 330nm emission wavelengths. Results were collected and 
integrated using a Spectra Physics Chromjet integrator. Retention times for tocol 
and vitamin E were about three and five minutes respectively. The concentration of 
a-tocopherol is calculated by comparison to an a-tocopherol standard curve (using 
peak areas).
2.3 TISSUE FIXATION AND PROCESSING
2.4 Fixation
Preparation of all fixatives, buffers, stains etc. are given in 8 Appendix (page 201), 
specific page numbers being given in the heading.
2.5 Fixatives
2.5.1 Buffered neutral formaldehyde, 4% (BNF) (page 202)
This was used for the preservation of tissues used for embedding in paraffin wax.
2.5.2 Karnovsky's modified fixative 
(paraformaldehyde/glutaraldehyde 4%/5%) (page 202)
This was used for the preservation of tissue destined for embedding in Araldite 
resin.
2.6 Techniques
Brain and spinal cord were removed by the routine procedure used in the post 
mortem room at GUVS. During removal of the spinal cord both the dorsal and 
ventral aspects of the vertebral canal were examined for the presence of lesions 
which could potentially have caused spinal cord compression.
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2.6.1 Immersion
Brain, spinal cord and body tissues were immersion-fixed in 4% BNF for a 
minimum of 24 hours. Spinal cords were suspended and weighted to prevent 
curling during fixation. Brains were cut transversely at the level o f the optic 
chiasma to ensure adequate fixation throughout the tissue. The following body 
tissues were collected from ten of the CDRM cases post mortemed; stomach, 
duodenum, jejunum, caecum, ileum, colon, thyroid gland, adrenal gland, pancreas, 
kidney, liver, spleen as well as optic nerve, sciatic nerve, stellate ganglion and 
cranial mesenteric ganglion.
2.6.2 Intra-aortic perfusion
Tissues required for electron microscopy were perfusion-fixed in Kamovsky's 
modified fixative. All perfusions were carried out in a suitably designated room, the 
solutions were administered by gravity. Euthanasia was carried out by intravenous 
injection with 20ml of pentobarbitone sodium (Euthatal) (Rhone Merieux Ltd.). 
This was followed immediately by 10ml of heparin (Heparin injection BP) (Leo 
Laboratories Ltd.) to prevent clotting. The dog was lifted onto the table in right 
lateral recumbency. The left chest wall was removed to allow access to the dorsal 
aorta. A small incision was made into the aorta and a rubber tube inserted and tied 
in position. A cut was made in the right auricle to allow the blood to escape. The 
vascular system was initially flushed with five litres o f 0.85% saline, followed by 
eight litres o f Kamovsky's modified fixative. The flow rate for these fluids was 13 
litres per hour. The head of pressure was two metres.
2.7 Processing
2.7.1 Paraffin processing
Tissues for paraffin wax embedding were processed using one of two Shandon 
Elliot automatic tissue processors (Histokinettes). Spinal cord and body tissues 
were processed in the 24 hour histokinette while brain was processed in the seven 
day histokinette. For processing protocol see page 204.
All tissues were subsequently embedded in paraffin wax (Merck) at 60°C.
2.7.2 Resin processing
Samples were processed using a Lynx el microscopy tissue processor (Leica) for 
embedding in Araldite resin (page 205).
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2.7.3 Sections
2.7.3.1 Paraffin-embedded tissue
Paraffin-embedded tissue sections were cut on a Biocut 2035 microtome (Leica) at 
eight Jim for routine histology and six pm for immunocytochemistry, mounted onto 
APES-coated microscope slides and allowed to dry overnight in a 60°C oven.
2.13.2  Preparation of APES coated slides
Cleaned slides were coated with 3-aminopropyltriethoxy-silane (APES) (Sigma). 
Slides were washed overnight in the detergent Decon 90 (5%) (Decon Lab Ltd) to 
remove grease, washed well in distilled water (DW) and oven dried wrapped in foil. 
Slides were soaked, in a fiimehood, in 0.25% APES in methylated spirits for 2mins 
followed by 0.01% DEPC SDW for 2mins prior to oven drying wrapped in foil. 
Slides were stored at room temperature.
2 .1 3 3  Resin sections
Sections for light microscopy were cut at one pm on an Ultracut E ultratome 
(Reichert-Jung) and mounted on sulphuric acid-washed slides.
2.7.3.4 Ultra-thin sections
Sections for electron microscopy were cut at approximately 70nm (ultratome as 
above) and mounted on 2 0 0  mesh-3.06mm diameter copper grids.
2.7.4 Staining Techniques
2.7.4.1 Light microscopy
2.7.4.1.1 Routine stains
2.7.4.1.1.1 Haematoxylin and eosin (H&E)
Sections from paraffin blocks were stained routinely with H&E for routine 
assessment of tissue morphology. Details o f the technique are given on page 206. 
Sections were mounted in DPX mountant (BDH).
2.7.4.1.1.2 Haematoxylin
A number of immunocytochemistry sections were counterstained using 
haematoxylin to identify cell nuclei. Details o f the technique are given on page 207. 
Sections were then dehydrated and mounted as for H&E staining.
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2.7.4.1.1.3 Cresyl violet (CV)
Brain and spinal cord sections from paraffin blocks were stained with cresyl violet 
to demonstrate Nissl substance. Details of the technique are given on page 207. 
Sections were dehydrated and mounted as for H&E staining.
2.7.4.1.1.4 Congo Red
Sections of red nucleus from paraffin blocks were stained with Congo Red to 
investigate whether or not amyloid was present. Details of the technique are given 
on page 208. Sections were dehydrated and mounted as for H&E staining.
2.7.4.1.1.5 Methylene blue/azur II
Resin sections were stained routinely with methylene blue/azur II (see page 210) to 
demonstrate myelin. Slides were heated on a hot plate to 60°C, flooded with stain 
for 10-30 seconds then rinsed in running tap water. They were dried overnight on 
the hot plate and mounted in DPX (BDH).
2.7.4.1.2 Immunocytochemistry
2.7.4.1.3 Peroxidase anti-peroxidase (PAP) technique
The peroxidase anti-peroxidase technique was carried out on six pm paraffin- 
embedded sections. The primary antibodies, sources, dilutions and links are 
summarised in Table 3, page 54. Sections were initially hydrated, endogenous 
peroxidase activity was quenched by immersing slides in 3% hydrogen peroxidase 
(in absolute alcohol) for 30 minutes followed by washing in running water for 30 
minutes. Non-specific binding was blocked by incubation in 10% normal goat 
serum (NGS) in PBS for two hours at room temperature. Sections were incubated 
in the primary antibody in 1% NGS in PBS overnight in a humidifying chamber at 
4°C.
Sections were adjusted to room temperature then washed for 30 minutes in six 
changes of PBS. The secondary antibody (link) in 1% NGS in PBS at room 
temperature was applied to the sections and left one hour. Excess antibody was 
removed by washing in PBS for 30 minutes (as before) before incubating sections in 
the PAP complex diluted in 1% NGS in PBS, for 30 minutes at room temperature. 
Again, excess was removed by serial washes in PBS over 30 minutes. The 
chromogen was developed in filtered 0.1M phosphate buffer (pH 7.3) containing 
0.5mg/ml 3,4,3',4',-tetraminobiphenyl hydrochloride (DAB) and 0.003% hydrogen 
peroxide until the required colour intensity had been achieved (up to five minutes).
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Sections were washed in running water, or counterstained in haematoxylin, 
dehydrated and mounted in DPX.
2.7.4.1.4 ABC technique
The ABC technique bore some resemblance to the PAP technique but differed in 
that the secondary antibody was biotinylated and the colour reaction used a 
preformed avidin and biotinylated horseradish peroxidase macromolecular complex 
called Vectastain (Vectastain Elite ABC Kit, Vector Laboratories). The primary 
antibodies, sources, target antigens, and range of dilutions are summarised in Table 
4, page 55.
Paraffin-embedded sections were initially dewaxed in histoclear and hydrated by 
passage through graded alcohols before being rinsed for five minutes in water. 
Quenching of endogenous peroxidase activity involved incubation in 3% hydrogen 
peroxide in ethanol at room temperature followed by washing in PBS for 20 
minutes. Sections were incubated for two hours with 10% NGS blocking serum. 
Excess serum was removed by blotting. Sections were incubated overnight at 4°C 
with the primary antiserum diluted in 1% NGS in PBS. Sections were allowed to 
reach room temperature and washed in PBS for 10 minutes.
Sections were incubated for 30 minutes with diluted biotinylated secondary 
antibody solution before being washed for 10 minutes in PBS. The chromogen was 
applied i.e. Vectastain Elite ABC reagent (for details see page 209) and sections 
incubated for 30 minutes. Excess was then removed by a 10 minute wash in PBS. 
Sections were incubated in peroxidase substrate solution until the desired staining 
intensity had developed.
Negative controls used non-immune mouse and rabbit sera, as appropriate, in lieu of 
primary antibodies.
2.7.4.1.5 Immunofluorescence
Immunofluorescence double staining was carried out on paraffin-embedded sections 
of spinal cord. The primary antibodies, dilutions, sources and secondary antibodies 
used are summarised in Table 5, page 56. Sections were initially dewaxed and 
hydrated, washed briefly in PBS before incubation with the two primary antibodies 
(these were made up at double strength in 1% NGS in PBS, then added 
simultaneously) overnight at 4°C in a humidifying chamber. Sections were adjusted 
to room temperature and washed three times in PBS.
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Detection involved addition of the relevant fluorochrome-labelled secondary 
antibodies (made up at double strength in PBS then both added together as before) 
which were left at room temperature for 30 minutes. Sections were washed in water 
for 20 minutes before being wet-mounted in Citifluor antifade mountant (page 209). 
Sections were stored at 4°C in a lightproof box if immediate photography was not 
possible.
2.7.4.2 Electron microscopy
Blocks of tissue were processed for embedding in Araldite resin (see 2.7.2 Resin 
processing, page 49). Sections for light microscopy were cut at one pm on a 
Reichert-Jung Ultracut E ultratome, then stained with methylene blue/azur II (page 
210). Thin sections for electron microscopy were cut at 70nm and placed on 200 
mesh copper grids. Grids were stained with uranyl acetate and lead citrate (page 
210).
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Materials and methods
2.8 Molecular Genetics Techniques
All solutions were prepared and sterilised as appropriate. Bulk solutions were 
autoclaved while small volumes and fluids which were unsuitable for autoclaving 
were filter sterilised using a Flowpore 0.45pm filter (Biomedicals Ltd.).
2.8.1 Genomic DNA (gDNA) extraction
2.8.1.1 gDNA extraction from blood
Blood was collected into 5ml EDTA(K2) tubes as detailed previously. Subsequent 
storage was at 4°C if the DNA was to be extracted within five days o f collection, 
otherwise at -20°C. The Nucleon II Kit (Scotlab) was used to extract gDNA from 
blood. This technique was based on the principle o f separating DNA from cell 
impurities using the proprietary resin Nucleon®. Expected yield from five ml of 
blood was 150-220pg gDNA.
Blood samples at room temperature were transferred into sterile 40ml polypropylene 
centrifuge tubes. Nucleon II cell lysis solution, 30ml, (details on page 215) was 
added to each. The tubes were rotated at room temperature for four minutes then 
spun in a Beckman J2-21M/E centrifuge for four minutes at 4000rpm. The 
supernatant was poured off carefully leaving the cell pellet. Two ml of Nucleon II 
washing solution (for details see page 215) was added to the cell pellet and vortexed 
to resuspend the cells. The suspension was transferred to a 15ml chloroform- 
resistant Falcon tube, 15 pi of a 50pg/ml RNase A solution was added and incubated 
at 37°C for 30 minutes. Deproteinisation involved the addition of sodium 
perchlorate to a final concentration of 1.25M, a 15 minute rotary mix at room 
temperature, followed by a 25 minute incubation in a 65°C shaking water bath.
Two ml of cold chloroform was added to each tube. The tubes were rotary-mixed 
for 10 minutes before centrifugation at 857g (Labofuge 400, Heraeus) for one 
minute. Without disturbing the separate layers, 300pl o f Nucleon silica suspension 
were added to each tube before a further spin, at 1400g, was carried out for three 
minutes. At this stage any gDNA is above the silica suspension layer. This top 
layer was transferred into a fresh Falcon tube. Some of the silica was inevitably 
transferred, this was removed by a four minute spin at 1300g, and transferred to a 
fresh tube. Two equal volumes of cold absolute alcohol were added to the aqueous 
phase. Gentle inversion of the tubes resulted in precipitation of the gDNA. gDNA 
pelleted by spinning for 5 minutes at 4000g was washed in 70% alcohol. The 
gDNA was allowed to air dry before resuspension in an appropriate volume of TE 
buffer, pH 8.0.
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2.8.1.2 gDNA extraction from tissues
Tissues were snap frozen and stored in liquid nitrogen.
a) small scale gDNA extraction from tissues
gDNA was extracted using the QIAamp® Tissue Kit (Qiagen), which involved 
using an ion exchange resin which selectively binds gDNA. gDNA can be washed 
from the column and concentrated by ethanol precipitation. An RNase A step was 
included. The yield of gDNA was dependent on the tissue type used, 25mg of brain 
or liver should yield 15 to 30 jig gDNA; lOmg of spleen should yield five to 30pg 
gDNA.
b) large scale gDNA extraction from brain
This technique was applied for the extraction of gDNA from 200 mg to one g 
samples of brain. The tissue was weighed, then crushed in a mortar and pestle in the 
presence of liquid nitrogen. The powdered tissue was suspended in 1.2ml of 
digestion buffer (for details see page 215). This mixture was incubated at 50°C for 
12 to 18 hours. Once the samples were viscous, any RNA was removed by the 
addition of 0.1% SDS and one pg/ml DNase-free RNase A (for details see page 
215) and incubation at 37°C for one hour. Deproteinisation of nucleic acids was 
performed using phenol:chloroform:isoamyl alcohol (25:24;1) (Sigma) extraction. 
An equal volume of phenol : chloroform was added to the nucleic acid sample in a 
polypropylene tube with a tight fitting lid. The contents were mixed until an 
emulsion formed, this was centrifuged at 12000g for 15 minutes at room 
temperature. The phases separated and the aqueous phase containing the gDNA 
was transferred to a clean tube. This organic extraction step was repeated until there 
was no longer a white precipitate at the interface. Purification of the gDNA was 
carried out by ethanol precipitation. gDNA was precipitated routinely in the 
presence of 0.3M sodium acetate (NaAc), pH 5.2, and three volumes of ice cold 
ethanol. Amounts less than one pg were precipitated overnight at -70°C. Larger 
amounts were precipitated either at -70°C for at least an hour, or -20°C for at least 
two hours. Samples were centrifuged at 4°C for 15 to 30 minutes at 13000rpm and 
the supernatant removed. The gDNA pellet was washed with 70% ethanol and 
centrifuged at 4°C for 5 minutes at 13000rpm. The pellet was air dried for up to 10 
minutes before reconstitution in the appropriate volume of TE buffer (for details see 
page 211). Expected yield from this technique was approximately two mg DNA per 
one g of tissue.
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2.8.2 Genomic DNA assessment
2.8.2.1 Quantity
gDNA samples were quantitatively assessed by spectrophotometry (Genequant 
Spectrophotometer, Pharmacia Biotech). Working concentrations were a mean of 
two readings, o f different dilutions, the results of which had to be within 1 0 % of 
each other. The concentrations of small quantities o f DNA were estimated by gel 
analysis, against varying aliquots o f an appropriate sample of known concentration.
2.8.2.2 Quality
The integrity of the gDNA was assessed qualitatively by electrophoresis on a 0.8% 
agarose mini-gel (for details see 2.8.3 Nucleic acid electrophoresis, page 59). This 
was followed by a check on the digestibility o f the gDNA. One pg samples were set 
up in three conditions, one digestion at 37°C in the presence of 30 units o f a six- 
cutter enzyme for two hours, a second incubated at room temperature for the same 
length of time and a third incubated at 37°C without the enzyme (Figure 2, page 60).
2.8.3 Nucleic acid electrophoresis
2.8.3.1 Agarose gels
Routine electrophoresis of DNA was performed using 0.7 to 2% regular agarose 
gels of ultra-pure electrophoresis-grade agarose (Gibco BRL). Gels were cast by 
melting the agarose in the presence of Tris acetate EDTA buffer (TAE) (0.04M Tris 
acetate, 0.001M EDTA), and were run in the same buffer. The gel was cooled to 
60°C and ethidium bromide was added to a final concentration of 0.5pg/ml. 
Samples were loaded with a suitable amount of a 6 x gel loading buffer ( lx  TAE; 
30% glycerol (Sigma); 0.25% bromophenol blue (BDH Chemicals Ltd.); 0.25% 
xylene cyanol FF (Sigma). Gels were viewed using a “Fotoprep I” ultraviolet 
transilluminator (Fotodyne Inc.) and photographed using a Polaroid MP4 land 
camera (Polaroid), a T2201 transilluminator (Sigma), a Wratten 22A filter (Kodak) 
and Polaroid 665 (ASA 80) film.
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1 2 3 4  5 6  7 8 9 10 11 12 13 14 15 16
M
23kb
Figure 2. Assessment of the quality of gDNA extracted from fresh (lanes 1-6 
and 8-13) and frozen (lanes 14-16) canine blood samples. Lanes 1, 4, 8 , 11, 14 
gDNA incubated at room tem perature; lanes 2, 5, 9, 12, 15 incubated at 37°C in 
the presence of buffer and the absence of enzyme; lanes 3, 6 , 10, 13, 16 Ecu RI 
digest at 37°C; lane 7 X Hind III m arker.
60
Materials and methods
2.8.4 Amplification of specific genomic regions harbouring the CAG 
repeats by PCR
Primer pairs were obtained from Cruachem (Table 6 , page 61).
PCR
Product
Forward primer Reverse primer Product 
length (bp)
ataxin- 1 5/CAACATGGGCAGTC 
TAGAG 31
5/AACTGGAAATGTGG 
ACGT 3!
214
atrophin-1 5/CACC AGTCTCAACA 
CATCACCATC 3>
5/CCTCCAGTGGGTGG 
GGAAATGCTC 3/
140
Table 6. PCR primer pairs for amplification of specific genomic regions that 
have been demonstrated to harbour CAG repeats in man (See 6.2.2 
Neurodegenerative conditions resulting from CAG repeat expansions, page 
164).
All amplifications were carried out on a Perkin Elmer DNA thermal cycler. 
Reactions were carried out in 50pl volumes in 0.5|il eppendorfs overlaid with 50|il 
of molecular biology grade mineral oil (Sigma), to prevent evaporation. Reactions 
contained lOOng of target gDNA, 0.2mM dNTP's, 0.3pM of the forward and 
reverse primers, 1.5 to 5mM magnesium chloride as appropriate, 2% formamide if 
necessary, and in the presence of 2.5U Taq polymerase (Bioline) and ammonium 
buffer (Bioline) (20mM Tris HC1 pH 8.0, lOOmM KC1, 0.1 mM EDTA, ImM DTT, 
50% Glycerol, 0.5% Tween-20). Thirty nine cycles were used for all primer pairs. 
An initial denaturation step at 94°C for one minute 30 seconds was followed by 38 
cycles of annealing at 60°C (dependent on primer pair in use) for 45 seconds, 
extension at 72°C for one minute and denaturation at 94°C for 45 seconds. The 
final cycle consisted of an annealing step at 55°C for one minute and an extended 
extension step at 72°C for five minutes, followed by a 4°C soak cycle.
2.8.5 Southern blotting
2.8.5.1 DNA radiolabelling
Random primed 32P labelled DNA probes were generated from the DM 200 cloned 
PCR product which was comprised of -100 base pairs of human flanking DNA and 
200 CTG repeats from the human Myotonic Dystrophy locus (DM) using the “High 
prime” labelling kit (Boehringer Mannheim). This was an optimised mixture of 
random hexamers, dNTPs and Klenow enzyme in 5x buffer containing 0.5M Tris
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HC1 (pH 7.5), 0.1M MgCl2 , and glycerol. The kit was optimised for use with 32P a 
dCTP.
30ng of fragment in a final volume of 11 pi o f SDW was denatured in a boiling 
water bath for 10 minutes then quenched on ice. This was used as template in a 
20pi reaction containing four pi “High Prime” solution and five pi (50pCi) 32P a  
dCTP, 3000Ci/mMol, aqueous solution. These were mixed thoroughly and 
incubated at 37°C for 10 minutes. The reaction was stopped in the presence of 
lOmM EDTA and incubated at 65°C for 10 minutes.
2.8.5.2 Removal of un-incorporated nucleotides
Un-incorporated nucleotides were removed by passage of the labelled mixture 
through a Nick column (Pharmacia Biotech) which contain Sephadex® G-50 beads 
and allowed rapid purification of labelled DNA (20 base pairs and larger) from 
unincorporated radiolabelled nucleotides by size exclusion chromatography. The 
eluted labelled DNA fragment was stored at -20°C until use. Routine specific 
activities were 7-9x 108 cpm/pg DNA.
2.8.5.3 Restriction enzyme digestions
Restriction enzymes were supplied by Gibco BRL, Promega and New England 
Biolabs and used according to manufacturers’ instructions. The following 
restriction enzymes were used in combination:
Digest Restriction Enzymes
i) Hind III + Bam HI
2 ) Hae III + Hha I
3) Hae III + Hha I + Sou 3AI
4) Bam HI + Hind III + Hae III + Hha I + Sau 3AI
Table 7. Restriction enzymes used in creating restriction fragment profiles. 
2.8.5.4 Gel preparation
Digested DNA was run on agarose gels of 1.25 to 2% concentration, using a mid-gel 
system (Model H3-SET, Anachem) with a bed volume of 15 x 13 cms. Two DNA 
size markers were used as appropriate, X Hind III and 100 base pair DNA ladder. A 
photographic record was kept to aid interpretation of the autoradiograph. The size-
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separated gDNA fragments were denatured by soaking the gel in denaturing 
solution (0.5M NaOH/1.5M NaCl) in a covered plastic dish and shaking gently for 
30 minutes on a platform shaker. The gel was washed twice in distilled water, 
rinsed and shaken in neutralisation solution (1.5M NaCl/0.5M Tris pH 7.4) for 45 
minutes, twice, in order to lower the pH to below 9.0.
2.8.5.5 Transfer
DNA was transferred using a Model 785 vacuum blotter, liquid trap, vacuum 
regulator and pump (Biorad) for 90 minutes in lOxSSC with a pressure o f five in. 
Hg onto a nylon filter (Hybond-N, Amersham). After transfer, filters were washed 
in 2xSSC to remove any gel fragments before blotting dry on Whatman® filter 
paper. Nucleic acids were immobilised by UV crosslinking using an XLL 100 
(Spectronics Corporation).
2.8.5.6 Prehybridisation
Prehybridisation was carried out in a hybridisation oven rotisserie (Micro-4, 
Hybaid) using Rapidhyb buffer (Amersham). The volume of Rapidhyb depended 
on the size of bottle used, and varied from five ml for the small bottle, to 15ml for 
the large bottle. The oven, bottles and hybridisation buffer were preheated to 65°C. 
Prehybridisation was carried out for a minimum of two hours.
2.8.5.7 Hybridisation
Labelled probe was denatured for 10 mins at 95°C. The reaction was quenched on 
ice. Approximately two ng of heat-denatured labelled probe was added per one ml 
of Rapidhyb solution (Amersham). Initially, a one ml aliquot of the 
prehybridisation solution was removed from each bottle and the labelled probe 
added. This was returned to the bottle, ensuring even mixing of the probe. 
Hybridisation was carried out overnight at 65°C.
2.8.5.8 Washing
Washes were carried out in a shaking water bath at 65 °C. The first two washes 
were carried out in 2xSSC, 0.1% (w/v) SDS for 30 minutes. The third and fourth 
washes were carried out in O.lxSSC, 0.1% (w/v) SDS, for 30 minutes each wash. 
Reduction in background levels of probe was monitored using a mini-monitor, the 
stringency and length of washes were then altered as necessary.
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2.8.5.9 Autoradiography
Hybridised filters were allowed to air dry and placed in heat-sealed plastic bags. 
Autoradiography was performed using Cronex 10S X-ray film (Dupont) with Kodak 
“X-Omatic” regular intensifying screens for the appropriate times.
2.8.6 Repeat Expansion Detection (RED) technique
2.8.6.1 DNA radiolabelling
32P a  dCTP Redivue (Amersham) was used to radiolabel a (CAG)iq using terminal 
deoxynucleotidyl transferase which, in the presence of a divalent cation, catalysed 
the addition of dNTPs to the 3^-hydroxyl termini of DNA molecules. The reaction 
mixture contained one pg (CAG)io, 50pCi 32pa  dCTP, 15U TdT (GibcoBRL), five 
pi TdT buffer (xlO) which contained 0.5M potassium cacodylate (pH 7.2), lOmM 
C0 CI2 and one mM dithiothrietol (DTT) made up to 50pl with SDW. This was 
incubated at 37°C for one hour. The reaction was placed on ice and quenched by 
the addition o f EDTA to a final concentration of lOmM. Ethanol precipitation (see 
page 2.8.1 Genomic DNA (gDNA) extraction, page 57) was carried out with one 
adaptation, one pi of glycogen at 2 0 mg/ml was added to the reaction mixture to 
ensure pellet visibility. Specific activity levels of >1.4 x 107cpm/pg DNA were 
obtained.
2.8.6.2 Kinase reaction
Suitable quantities of fresh (CTG )n were phosphorylated immediately prior to each 
ligation. This involved the addition of 50ng (CTG)i7 , three U T4 polynucleotide 
kinase (PNK) (New England Biolabs) in the presence of 50mM dATP, lOxPNK 
buffer (70mM Tris HC1, lOmM MgCl2 , 5mM DTT pH 7.6), were adjusted to five pi 
with SDW for each downstream reaction. The mixture was incubated at 37°C for 
one hour.
2.8.6.3 Ligation
The ligation reaction was carried out in two steps. Ten pg of target gDNA was 
added to 500ng of the phosphorylated CTG17 and 2pl SDW to give a reaction 
volume of 17pl in a 0.5ml eppendorf. This reaction mixture was incubated for 5 
minutes at 95°C before the addition of 5U Ampligase (Epicentre Taq Ligase, UK 
supplier; Cambio) and 2pl of lOx Ampligase buffer containing 50mM Tris-HCl (pH 
7.5), lOOmM NaCl, O.lmM EDTA, 0.1% Triton® X-100 and ImM dithiothreitol 
(DTT). Reagents were then overlaid with 20pl mineral oil (Sigma).
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Positive internal controls were supplied by using mouse gDNA (Jackson Labs., 
Maine). The strain used was 690 129J which had been cut with Hind III and was 
known to result in a suitable ladder.
2.8.6.4 Thermocycling conditions
The annealing and ligation steps were carried out in a Perkin Elmer DNA Thermal 
cycler. An initial denaturation of the phosphorylated (CTG)i7 and target DNA was 
carried out at 94°C for five minutes before the addition of the Ampligase and 
Ampligase lOx buffer. This was followed by 396 cycles o f a two-temperature 
cycling protocol with ten seconds at 94°C followed by 30 seconds at 70°C. The 
Ampligase enzyme and buffer were replenished after 99 cycles.
The product was extracted from under the mineral oil by direct removal o f the lower 
aqueous layer.
2.8.6.5 Gel preparation
Resolution of ligation products was achieved by preparing a 6% denaturing 
polyacrylamide gel containing 6 M urea in a buffer of lOOmM Tris borate, (pH 8 ) 
one mM EDTA for two hours 30 minutes at 1500V constant voltage at 50°C. This 
was performed on a sequencing gel rig (Model V4-II, Anachem). A gel measuring 
15cm by 40cm and 0.4mm thick was prepared as follows; preprepared 40% bis- 
acrylamide was stored at 4°C (for details see page 8.6.2 Polyacrylamide gel 
compositions, page 217); to 15ml of this was added 42g of urea and 20mls of 
5xTBE buffer; SDW was added to a final volume of lOOmls. The urea was 
solubilised by warming. The solution was allowed to cool before the addition of 
35pi of N,N,N',N',-tetramethylethylenediamine (TEMED) and 400pl o f 10% 
ammonium persulphate (APS), immediately prior to pouring the gel. Following 
removal of the comb the wells were flushed to rid them of urea.
2.8.6.6 Transfer
The gel was transferred onto a Hybond N+ membrane (Amersham) by capillary 
transfer on the bench overnight. The membrane was wet in distilled water and 
equilibrated by soaking in lxTBE buffer for ten minutes. Five pieces of Whatman® 
3MM paper were cut to the size o f the gel. On completion of the gel run, the gel rig 
was laid flat on the bench and one of the glass plates carefully removed. The gel 
was rinsed with lxTBE, which was then rolled off with a plastic pipette. The 
soaked membrane was carefully placed over the gel, rolling again to exclude any 
bubbles. One sheet of 3MM was wet in distilled water and laid over the filter, the 
other four (dry) 3MMs were also placed on top, the second glass plate was replaced.
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Following transfer for five hours the filter was removed from the sandwich and 
soaked in 5xSSC for up to one minute to ensure no fragments o f polyacrylamide 
were still attached. The membrane was left on filter paper for up to one hour to dry 
then UV-crosslinked (XLL 100, Spectronics Corporation).
2.8.6.7 Prehybridisation
Prehybridisation was undertaken in a hybridisation oven with rotisserie (Micro-4, 
Hybaid) using 15ml of Rapidhyb hybridisation buffer (Amersham). Oven, bottles 
and solutions were all preheated to 65°C. Prehybridisation was carried out for a 
minimum of five hours.
2.8.6.8 Hybridisation
Approximately lOOng/ml of labelled probe was added to the prehybridisation 
solution. A small volume of the prehybridisation solution was transferred into a 
universal, mixed with the labelled probe, and poured over the filter. Hybridisation 
was carried out overnight at 65°C.
2.8.6.9 Washing
The filters were initially washed at 65°C in 5xSSC, 0.1% (w/v) SDS for ten 
minutes. The waterbath temperature was then altered to 42°C and a second wash 
was carried out in O.lxSSC, 0.1% (w/v) SDS for ten minutes. The reduction in 
background levels o f probe was determined using a mini-monitor, allowing the 
stringency and length of washes to be changed as necessary.
2.8.6.10 Autoradiography
Hybridised filters were allowed to air dry, then placed in heat-sealed plastic bags. 
Autoradiography was carried out using Kodak X-Omat AR X-ray film with Kodak 
“X-Omatic” regular intensifying screens for four days and 24 days at -70°C.
2.8.7 Western blot analysis
2.8.7.1 Sample preparation
Protein was isolated from 200mg samples of canine brain by homogenisation in 
0.1M Tris (pH 6 .8 ), ImM Na-p-tosyl-l-lysine chloro-methyl ketone (TLCK), 2% 
SDS and boiled for 5 minutes. Samples were centrifuged at 13000g for five minutes 
in a Heraeus Biofuge at 4°C, the supernatant was retained and stored at -20°C. 
Total protein was measured using the BCA protein assay reagent (Pierce) (see page
8.6.1 Pierce Protein Assay, page 216).
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2.8.7.2 Separation of proteins
50pg of each sample was boiled for 5 minutes in SDS-PAGE loading buffer (see 
page 214).
Electrophoresis of proteins was carried out on vertical SDS-polyacrylamide gels (for 
details see 8.6.2 Polyacrylamide gel compositions, page 217). The accelerator used 
was TEMED, and the catalyst was APS (Johnstone and Thorpe, 1987; Hames, 
1988).
A 4% to 10% gradient gel was formed using an LKB Bromma 2120 Varioperpex II 
pump. The top of the resolving gel, which interfaced with the stacking gel, was 
made even by layering isopropanol over the top of the resolving gel before it 
polymerised. This was discarded before layering the 2.5% bis-acrylamide stacking 
gel over the resolving gel. Due to its large pore size the stacking gel had very little 
sieving effect, ensuring that the proteins all became concentrated into a narrow band 
at the stacking/resolving gel interface (Johnstone and Thorpe, 1987; Hames, 1988). 
The gel was left for thirty minutes at room temperature to polymerise.
Samples were loaded and run with Color Markers (Sigma) which were a mixture of 
proteins of known molecular weight ranging from rabbit muscle myosin at 205 kDa 
to bovine lung aprotinin at 10.5 kDa. Each marker was conjugated to a different 
dye such that an estimate could be made regarding the rate of progress o f the protein 
of interest. A constant current o f 35mA was applied until the 10.5 kDa protein-dye 
conjugate band reached the bottom of the gel. To minimise any band distortion, 
which can occur on passage of an electrical current through the gel, an LKB 
multicool was used to maintain a constant temperature of 4°C.
The marker used in the western analysis carried out by Dr Bonnie King was a SCA1 
cell line from a patient with an expansion in the SCA1 gene (Coriell Laboratories, 
Bar Harbor) which was known to consistently produce product bands of suitable 
size Figure 35, page 191.
2.8.7.3 Transfer
Following electrophoresis, the size-fractionated proteins were transferred to a 
Hybond membrane (Amersham) using a Bio-Rad Transblot cell®. The filter and gel 
were equilibrated initially in Western Blot transfer buffer (for details see page 213), 
then assembled sandwiched in the Transblot cell, and transferred overnight at 
100mA at 4°C. After transfer, the filter was washed for five minutes in lxPBS. 
This was followed by blocking with Tris buffered saline-Tween (TBS-T) buffer, 
which is made up of; 0.2% gelatin, 0.1% Tween 20 and 5% dried skimmed milk,
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either for one hour at room temperature or overnight at 4°C. The filter was then 
given a brief wash in lxTBS-T before applying the primary antibody, 1C2 (non- 
purified ascites) (Dr Jean-Louis Mandel, INSERM), at 1/5000 dilution in TBS-T 
and agitating on an orbital shaker for one hour at room temperature. The antibody 
was removed (and stored at 4°C for re-use). The membrane had three 10 minute 
washes in 0.5% milk in TBS-T, before incubation with the secondary antibody 
(goat-anti-mouse conjugated to peroxidase, 1 /1 0 0 0 0  dilution in blocking buffer) 
(Jackson Laboratories) for one hour at room temperature with agitation. Three 
additional, 10 minute washes with 0.5% milk in TBS-T were completed before 
applying the ECL detection technique (Pierce).
2.8.7.4 Detection system and development
The two ECL detection solutions (exact recipes not given) were mixed in equal 
quantities such that there was sufficient solution to completely cover the 
membranes. Any excess wash buffer was drained from the washed blots, which 
were placed protein-side uppermost on a sheet of SaranWrap™. The prepared ECL 
solution was poured onto the membrane. This was incubated on the bench for five 
minutes (making sure that the blots did not dry out). Excess detection reagent was 
drained off before placing the blot, protein-side down, onto a fresh piece of 
SaranWrap™. The SaranWrap™ was folded back over the blot to form an envelope. 
The blots were immediately placed protein side uppermost in the film cassette. The 
membrane was exposed to a sheet of Kodak X-Omat Imaging film for 30 minutes to 
allow the signal to develop. The film was developed in a Cronex CX-130 automatic 
processor (DuPont).
2.8.8 Microbiological manipulations
2.8.8.1 Bacterial media
2.8.8.1.1 Luria-Bertani medium (LB medium) (page 218).
2.8.8.1.2 Luria-Bertani (LB) agar plates
LB agarose plates were prepared at a concentration of 1.2% by the addition of 12g 
agar per litre of LB, before autoclaving. The mix was allowed to cool to 50°C 
before pouring approximately 30ml per 90mm plate. Ampicillin (NBL) was added 
to media and plates at a concentration of lOOpg/ml. Both medium and plates were 
stored at 4°C. Plates were removed from storage two hours before use and placed at 
37°C to dry.
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2.8.8.2 Competent cell preparation
Competent cells were prepared from JM101 Escherichia coli bacteria (supE, thi, 
A(lac-proAB), [F \ traD36, proAB, lacI9ZAM15]) (Pharmacia) maintained on M9 
thiamine agarose plates as single colony cultures. Cultures were re-plated every six 
to eight weeks in order to maintain the population as a single clone.
A single colony was inoculated into a 10ml LB broth and cultured overnight at 37°C 
at 200rpm in an orbital incubator (Gallenkamp). One ml o f the overnight culture 
was then inoculated into 100ml LB broth and incubated under the same conditions 
for 1.5 to 2 hours, until the optical density at 600nm was between 0.2 and 0.3, thus 
ensuring that the cell density was not greater than 108 cells/ml. At this 
concentration the bacterial population will be in the exponential part of its growth 
phase. For operational reasons the bacteria was pelleted by centrifuging the broth as 
three 40ml aliquots into sterile, ice cold polypropylene tubes (Becton Dickinson) 
followed by incubation on ice for 20 minutes. Bacteria were then recovered by 
centrifugation at 5000rpm (JA-20 rotor) for 10 minutes at 4°C. These were gently 
reconstituted in 50ml of chilled sterile lOOmM magnesium chloride and recovered 
as in the previous step. Following reconstitution, as before, the pelleted cells were 
incubated on ice with occasional agitation for one hour. The cells were recovered as 
above and reconstituted in 10ml of ice cold sterile lOOmM calcium chloride 15% 
glycerol. Aliquots were stored at -70°C for a minimum of 24 hours prior to use.
2.8.8.3 Transformations
Transformations were carried out in sterile 10ml Falcon tubes, pre-chilled on ice. 
To allow for variations in preparations acquired from other laboratories three 
transformations were performed with nominal amounts equivalent to lng, lOng and 
lOOng DNA, all made up to lOOpl with TE buffer (page 211). An aliquot of 
competent cells was thawed in the hand. A lOOpl volume of competent cells was 
then added to each DNA sample, swirled gently to mix, and incubated on ice for 30 
minutes. Cells were heat shocked at 42°C for 45 seconds then rapidly transferred to 
ice for 2 minutes. 800pl of SOC medium (page 218) was added before incubation 
in an orbital incubator at lOOrpm, 37°C for an hour. 200pl aliquots were plated out 
on LB ampicillin agar plates and incubated overnight at 37°C.
2.8.8.4 Plasmid preparations
The Wizard™ minipreps DNA purification system (Promega) was used to isolate 
plasmid DNA from transformed bacterial cells. This is based on the alkaline lysis 
procedure (Bimboim and Doly, 1979) with lysis of bacteria using sodium dodecyl 
sulphate (SDS) and NaOH (SDS denatures bacterial proteins and NaOH denatures
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chromosomal and plasmid DNA). Neutralisation with potassium acetate causes the 
covalently closed plasmid DNA to reanneal rapidly whilst most chromosomal DNA 
and bacterial proteins precipitate with the SDS and form a complex with the 
potassium which is then removed by centrifugation. Plasmid DNA is further 
purified by passage through a proprietary chromatography column before elution 
with TE buffer. Yields of up to 1 Optg were obtained from three ml overnight 
cultures. Plasmids were stored as purified DNA at -20°C.
2.8.9 Image recording
2.8.9.1 Photomicrographs
Photographs of histological sections were taken on an Olympus Vanox-S.
2.8.9.2 Immunofluorescent photography
Photographs were taken using a Reichert-Jung Diastar photomicroscope with 
epifluorescence (Model 2090).
2.8.9.3 Confocal microscopy
The confocal system was an MRC 600 (Biorad).
2.8.9.4 Electron microscopy
The electron microscope was an AEIEM 6 B.
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3.1 Introduction
The clinical signs o f CDRM have been recognised for many years and described by 
a number o f authors (Averill, 1973; Griffiths and Duncan, 1975a; Braund and 
Vandevelde, 1978; Waxman et al., 1980b; Clemmons, 1989; Clemmons, 1992). 
Although it was not anticipated that we would find any novel clinical signs it was 
necessary to perform detailed clinical examinations for selection of dogs for further 
studies. In addition, it was anticipated that as the present study was dedicated solely 
to the investigation of CDRM in GSDs it would provide the largest database so far 
collected on this disorder.
3.2 Aims
The underlying aim of this study was to improve the clinical knowledge of CDRM 
by regularly examining a large group of affected dogs. The most common 
presenting sign(s), the age at onset, and whether there was any previously 
unreported sex predisposition were of particular interest. Additional aims were to 
tabulate rates of degeneration and note the most commonly seen clinical 
“syndrome”.
3.3 Materials and Methods
3.3.1.1 Selection of cases
Cases were sourced from all over the United Kingdom (northern Scotland to the 
south of England) but the majority that were examined repeatedly were from the 
central belt o f Scotland (Strathclyde, Ayrshire, Lanarkshire, West Lothian, 
Perthshire). All dogs with clinical signs suggestive of CDRM were seen i.e. pelvic 
limb ataxia and paresis with a loss of proprioception. In order to increase the 
number of cases, a request for extra material was made to all veterinary practices in 
Scotland and the north of England. Cases were also obtained from other 
specialities, such as the orthopaedic clinic within the veterinary school. The animals 
in the study were therefore a highly selected group within the general population.
A complete physical and neurological examination was performed on referral to the 
CDRM clinic at which point they were separated into one of three groups. Cases 
with non-neurological problems were discarded from the study while those with 
neurological signs not typical of CDRM were evaluated by the department of 
neurology, then excluded or included in the study as appropriate. Cases for
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inclusion were chosen on the basis of a history and clinical examination which 
suggested a chronic progressive neurodegenerative disease which affected primarily 
the thoracolumbar spinal cord. An outline of the procedure, including the further 
investigations which were carried out as appropriate, is illustrated in Figure 3, page 
74.
3.3.1.2 Investigation of cases
The signalment and full history were obtained for all dogs, this included details of 
other diseases or injuries as well as medication. Family histories and pedigrees 
were also recorded.
A full physical assessment and neurological examination were carried out as 
detailed by Oliver and Mayhew (1987) (for details see 2.2 Case Selection, page 32). 
The following functions were found to be the most useful in the assessment of 
CDRM.
Gait was assessed initially with the animal moving in a straight line on a flat 
surface. This was observed from the side, in front and behind the animal. This was 
followed by assessment of gait during circling or when going up and down stairs.
The wheelbarrow and hopping tests were used primarily to detect weakness of limbs 
and to highlight any asymmetry between limbs.
Proprioception is the ability of the animal to recognise the location of its limbs 
without visual input. Neurological tests used to evaluate the sensory modality of 
proprioception also required adequate motor function by the animal to perform 
properly. These tests included paw position, reflex step and hip sway tests.
Muscle tone, muscle bulk and the local spinal reflexes (patellar reflex and pedal 
reflex) were assessed in the pelvic limbs. In the thoracic limbs a similar 
examination was made, omitting any myotactic reflexes (local reflex arc related to 
muscle stretch receptors). Such reflexes were omitted on examination of the 
thoracic limbs as they were known to be inconsistent, even in the normal animal. 
The perineal reflex and panniculus reflex were also evaluated.
Further investigations were carried out in cases where there was some doubt, 
following the clinical and neurological examinations, that the dog had CDRM. Nine 
cases underwent further investigations. These involved spinal radiographs, 
myelography, CSF analysis and EMG as appropriate (see 2.2.1 Ancillary 
investigations, page 45).
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r
Yes
Clinical
Examination
Neurological
Lesion
Refer to 
appropriate clinic
Neurological
ExaminationHistory
no abnormalities found
Tentative Diagnosis of CDRM
Evidence of ataxia and/or weakness referable to the 
thoracolumbar region
Diagnostic Tests 
Survey spinal radiographs
Myelography
Electromyography 
CSF analysis
Differential Diagnoses
Chronic Disc Disease 
Neoplasia 
Cauda Equina/Peripheral Neuropathies 
Inflammatory Disease 
CDRM 
Other
Figure 3. Diagrammatic representation of the complete work up for dogs, with 
atypical history or clinical signs, before their inclusion in the clinical study.
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Based on the results of the neurological examination the lesion was localised within 
the nervous system. If  the localisation was consistent with the picture of CDRM 
then the dog was included in the study. Inclusion in the study was reassessed with 
every subsequent re-examination.
Blood samples were obtained at each examination. Routine haematology and 
biochemistry were checked for 30 of the dogs on first consultation, and a list of 
parameters measured (for details 2.2.3 Collection of samples, page 47).
3.3.1.3 Therapies
Clemmons (1989; 1992) suggested that a combination of vitamins and essential 
fatty acids may slow the rate of neurodegeneration in cases of CDRM. These 
claims remained to be substantiated, however a number of owners decided to give 
their dogs the therapies listed in Table 8 , page 75. Dogs were given either all three 
therapies simultaneously or none at all.
Therapy Dose Rate
Evening primrose oil 
(EPO)
500IU/day
Vitamin B complex 200IU/day
Vitamin E 500IU/day
Table 8 . Therapies suggested to owners of dogs with suspected CDRM.
3.3.2 Statistical methods
The difference in distribution of the two genders between the affected and 
unaffected groups compared to the general referral population was assessed by chi- 
squared analysis. Significance was set at the 5% level.
3.4 Results
3.4.1.1 Num ber of cases in the study
The total number of GSDs examined in the study and their subsequent fate are 
shown in Table 9, page 78. Of these there were two littermate pairs (Dogs 6  and 15; 
41 and 47). In addition, the sire of the latter pair (Dog 14) was also included in the 
study.
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Three dogs of other breeds were seen, two Boxers and one Rough collie. These 
were not included in the clinical study as we were selecting for GSDs.
Breed
The number of GSDs and GSD crosses included in the study are given in Table 10, 
page 78.
Age at first presentation
Owners were vague about the exact age of onset of clinical signs, so recording of 
accurate information regarding age of onset was not feasible. Figure 4 (page 79) 
illustrates age at first presentation for all dogs included in the study.
3.4.1.2 History
Cases were most commonly presented to the referring veterinary surgeon because 
owners heard scuffing of the nails of the pelvic limbs when exercising the dogs on 
hard surfaces. Owners reported progression of signs over a six week to six month 
period before initial presentation. Typically, the signs which developed as the 
disease progressed were as follows: wearing of the nails became increasingly 
noticeable and more persistent; all dogs started to have problems turning, 
developing a tendency for the hindquarters to fall to the outside on a turn. These 
difficulties were more obvious on slippery surfaces and on stairs. Most cases were 
still keen to exercise at this stage. Crossing of the pelvic limbs then developed, 
where one leg would get caught behind the other which often resulted in the dog 
falling over. Collapsing to one side when walking in a straight line followed. 
Eventually, after a period of six to 18 months, the dogs were unable to rise to a 
standing position so pulled themselves along with their thoracic limbs. Only two 
cases developed signs of thoracic limb involvement, these had both been in a “K-9 
Kart®” or “Dogmobile®” for more than 12 months. O f these two cases only one 
(Dog 160) was subsequently post mortemed.
3.4.1.3 Physical examination
Twenty nine cases had concurrent degenerative joint disease which was being 
treated with anti-inflammatory drugs. O f these, 11 owners reported some degree of 
improvement in gait while on anti-inflammatory treatment. One case had evidence 
of heart disease and was referred to the cardiology clinic for further investigation, 
the dog was also affected by CDRM. The rest of the cases included in this study 
were otherwise normal.
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3.4.1.4 Neurological examination
The results of the neurological examination performed at first presentation for all 
dogs examined and last presentation for all dogs seen at the time of euthanasia or 
within the last six weeks of life are shown in Table 12, page 80. Variations in the 
quality of the patellar reflex concurrent with the presence of CDRM are presented in 
Table 13 and Table 14 (page 81).
3.4.1.5 Rates of deterioration
The rate of deterioration was plotted for all dogs seen three times or more in the 
CDRM clinic. Gait score as detailed in 2.2.2 Gait scoring system, page 46 was used 
as a measure of deterioration for each case. These results are illustrated in Figure 5 
(pages 82-83).
3.4.1.6 Further investigations
Further investigations were carried out on nine cases. Results of these
investigations are detailed in Table 15, page 84.
3.4.1.7 Sample treatments
Owners either gave all three suggested therapies or gave none. Numbers of dogs in 
each group are given in Table 16, page 84. The rate of deterioration was not 
obviously altered in the cases given the vitamins and evening primrose oil therapies. 
The rate of deterioration for those dogs on the therapies which were seen three times
or more are illustrated in Figure 5, pages 82-83.
3.4.1.8 Blood results
No significant abnormalities were found on routine haematology and biochemistry 
for any of the dogs tested.
i
I
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Total number of dogs seen 93
Proportion of dogs seen then excluded 
from the study
27
Proportion of dogs seen which were 
included in the study
6 6
Proportion of included dogs seen once 32 48%
Proportion of included dogs seen twice 19 29%
Proportion of included dogs seen three 
times
5 8 %
Proportion of dogs seen four times 5 8 %
Proportion of dogs seen five times 2 3%
Proportion of dogs seen six times 2 3%
Proportion of dogs seen seven times 1 2 %
Table 9. Numbers of GSDs and GSD crosses examined in the study with 
number of examinations.
Number of GSDs 60 (91%)
Number of GSD crosses 6  (9%)
Table 10 Number of GSD and GSD crosses included in the study.
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Age of CDRM cases at first 
presentation
A ge in years
Figure 4. Age of CDRM cases at first presentation (a particular age represents 
a range of ± 6  months).
Sex Number of dogs
Male (intact) 38 (58%)
Male (neuter) 2 (3%)
Female (intact) 15 (23%)
Female (neuter) 11 ( 16%)
Total 66
Table 11. Sex of GSDs and GSD crosses included in the study.
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Clinical Sign Number of dogs at first 
presentation
Number of dogs late in 
disease*
Ataxia 6 6 /6 6 (1 0 0 %) 38/38 1 0 0 %
Paresis 64/66 (97%) 38/38 1 0 0 %
Paw position reflex 
slow/absent
62/66 (94%) 38/38 1 0 0 %
Reflex step slow/absent 65/66 (98%) 38/38 ( 1 0 0 %)
Sway reflex slow/absent 61/66 (92%) 37/38 (97%)
Worn nails 64/66 (97%) 36/38 (95%)
Scuffed paws 27/66 (41%) 20/38 (53%)
Ulceration 17/66 (26%) 17/38 (45%)
Muscle atrophy 9/66 (14%) 11/33 (33%)
Muscle tone decreased 3/66 (5%) 8/32 (25%)
Panniculus intact 64/66 (97%) 38/38 ( 1 0 0 %)
Perineal reflex intact 6 6 /6 6 ( 1 0 0 %) 38/38 ( 1 0 0 %)
Table 12. Results of neurological examination of pelvic limbs at first 
presentation and last presentation before euthanasia.
* 28 of the dogs included in the study were not examined within the last six weeks 
o f life so were excluded from the “late in the disease” column.
The denominator denotes the number of dogs examined for each sign.
The numerator denotes the number of dogs with the mentioned sign.
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Response to test Patellar reflex
Hypertonic with clonus 1/66 1%
Hypertonic 8/66 12%
Normal 47/66 71%
Hypotonic 8/66 12%
Absent 2/66 3%
Table 13. Results of patellar reflex testing at first presentation
Response to test Patellar reflex
Hyperreflexia with 
clonus
2/37 (5%)
Hyperreflexia 3/37 (8%)
Normal 20/37 (54%)
Hyporeflexia 10/37 (27%)
Absent 2/37 (5%)
Table 14. Results of patellar reflex testing at last presentation for those dogs 
examined at a late stage in the disease.
The denominator represents the number of dogs tested.
The numerator represents the number with the mentioned response.
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Figure 5a. Rates of deterioration for dogs seen three times or more. All dogs 
on vitamin therapies except those marked with an asterisk.
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Figure 5b. Rates of deterioration for dogs seen three times or more. All dogs 
were on vitamin therapies.
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Dog ID 
Num ber
Survey
radiography
Myelography CSF EMG
13 HD*/OA** NAD NAD NAD
14 NAD NAD NAD N/A
16 NAD NAD NAD NAD
21 Lumbosacral
disease
Lumbosacral
disease
NAD NAD
29 NAD NAD NAD NAD
128 Spondylosis NAD NAD NAD
129 NAD NAD NAD N/A
154 Spondylosis NAD NAD NAD
168 NAD NAD NAD NAD
Table 15. Results for dogs undergoing fu rther investigations.
*Hip dysplasia 
: * * Osteoarthritis o f hips
! NAD: no abnormalities found N/A: not applicable
i
Number of dogs on no therapies 6  18%
Number of dogs on vitamin B, 
vitamin E and evening primrose 
oil
28 82%
Table 16. Num ber of dogs on therapies and those on no therapy, as a 
proportion of the total num ber of dogs seen more than once.
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3.5 Discussion
Although dogs o f all breeds which had clinical signs of CDRM were potential 
candidates for inclusion in the study the nature of the funding meant that we were 
selecting for GSDs. All dogs included in this study were GSDs or GSD crosses. 
Previous studies using an unselected population of dogs had 95.5% GSD and GSD 
crosses (Averill, 1973) and 56% GSDs (Griffiths and Duncan, 1975a). The finding 
of CDRM in several littermate pairs combined with the acknowledged high 
incidence of the disease in the German shepherd breed in general suggested that a 
genetic factor may well be involved in the aetiology of the disease, as previously 
suggested (Clemmons, 1989).
Age of onset was difficult to calculate accurately as owners were often vague as to 
the length of time the dog had been demonstrating clinical signs, however most 
cases were presented at the CDRM clinics between the ages of eight and ten years. 
Mean age at first presentation was 9.2 years which correlated with previous reports 
(Averill, 1973; Griffiths and Duncan, 1975a) which had suggested a mean age of 
onset of 9 years.
Three previous studies (Averill, 1973; Griffiths and Duncan, 1975a; Braund and 
Vandevelde, 1978) stated that there was no sex predisposition in this disease, 
although two of them had reported more males affected than females. In the present 
study a ratio o f 1 .6  males to females was found, which was not statistically 
significant by the chi-squared test.
The deterioration in clinical signs seen in the present study followed a similar 
pattern in all cases and agreed with previous reports (Averill, 1973; Griffiths and 
Duncan, 1975a; Braund and Vandevelde, 1978). Most cases were presented initially 
as having a unilateral problem as reported by Griffiths (1975a) and Averill (1973). 
The clinical signs often continued to be asymmetrical although both pelvic limbs 
became involved to some extent as the disease progressed. Cases maintained for 
two years after first developing clinical signs did begin to show thoracic limb signs, 
usually manifested as stumbling.
Clinical signs were present for six weeks to six months before presentation at the 
CDRM clinic. The rate of deterioration varied markedly between cases, the most 
rapidly deteriorating case was euthanased within four months of first examination at 
the clinic while more slowly progressive cases were followed for up to 12  months 
before euthanasia at the owners request. This suggested a clinical course of six to 
18 months compared to six to 12  months which had been previously suggested
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(Clemmons, 1992). A number of cases were euthanased at the owners request while 
the dogs were still able to walk, however all cases maintained for longer did lose the 
ability to ambulate due primarily to the severe involvement of the pelvic limbs. The 
two cases in this study maintained for more than a year were in a “K-9 Kart®” or 
“Dogmobile®” for the last 12 to 14 months o f life.
The data were assessed visually for evidence that the rate of deterioration might be 
linked to age of onset, however, there did not appear to be any obvious relationship.
The clinical "syndrome" of CDRM was represented by a dog which must have had a 
history of a gradually progressive pelvic limb gait problem and worn nails but no 
evidence of spinal pain. On physical examination the dog was likely to be 
otherwise normal (Averill, 1973; Griffiths and Duncan, 1975a). The gait 
abnormality was due to both ataxia and paresis, the ataxia being more prominent 
than the paresis, as reported by Griffiths (1975a), Averill (1973) considered the 
distinction to be unclear. On neurological examination all cases had altered 
conscious proprioception as evidenced by the paw position, reflex step and hip sway 
reflexes initially becoming sluggish then, as the disease progressed, disappearing 
completely. Panniculus and perineal reflexes were almost always intact. Any cases 
found to have restricted panniculus reflex during the course of the study underwent 
radiography and myelography (two cases). In this instance neither had any evidence 
of cord compression, so were included in the study. Slight decreases in muscle tone 
were found, usually unilaterally, in a small number of dogs. The proportion of 
animals with decreased muscle tone increased as the disease progressed. This was 
in contrast to a previous report which had suggested that muscle tone remained 
normal (Griffiths and Duncan, 1975a).
Additional signs of importance were a lack of any spinal pain and no evidence of 
faecal or urinary incontinence (except very late in the course of the disease). The 
clinical signs had been well documented in previous studies (Averill, 1973; Griffiths 
and Duncan, 1975a; Braund and Vandevelde, 1978; Waxman et al., 1980b; 
Clemmons, 1989; Clemmons, 1992).
The clinical signs indicated both motor (paresis) and sensory deficits (abnormal 
proprioception) and suggested that the major abnormalities occurred within the T3 
to L3 region of the spinal cord. None of the cases in the present study showed any 
evidence of focal localisation of signs within this region of the spinal cord. Even 
the two cases which had a restricted panniculus reflex had no evidence of a focal 
lesion on further investigation.
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Ataxia indicated the failure of muscle coordination which resulted in staggering and 
irregular muscular movements and resulted from disruption to the sensory pathways 
responsible for proprioception.
Paresis indicated a deficit of voluntary movements and resulted from disruption of 
the voluntary motor pathways. The clinical deficits suggested that the 
neuropathology should involve both the motor pathways and the sensory tracts 
which dealt with proprioception. These are discussed in 5 An investigation into the 
pathology associated with CDRM, page 112.
Asymmetry of signs had been reported by Griffiths and Duncan (1975a) and this 
finding was supported by this study. Many dogs had one pelvic limb more severely 
affected than the other, although as the disease progressed both pelvic limbs did 
invariably become involved.
The vast majority of cases in this study had an intact panniculus reflex despite the 
evidence that the lesion(s) affected cord segments which mediated the reflex (C8 - 
L l). The probable explanation is that the specific fibres or intemeurones concerned 
with the panniculus reflex were not involved in the pathology of CDRM.
Perineal reflex was normal which indicated that there was functional integrity of the 
sacral spinal cord segments and sacral nerve roots.
Some variation was found in the patellar reflex both between individuals and in the 
same animal at different stages in the disease. In the majority of instances the 
reflexes were present, whether normal or exaggerated. This would be consistent 
with a major pathology within the regions of cord (T3-L3), as indicated above. A 
small proportion of affected dogs (32%) showed decreased or absent patellar reflex, 
usually unilaterally. There were a number of possible explanations for this finding. 
In the cases where there was no other evidence of a LMN lesion, such as atrophy, it 
was probable that the defect which resulted in the hyporeflexia occurred within the 
afferent side of the reflex. This had been suggested previously (Griffiths and 
Duncan, 1975a). Three of the dogs (Dogs 1,2, 16) with decreased or absent patellar 
reflexes also had some muscle atrophy late in the disease. The most likely 
explanation for this was a secondary atrophy due to decreased levels of physical 
activity as a result o f the gradually progressive ataxia and paresis. Another possible 
explanation was that the spinal cord changes had extended caudal to L4 leading to 
atrophy due to LMN involvement, this was not borne out by the pathology found in 
these cases (5 An investigation into the pathology associated with CDRM, page 
1 1 2 ) as there was no significant loss of ventral grey matter neurones in the caudal 
lumbar and sacral segments.
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Four of the cases radiographed during this project showed abnormalities, two had 
spondylosis, one lumbosacral disease and the fourth hip dysplasia with secondary 
osteoarthritis. These findings would be expected in a population of middle-aged 
and old GSDs. Spondylosis was a common finding during radiographic or post 
mortem examination of the vertebral column. It was characterised by the formation 
of bony spurs and bridges at the intervertebral spaces and occurred most commonly 
in the caudal thoracic and caudal lumbar vertebrae (Oliver and Lorenz, 1983). This 
condition is rarely the cause of neurologic signs although it may occasionally result 
in spinal pain. Neither of the dogs with spondylosis had any evidence of 
compression of the spinal cord. Disease in the lumbosacral region may be due to a 
number of causes such as intervertebral disc degeneration, discospondylitis or 
neoplasia. Signs resulting from disease in this area may include pelvic limb gait 
abnormalities, lameness or LMN neurological deficits (Palmer and Chambers, 1991; 
Wheeler, 1992; Ness, 1994). The lower urinary tract, tail and anus may all be 
affected and pain is a relatively common sign. A likely diagnosis of these 
conditions may be made on recognition of the clinical signs described here and on a 
careful clinical examination which may pinpoint the focus of pain, followed by 
survey radiography and myelography. The dog in this study which had signs of 
disease in the lumbosacral region had no evidence of associated pain. It was 
concluded that the changes seen on radiography and myelography were incidental 
and the dog was included in the CDRM study.
In the case with hip dysplasia and secondary osteoarthritis these conditions were 
contributing to, and complicating the assessment of, the pelvic limb gait. However, 
there were neurological deficits not attributable to either of these conditions which 
suggested concurrent CDRM.
Routine haematology and biochemistry results were normal in all cases, which 
suggested the lack of any detectable systemic disease which could have caused the 
neurological signs in CDRM. In addition, CSF samples from eight of the dogs were 
analysed and no abnormalities were found, in agreement with a previous report 
(Griffiths and Duncan, 1975a).
Visual analysis of the rates of deterioration of dogs given vitamin E, vitamin B and 
evening primrose oil, showed no obvious difference to the rates o f deterioration of 
those in the “untreated” group. Ideally the numbers of dogs in these two groups 
would have been more balanced. As this was not a clinical trial o f any kind, and as 
there was no known effective treatment for this condition, the decision of whether or 
not the dogs were given the supplements was left to the owner. As the owners 
represented a highly motivated population the inevitable result was that the vast
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majority of cases seen were on the dietary supplements (26/34). A further problem 
with analysing this information was the fact that dogs with CDRM do deteriorate 
such that they have periods of deterioration interspersed with periods o f no apparent 
deterioration. Thus in the short term, the supplements could have appeared to slow 
down the degeneration depending on the precise timing of the initiation o f therapy. 
However, as the dogs were being objectively reassessed at GUVS on a regular basis 
throughout the clinical course of disease any such discrepancies should have been 
minimised.
As a result of the information collected in this clinical study, the earliest and most 
useful clinical signs seen in CDRM were scuffed nails and deterioration in gait on 
circling and going down stairs. Very early cases were seen which had the gait 
abnormalities described above but only went on to develop evidence o f conscious 
proprioceptive deficits at subsequent examinations. Repeated clinical examinations, 
in the absence of further investigations, were useful in increasing the index of 
suspicion that a dog with pelvic limb ataxia and paresis had CDRM. The rate of 
deterioration varied between individual animals. It was not possible to accurately 
predict the rate of deterioration for any one animal. Individual dogs tended to either 
deteriorate rapidly throughout the course of disease or deteriorate more slowly 
throughout. However, all affected dogs had periods of deterioration in clinical signs 
interspersed with periods when there was no apparent deterioration.
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4.1 Background information
Vitamin E was first identified seventy years ago although its function had only 
recently been established.
4.1.1 Forms and structure
Vitamin E was the generic term given to a group of lipid soluble compounds which 
were derivatives of tocopherol which had a saturated side chain and tocotrienol 
which had an unsaturated side chain (Southam et al., 1991). There were eight 
naturally occurring forms of vitamin E; a,p,y and 8 -tocopherol and a,p,y and 8 - 
tocotrienol (Kayden and Traber, 1993b). It was known that a-tocopherol was in 
higher concentrations in the plasma and tissues than y-tocopherol despite dietary y- 
tocopherol concentrations being much higher than a-tocopherol. This suggested 
that a mechanism existed which discriminated between the various forms of vitamin 
E. Experiments had shown that a  and y tocopherols are absorbed from the intestine 
equally and transported by chylomicrons in the plasma. The discrimination arose in 
the liver, where a-tocopherol was preferentially secreted in association with nascent 
very low density lipoproteins (VLDL), while y-tocopherol taken up by the liver was 
eventually excreted in bile (Arita et aL, 1995). O f the eight naturally occurring 
forms, a-tocopherol had the greatest biological activity due to its selective 
concentration in the liver and subsequent secretion in blood relative to the other 
compounds and accounted for over 90% of the vitamin E in tissues (Arita et al., 
1995).
4.1.2 Regulation of plasma a-tocopherol
Plasma a-tocopherol concentrations were maintained within narrow limits due to 
the activities of a-tocopherol transfer protein (a-TTP), also called tocopherol- 
binding protein. It had been demonstrated that in human patients who demonstrate a 
lack of transfer protein, plasma a-tocopherol concentrations fell rapidly, which 
suggested that the protein was necessary to maintain minimal levels (Ouahchi et al., 
1995). In addition, in normal patients supplementation with up to 100 times the 
normal daily intake (15mg) of a-tocopherol did not result in a proportional increase 
in plasma a-tocopherol concentrations (Kayden and Traber, 1993b). Vitamin E, 
unlike the other fat soluble vitamins, was not toxic if given in high doses, possibly 
because it was not stored in the liver. Excess absorbed tocopherols were readily 
excreted in bile; a-TTP was necessary both for salvage of a-tocopherol to prevent 
excretion, and to facilitate incorporation into VLDL for secretion into plasma.
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4.1.3 Mechanism of action
In vitro, and probably in vivo, a-tocopherol acted as an antioxidant. Antioxidants 
were defined as substances which slow down or prevent oxidation of vulnerable 
substrate, a-tocopherol was a lipid-soluble, chain-breaking, antioxidant or free 
radical scavenger which reacted with lipid peroxyl radicals to yield a relatively 
stable lipid hydroperoxide, thus it protected against membrane lipid peroxidation 
(Cummings et a l , 1997) and appeared to be the only significant lipid-soluble, chain- 
breaking, antioxidant in vivo. Peroxidation of membrane lipids had several 
consequences which included inactivation of membrane enzymes, decreased 
membrane fluidity and formation of lipoperoxide clusters which eventuated in 
membrane pores for Ca2+ influx. Vitamin E could terminate free-radical generated 
chain reactions by scavenging peroxyl radicals formed by the action of oxygen- 
derived free radicals on unsaturated fatty acids (Mascio et a l , 1991). In addition it 
might also protect other molecules, such as membrane proteins, from oxidation. It 
had also been suggested that the phytyl side chain of the tocopherol molecule could 
interact with the arachidonyl fatty acid chains of membrane phospholipids and so 
facilitated molecular packing and the maintenance of membrane stability (Southam 
et al., 1991). The CNS was reported to be particularly susceptible to oxidative 
injury. This was due to the high level of neuronal oxidative metabolism and the 
associated generation of reactive oxygen species combined with the abundance of 
membrane vulnerable to peroxidative damage and the lack of regenerative capability 
in neurones (Cummings et al., 1997).
4.1.4 Neurodegenerative disorders associated with experimentally 
induced vitamin E deficiency
Experimental animals which included monkeys (Nelson et al., 1981), rats 
(Pentschew and Schwarz, 1962; Southam et al., 1991) and dogs (Hayes et a l, 1970; 
van Vleet, 1975) fed a vitamin E-deficient diet exhibited a wide range of 
pathological states involving the haematopoietic, vascular, nervous, musculoskeletal 
and reproductive systems. A number of specific neurological changes had been 
found in both monkeys and rats (Pentschew and Schwarz, 1962; Nelson et al., 1981; 
Southam et al., 1991).
Prolonged and severe experimental vitamin E deficiency in rats resulted in a 
neurological syndrome which was characterised by muscle weakness, tremor, ataxia 
and hyperaesthesia. Morphological studies had shown that this was associated with 
the development of axonal dystrophy in the cranial parts of the dorsal columns and 
the gracile and cuneate nuclei with secondary loss of myelin and accompanying
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Wallerian-like fibre degeneration i.e. changes which are typical o f a central- 
peripheral distal axonopathy (Pentschew and Schwarz, 1962; Southam etal., 1991).
Progressive neuropathological lesions had been seen in vitamin E deficient rhesus 
monkeys (Nelson et al., 1981). In this study a group of monkeys were maintained 
on a vitamin E deficient diet for over two years. The most dramatic CNS change 
which resulted from this diet was the concomitant loss of axons and myelin sheaths 
in the dorsal columns accompanied by mild, fibrillary astrocytosis.
4.1.5 Naturally occurring neurodegenerative disorders associated 
with vitamin E deficiency
The specific mechanism of the neurological abnormalities seen with vitamin E 
deficiency had not been absolutely established. It had been suggested that these 
could be the result of damage to the function of mitochondrial and other intra- 
axonal membranous structures which would have interfered both with fast 
anterograde transport and “turnaround” so leading to a distal degeneration of axons 
(Southam et al., 1991).
4.1.6 Equine neurodegenerative disorders associated with vitamin E 
deficiency
Equine degenerative myelopathy (Liu et al., 1983; Scarratt et al., 1985), equine 
degenerative myeloencephalopathy (EDM) (Dill et al., 1990; Blythe and Craig, 
1992a; Blythe and Craig, 1992b) and neuroaxonal dystrophy (Baumgartner et al.,
1990) were all conditions which had been tentatively linked to vitamin E deficiency, 
although some workers had suggested that horses with, for example, EDM did not 
have significantly different serum vitamin E concentrations compared with control 
animals (Dill et al., 1989). These have been considered in detail on pages 24-26.
Horses with equine motor neurone disease (EMND) had markedly depressed blood 
levels of vitamin E (Summers et al., 1995). EMND was a neurodegenerative 
disease of the somatic LMNs which resulted in a syndrome of diffuse 
neuromuscular disease in the adult horse characterised by weight loss, muscle 
atrophy, increased periods of recumbency and fasciculations of the proximal limb 
musculature. The neurodegenerative changes involved the cell bodies of the 
bulbospinal motor neurones and, to some extent, the primary sensory neurones. A 
number of aetiological factors had been associated with this condition. Vitamin E 
deficiency was thought to lead to oxidative injury to motor neurones which caused 
profound extensor weakness of the major weight-bearing muscle masses especially
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the triceps and quadriceps (Mayhew, 1994; De la Rua-Domenech et a l , 1997; 
Valentine et al., 1997).
4.1.7 Human diseases associated with vitamin E deficiency
Vitamin E deficiency was very uncommon in man but could occur either due to 
chronic fat malabsorption, as occurred in atresia of the bile ducts and other severe 
forms of chronic cholestasis in children, or secondary to a number of genetic 
disorders. Abetalipoproteinaemia produced the most severe vitamin E deficiency. 
In these conditions the neurological signs attributable to vitamin E deficiency 
formed part of a complex multisystemic disorder which resulted from multiple 
defects of other fat-soluble vitamins and essential factors (DiDonato, 1995). The 
end result in all these conditions was vitamin E deprivation of a number of organs, 
which included the CNS and PNS. The resulting neurological deficit was a 
peripheral neuropathy caused by the dying-back of large diameter axons. All 
patients demonstrated decreased vibration sense. A number also developed 
areflexia and ataxia.
There was one distinct clinical and genetic entity which had been recognised and 
resulted in spinocerebellar degeneration. This condition, previously known as 
familial isolated vitamin E deficiency (FIVED), was first recognised by Burck et al., 
(1981), and was subsequently called ataxia with vitamin E deficiency (AVED). 
AVED is an autosomal recessive neurodegenerative disease which mapped to 
chromosome 8ql3. In this condition the intestinal absorption of dietary a - 
tocopherol was normal, as was incorporation into chylomicrons but hepatic 
secretion into the blood was impaired, which resulted in plasma vitamin E 
concentrations which were approximately 10% of normal. This was thought to be 
due either to the lack of a-tocopherol transfer protein (a-TTP) or the impaired 
ability of a-TTP to incorporate a-tocopherol into nascent VLDLs which were then 
secreted by the liver (Arita et al., 1995), the process by which efficient recycling of 
plasma vitamin E occurred in normal individuals. Mutations in the a-TTP gene in 
AVED patients demonstrated that vitamin E deficiency was the primary cause of the 
neurodegenerative process (Ouahchi et a l , 1995).
Abetalipoproteinaemia patients had been shown to have a defect in the gene for the 
microsomal triglyceride transfer protein, an essential protein for the synthesis of 
VLDL in the liver. Age of onset was generally between four and 18 years, patients 
showed progressive development of cerebellar ataxia, dysarthria, absence of deep 
tendon reflexes, vibratory and proprioceptive sensory loss and positive Babinski 
sign. Patients with AVED had almost undetectable plasma vitamin E concentrations
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if they consumed a normal diet. If they were given vitamin E supplements of 400- 
1200IU/day they were able to maintain normal plasma a-tocopherol concentrations. 
Effective vitamin E supplementation required multiple dosing throughout the day. 
Such supplementation of vitamin E did seem to override the rapid elimination of the 
vitamin and appeared to prevent progression of the disease.
4.2 Justification for the study
A number of neurodegenerative diseases which had been identified in other species 
had been associated with low circulating vitamin E concentrations, in some 
conditions treatment with high doses of vitamin E from an early age could reduce 
the rate of neurodegeneration (Blythe and Craig, 1992b; Ouahchi et al., 1995). 
Several authors (Williams et a l, 1984; Williams et a l , 1985) had suggested that the 
propensity of GSDs for small intestinal malabsorption conditions may have been 
related to the relatively common occurrence of CDRM in this breed, due to a 
deficiency in vitamin absorption. In addition Williams et a l  (1985) conducted a 
study on a small number of GSDs with CDRM (n=7) and concluded that GSDs had 
a slightly lower serum vitamin E concentration than other dogs. For these reasons it 
was appropriate to look at serum vitamin E concentrations in three populations of 
dogs: (a) GSDs affected by CDRM (b) GSDs unaffected by CDRM and (c) dogs of 
other breeds unaffected by CDRM. The aims of this study were to answer the 
following questions (i) do GSDs have significantly lower serum vitamin E 
concentration than the general canine population (ii) do GSDs with CDRM have a 
significantly different mean serum vitamin E concentration compared with GSDs 
unaffected by CDRM and (iii) is there any significant difference in “between dog” 
variation between GSDs with CDRM and GSDs unaffected by CDRM.
Although the clinical signs of CDRM were, restricted to the CNS, it was felt 
appropriate to measure serum concentrations of the vitamin as this technique had 
been used successfully in other species. For example, in conditions such as vitamin 
E related peripheral neuropathy in humans in which vitamin E concentrations from 
nerve biopsies had not been available serum concentrations were found to be 
significantly decreased (Kayden, 1993a).
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4.3 Materials and Methods
4.3.1 Collection, preparation and analysis of serum vitamin E 
concentrations
Blood samples were collected and serum prepared as described in 2.2.3 Collection 
of samples, page 47. Serum samples were stored at -70°C then processed at SAC, 
Auchincruive as described in 2.2.3.1 Measurement of serum vitamin E, page 47. 
The preliminary investigation involved six samples from dogs unaffected by CDRM 
and nine samples from affected dogs. A more detailed study was then instigated. 
This involved collection of serial samples from a control population of 26 non- 
GSDs (including two GSDXs) and 20 unaffected GSDs. The age range in the two 
control populations was two years to 15 years. The CDRM cases were sampled on 
each visit to the clinic. An attempt was made to sample all dogs at the same time of 
day following an overnight fast. Details o f all dogs used in the study are given in 
Table 1, pages 33-44. The dogs used in this study were diagnosed on clinical signs 
and history, many of them were not post mortemed, therefore definitive diagnosis 
was not always possible. O f the CDRM cases tested more than once, nine were on 
vitamin E therapy (as well as vitamin B and EPO) following collection of the initial 
blood sample while three received no therapy.
4.3.2 Statistical methods
The preliminary investigation was analysed using the two-sample t-test. 
Significance was set at the 5% level.
For the further investigation two methods of statistical analysis were undertaken. 
The mean concentrations of vitamin E in GSDs with CDRM, GSDs unaffected by 
CDRM and non-GSDs unaffected by CDRM were compared using one way 
analysis of variance. Analyses were undertaken on variation in vitamin E 
concentrations within dogs. This provided a measure of fluctuation in repeat 
determinations from the same dog in different groups using estimates of 
components of variance. Similarly, where possible, variation between dogs in 
different groups was compared. The statistical techniques used are detailed in 
Clarke and Kempson, 1997.
96
Serum vitamin E concentrations in CDRM
4.4 Results
4.4.1 Preliminary investigation
Analysis o f vitamin E concentrations for dogs in the preliminary investigation using 
the two-sample t-test, suggested that there was no significant difference between 
vitamin E concentrations in GSDs with CDRM and non-GSDs unaffected by 
CDRM, however a much larger study was required to confirm this finding. These 
data are presented in Table 17, page 102.
4.4.2 Further investigation
4.4.3 Mean vitamin E concentrations in different groups
Table 18 (page 103) shows the vitamin E concentrations for dogs in the three groups 
i.e. GSDs with CDRM, GSDs unaffected by CDRM and non-GSDs unaffected by 
CDRM. Clearly the means suggested that GSDs with CDRM have higher 
concentrations of vitamin E than GSDs unaffected by CDRM and also non-GSDs 
unaffected by CDRM. Statistical analysis for differences amongst means, shown in 
Table 18b (page 104), indicated a significant difference (p=0.026) and the Newman- 
Keuls multiple range indicated that GSDs with CDRM (mean 46.64pmoll-l) had 
significantly higher concentrations than non-GSDs unaffected by CDRM (mean 
34.15pmoll-1) but not significantly greater than GSDs unaffected by CDRM (mean 
37.32pmolH). Data were available on a further group of two non-GSDs with 
CDRM, both GSDXs, (mean 26.30jimoll-l) which was not included in any of the 
statistical analyses as the sample size was insufficient.
4.4.4 Variation in vitamin E concentrations in different groups
In addition to examining mean concentrations of vitamin E it was instructive to 
examine variation in vitamin E concentrations both between and within dogs. This 
was possible using components o f variation analyses.
Table 19a (page 105) investigated the variability in vitamin E concentrations in 
GSDs with CDRM. In view of the repeat determinations in individual dogs, it was 
possible to estimate two sources of variation. Table 19b (page 106) illustrates the 
procedure used to estimate variation within dogs and variation between dogs 
(Clarke and Kempson, 1997). The variation within dogs provided a measure of 
spread of measurements collected from one dog over a period of time and the 
standard deviation was found to be 23.7pmoll"1. In contrast the variation between 
dogs provided an estimate of variation from one dog to another and the standard
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deviation was found to be 18.0jj.molH. These findings suggested that for the group 
of GSDs with CDRM the variation from one measurement to another on the same 
dog was likely to be greater than the variation from one dog to another. This could, 
however, have been an artefact of the presence of disease.
In contrast, Table 20a and 20b (pages 107 and 108) show the results of estimates for 
within and between dog variation for GSDs unaffected by CDRM. The standard 
deviation for within dog variation was 7.7pmolH and the standard deviation for 
between dog variation was 10.4jj.molH suggesting that dog to dog variation in this 
group was greater than within dog variation.
For dogs in the general canine population, Table 21a and 21b (pages 109 and 110) 
indicated that the levels o f between and within dog variation were small. The 
standard deviation for within dog variation was 6.9pmolH and the standard 
deviation of between dog variation was 8.5jimolH suggesting that dog to dog 
variation was greater than within dog variation.
4.4.5 Comparison of within and between dog variation between 
groups
Table 22 (page 111) summarised the estimates o f components of variation obtained 
for each group. The F-test in Table 23 (page 111) clearly indicated that within dog 
variation concentrations were different for GSDs with CDRM and GSDs unaffected 
by CDRM. The GSDs with CDRM had a significantly higher (p=0.003) within dog 
variation than those unaffected by CDRM. This suggested that the presence of 
disease could have been producing large changes in vitamin E levels from one 
measurement to another.
Similarly, Table 24 (page 111) indicated that the differences in vitamin E 
concentrations from one dog to another in the group of GSDs with CDRM were 
significantly greater (p=0.009) than from one dog to another in the group of GSDs 
unaffected by CDRM. Once again this suggested that GSDs with CDRM had more 
variable concentrations than GSDs unaffected by CDRM.
Although not shown, it was evident from the low estimates of within and between 
dog variation for non-GSDs unaffected by CDRM (shown in Table 22, page 111) 
that GSDs with CDRM had significantly higher within and between dog variation in 
concentrations than the general canine population.
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4.5 Discussion
Inspection of mean vitamin E concentrations in the different groups suggested that 
these were significantly higher in GSDs with CDRM than for the general canine 
population but not significantly higher than in GSDs unaffected by CDRM. 
Estimates of components of variance indicated that fluctuations were higher in dogs 
with CDRM compared to dogs without CDRM, irrespective of breed. Fluctuation 
from dog to dog was higher in GSDs with CDRM compared to GSDs without 
CDRM. It was not possible to compare fluctuations from dog to dog for non-GSDs 
with and without CDRM.
It must be emphasised that the dogs included in the two control populations were 
age-matched as closely as was possible for a study based on clinical cases, however 
a number of the controls were under six years of age. Additionally, many of the 
dogs in the group of other breeds unaffected by CDRM were owned by veterinary 
surgeons and thus fed on high quality complete diets. In addition, the number of 
dogs in each group varied. The statistical analyses were undertaken such that the 
discrepancies in group size were taken into account. These factors did not 
invalidate the results but had to be considered when conclusions were drawn from 
the findings.
The results from this investigation suggested that, contrary to previous reports of 
comparable neurodegenerative disorders in other species (Blythe and Craig, 1992b; 
Mayhew, 1994; Ouahchi et al., 1995; Arita et al., 1995) where serum vitamin E 
concentrations were low, and to reports of decreased vitamin E concentrations in 
GSDs with CDRM compared to unaffected dogs (Williams et al., 1985) (i) GSDs 
did not have significantly lower serum vitamin E concentrations compared with the 
general canine population. In contrast, the vitamin E concentrations were found to 
be significantly higher in GSDs with CDRM than in the general canine population. 
Furthermore, (ii) GSDs with CDRM did not have significantly different mean serum 
vitamin E concentrations compared with GSDs unaffected by CDRM and (iii) the 
GSDs with CDRM had a significantly higher within dog variation than GSDs 
unaffected by CDRM. Although many of the CDRM cases were given vitamin E 
therapy this was started after collection of the initial blood sample which was used 
for calculation of the mean, so the initial values obtained did represent untreated 
dogs.
Hayes (1970) sampled a wide range of dog breeds and found vitamin E 
concentrations in the normal GSDs were within the normal range for the general 
canine population. However, Williams et al. (1985) investigated a small number of
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GSDs with CDRM (n=7) and found that they had a slightly lower serum vitamin E 
concentration than control dogs. These latter authors consider that the GSDs with 
CDRM also had an enteropathy which could cause improper absorption of essential 
nutrients. Williams (1984) investigated the possible involvement of vitamin B 12 
deficiency but ruled this out as a possible cause of CDRM. Serum vitamin E 
concentrations, when measured, were lowered in neurological disorders in other 
species which had been attributed to vitamin E deficiency (Mayhew et al., 1987; 
Baumgartner et al., 1990; Blythe et a l , 1991a; Blythe and Craig, 1992a). Work 
done in other species had suggested that serum vitamin E concentration was 
decreased quite considerably before any associated disease occurred. For example, 
there was at least a three fold drop in serum vitamin E concentration before it was 
associated with clinical disease in EMND (de la Rua-Domenech et a l , 1997) and a 
ten fold decrease before AVED occurred in humans (Doerflinger et a l , 1995).
The higher fluctuation found in GSDs with CDRM compared with GSDs without 
CDRM may have been due in part to the fact that many of the CDRM cases were on 
vitamin E therapy. However, of the 12 GSDs with CDRM which were sampled 
more than once, eight showed an increase in serum vitamin E concentration with 
time while four showed a decrease. O f the four dogs which showed a decrease in 
vitamin E concentration, two were on the vitamin therapies and two were not. This 
may have been a reflection of inconsistent treatment of particular cases or an 
indication that serum vitamin E levels were not significantly affected by the level of 
therapy given (500IU/day).
Serum vitamin E concentration was not the most accurate indicator of vitamin E 
concentration in the body. In man serum vitamin E represented only 1% of the total 
vitamin E concentration in the body. In this species the vitamin E concentration in 
adipose tissue was the most closely correlated with that in the nervous system. Also 
in man, measurement of RBC fragility had been used as a functional test to 
substantiate vitamin E deficiency (Blythe et al., 1991b). The conclusion from this 
information had to be that determination of serum vitamin E concentrations was 
useful as a screening test, but was unlikely to be an accurate indicator of vitamin E 
concentrations in the CNS of the dog.
Several authors (Beech, 1987; Blythe and Craig, 1992a) had argued that serum 
vitamin E level could not be used to diagnose EDM, as horses on the same farms as 
affected animals occasionally had equally low serum vitamin E levels with no 
associated clinical signs. In addition, a normal level at the time of measurement did 
not eliminate the possibility of an earlier deficiency during a critical period of 
development. This was especially relevant to EDM which had an early onset but
100
Serum vitamin E concentrations in CDRM
was less likely to be o f relevance in the case of a late onset disease such as CDRM. 
It was unlikely that any developmental abnormality caused by deficient nutrition in 
the first year of life would take six years or more to manifest itself. Further proof of 
this was provided by dogs which had been fed an experimental vitamin E deficient 
diet at weaning, these animals developed clinical signs within 40 to 60 days (van 
Vleet, 1975) which consisted of progressive muscular weakness, subcutaneous 
oedema, anorexia, depression, dyspnoea and eventual coma. Associated 
pathological changes were extensive skeletal muscle degeneration, focal 
subendocardial necrosis in the ventricular myocardium, intestinal lipofuscinosis and 
renal mineralisation. These findings suggested that dogs rapidly show 
multisystemic clinical signs when fed a vitamin E deficient diet. None of the dogs 
used in the present study had evidence of any of these systemic effects.
The data presented in this chapter, in the light of findings associated with vitamin E 
deficiency and disease in the dog and other species, suggested that deficiency of 
vitamin E is unlikely to be a primary factor in the aetiology of CDRM. In addition, 
the results have produced the interesting finding that vitamin E concentrations were 
higher in the GSDs with CDRM tested than in the unaffected dogs of other breeds 
tested, which were used to represent the general canine population. Measurement of 
the concentration of vitamin E in the CNS itself would provide a more accurate 
indication of whether or not abnormal vitamin E metabolism at the subcellular level 
was likely to be involved in the aetiology of CDRM.
Serum vitamin E concentrations in CDRM
Dogs 
with CDRM
Dogs
without
CDRM
53.4 48.5
33.8 58.2
18.1 24.8
52.7 75.7
28.5 57.7
39.7
27.2
76.8
42.3
32.7
mean 41.39 49.60
stdev 17.67 18.56
count 9 6
Table 17a. Preliminary serum vitamin E concentrations (fimolH) in dogs with 
CDRM and dogs unaffected by CDRM.
t-statistic df P
-0.86 10 0.41
Table 17b. Two-sampled t-tests results comparing serum vitamin E 
concentrations between dogs with CDRM and dogs unaffected by CDRM.
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Serum vitamin E concentrations in CDRM
mean
stdev
count
GSD 
with CDRM
51.0 
106.0
45.1
23.6
30.3
48.3
88.4
44.4
32.7 
36.9
35.1
29.1
38.7
99.8
59.2
46.9
46.3
33.5
45.2
33.5
56.3
20.5
38.2
35.3 
41.7
46.64
21.62
25
Group
GSD
without
CDRM
20.4
19.8 
29.7
52.6
29.6
60.6
38.1
48.6
47.5
23.2
22.6
26.3
44.4
50.5
32.4
47.5
55.7
18.9
40.9 
37.0
37.32
13.17
20
Non-GSD
without
CDRM
27.2
32.9
37.1
26.1
14.0
45.0
28.1
29.0
43.2
37.6
33.3
19.7
44.3
39.7
74.2
47.3 
26.6
28.7 
6.7
38.1
49.9
30.0
34.6
33.7
33.1
27.7
34.15
12.79
26
Table 18a. Vitamin E concentrations (|im olH) in GSDs with CDRM, GSDs 
without CDRM and non-GSDs without CDRM.
Serum vitamin £  concentrations in CDRM
Source df ss ms F P
Group 2 2115 1057 3.86 0.026
Error 68 18605 274
Total 70 20720
Table 18b. Results of one-way analysis of variance comparing mean Vitamin E 
concentrations in GSDs with CDRM, GSDs without CDRM, and non-GSDs 
without CDRM. Follow-up Newman-Keuls multiple range testing (Clarke and 
Kempson, 1997) indicated that the mean Vitamin E concentration in GSDs 
with CDRM was significantly greater than in non-GSDs without CDRM. df 
degrees of freedom, ss sum of squares, ms mean square, F test statistic and p 
significance level
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Serum vitamin £  concentrations in CDRM
Dog Mean Stdev Count
1 51.00 * 1
2 76.30 42.00 2
3 45.10 * 1
4 42.00 26.00 2
5 31.25 1.34 2
6 48.30 * 1
7 116.80 33.00 3
8 41.30 4.38 2
9 31.60 7.21 3
10 36.90 * 1
11 36.70 2.26 2
12 29.10 * 1
13 47.10 11.88 2
14 99.80 * 1
15 59.20 * 1
16 46.20 0.99 2
17 46.30 * 1
18 33.50 * 1
19 45.20 He 1
20 33.50 He 1
21 56.30 He 1
22 20.50 He 1
23 63.10 21.80 3
24 83.80 34.80 4
25 37.60 5.80 2
Table 19a. Mean and standard deviation of vitamin E concentrations (|iimolH) 
for GSDs with CDRM.
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Serum vitamin £  concentrations in CDRM
Source df ss ms F p ems
Dog 24 26385 1099 1.96 0.078 cj2 +
Error 17 9521 560 <j 2
Total 41 35906
Using the information from the one-way ANOVA,
23.7 
18.0
Table 19b. Results of analysis of variance, and estimates of components of 
variance for within and between dog measurements for GSDs with CDRM.
a 2 =560
Sd2 = —!— (1099 -  560) = 324 
1.663
Therefore,
Estimate o f standard deviation for within dog measurements 
Estimate of standard deviation for between dog measurements
i
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Serum vitamin E concentrations in CDRM
Dog Mean Stdev Count
1 24.85 6.29 2
2 17.45 3.32 2
3 29.70 * 1
4 52.60 * 1
5 39.05 13.36
6 60.60 * 1
7 38.10 * 1
8 48.60 * 1
9 47.50 * 1
10 23.20 * 1
11 22.60 * 1
12 26.30 * 1
13 44.40 * 1
14 50.50 * 1
15 32.40 * 1
16 47.50 * 1
17 51.45 6.01 2
18 25.45 9.26 2
19 45.95 7.14 2
20 39.15 3.04 2
Table 20a. Mean and standard deviation of vitamin E concentrations (jimolH) 
for GSDs without CDRM.
I
i
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Serum vitamin E concentrations in CDRM
Source df ss ms F P ems
Dog 19 3897 205 3.49 0.049 cj2 +
Error 7 411 59 cj2
Total 26 4309
Using the information from the one-way ANOVA,
X = - - ^ ^ L 2 + 2 2 + l 2 +...+22 + 2 2 +22j j  = 1.341
(j2 =59
on2 = — —^ (205 -  59) = 109 
1.341v ;
Therefore,
Estimate of standard deviation for within dog measurements 7.7
Estimate of standard deviation for between dog measurements 10.4
Table 20b. Results of analysis of variance, and estimates of components of 
variance for within and between dog measurements for GSDs without CDRM.
108
Serum vitamin E concentrations in CDRM
Dog Mean Stdev Count
1 29.00 * 1
2 36.23 4.81 4
3 39.50 4.78 5
4 33.83 5.65 4
5 74.20 * 1
6 42.70 7.21 2
7 33.30 * 1
8 25.93 6.41 3
9 27.20 * 1
10 31.17 7.98 4
11 28.10 * 1
12 26.60 * 1
13 40.16 13.08 5
14 31.72 5.68 4
15 26.92 8.76 4
16 33.80 1.35 3
17 37.10 * 1
18 32.88 3.78 5
19 26.10 * 1
20 28.70 *
21 14.00 * 1
22 32.90 * 1
23 45.00 * 1
24 6.68 * 1
25 46.20 4.92 4
26 19.35 5.66 4
Table 21a. Mean and standard deviation of Vitamin E concentrations (jimoH-l) 
for non-GSDs without CDRM.
109
Serum vitamin E concentrations in CDRM
Source df ss ms F P ems
Dog 25 5544 222 4.62 0.000 cj2 + XgyP'
Error 38 1822 48 cj2
Total 63 7366
Using the information from the one-way ANOVA,
A = _ 1 ^ 6 4 -A - jl2 + 42 + 52 +...+ 12 + 42 + 42} j =2.421
6.9 
8.5
| Table 21b. Results of analysis of variance, and estimates of components of
variance for within and between dog measurements for non-GSDs without
i  CDRM.I
|
I
j[
i
<j2 =48
6d2 = — —  (2 2 2 -4 8 )  = 72 
2.421v '
Therefore,
Estimate of standard deviation for within dog measurements 
Estimate of standard deviation for between dog measurements
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Serum vitamin E concentrations in CDRM
Group
Within
dog
variance df
Between
dog
variance df
GSDs with CDRM 560 17 324 24
GSDs without CDRM 59 7 109 19
Non-GSDs without 48 38 72 25
CDRM
Table 22. Summary of estimates of within and between dog variances for 
GSDs with CDRM, GSDs without CDRM and non-GSDs without CDRM.
Variance within GSDs with CDRM: 
Variance within GSDs without CDRM:
F = 560/59 = 9.49 dfi = 17, df2 = 7
p = 0.003
Table 23. Comparison of within dog variances between GSDs with CDRM and 
GSDs without CDRM.
Variance between GSDs with CDRM: 324
Variance between GSDs without CDRM: 109
F = 324/109 = 2.97 dfi = 24, df2 = 19
p = 0.009
Table 24. Comparison of between dog variances between GSDs with CDRM 
and GSDs without CDRM.
560
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5.1 Introduction and Aims
The pathology of the spinal cord in CDRM had been reported by a number of 
authors (Averill, 1973; Griffiths and Duncan, 1975a; Clemmons, 1989; Clemmons, 
1992; Barclay and Haines, 1994). Most descriptions had concentrated on the most 
severely affected areas of the spinal cord - the mid to caudal thoracic and lumbar 
segments. Wallerian-type (axonal) degeneration was prominent in the lateral 
funiculus in the region of the corticospinal and rubrospinal tracts. In addition, more 
scattered degenerating fibres were present in the remainder of the lateral and ventral 
funiculi. The dorsal columns also showed changes in both the lumbar and cervical 
segments. A number of cases exhibited gliosis in the intermediate grey matter of 
the lumbar enlargement. A smaller number of cases had degeneration o f fibres in 
the lumbar dorsal nerve roots. LMNs appeared to be spared. No specific 
abnormalities had been reported in the brain, although Clemmons (1989) referred to 
white matter changes which extended into the brain. The literature on the pathology 
of CDRM is reviewed in 1 Introduction, page 1.
The purpose of this study was to re-examine the distribution and nature of the spinal 
cord pathology using classical techniques, electron microscopy and 
immunocytochemistry. In addition to confirming, or otherwise, the previous reports 
it was hoped that fresh clues to the pathogenesis and aetiology might be derived 
from the more modem techniques. A second purpose was to examine carefully the 
brains of affected dogs to find any previously unreported changes. A detailed 
analysis of the neuropathology would allow a comparison with neurodegenerative 
diseases in man for which an aetiology had been determined.
5.2 Materials and Methods
5.2.1 Animals
Twenty GSDs (13 males and seven females) and five GSD crosses (two males and 
three females) with a clinical diagnosis o f CDRM were available for post mortem 
examination (for details see 2.2 Case Selection, page 32). The dogs were aged 
seven to 12 years. No significant clinical signs were noted, other than those 
referable to the neurological disorder. Six dogs, either GSDs or similar sized breeds 
with no neurological disease were used as one control group. In addition, 11 dogs 
with defined localised injuries, to the spinal cord were examined as a further control 
population, to determine the extent of secondary degeneration or retrograde 
reactions in brain nuclei and tracts following damage to spinal cord axons. Post
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mortem examination was performed within two hours of euthanasia which was 
carried out by intravenous injection of pentobarbitone sodium (Euthatal) (Rhone 
Merieux Ltd.). The brain and spinal cord were removed while maintaining the 
continuity of the dural sheath wherever possible. On exposure o f the vertebral canal 
both the dorsal and ventral aspects were examined for evidence of any lesions which 
might have caused spinal cord compression. Dogs which had either gross evidence 
or histopathological evidence of cord compression were not included as CDRM 
cases. SpG were dissected out and removed with the cord. Care was taken to 
maintain the cord as straight as possible throughout removal from the vertebral 
canal. The spinal cord was suspended in a long cylinder in 4% BNF (page 202) and 
weighted to avoid any bending which could have affected the structure. The brain 
was fixed in 4% BNF with one transverse cut at the level of the optic chiasma to 
ensure that proper fixation of deep structures occurred.
Details of the CDRM cases used in the pathology study are given in Table 25 (page 
115) and Table 26 (page 116). Signalments for dogs in the control group with no 
neurological lesions dogs are given in Table 27, page 117. Details o f the dogs in the 
control groups with focal spinal cord lesions are given in Table 28 (page 118), Table 
29 (page 118) and Table 30 (page 119).
A number of body tissues were collected into BNF from ten of the affected dogs at 
post mortem, these are detailed in 2.2.3 Collection of samples, page 47.
Three dogs were fixed by intravascular perfusion, after euthanasia, with 
Kamovsky's modified fixative (paraformaldehyde/glutaraldehyde 4%/5%). Details 
of the fixative are given page 2 0 2 , details of the perfusion technique are given in
2.6.2 Intra-aortic perfusion, page 49. These dogs were at different stages in the 
clinical course of CDRM.
i
I
i
i
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Case
number
Dog ID 
Number*
Breed Age at post 
mortem
Sex
129202 1 GSDX 10y2 m FN
126438 2 GSD 12y3m FN
126496 4 GSD 8y9m M
125636 5 GSD 7y8m M
126403 7 GSD 12ylm F
128951 19 GSD 9y4m M
132560 41 GSD 8y7m M
132913 47 GSD 8y7m M
128291 49 GSDX 8y5m FN
126541 55 GSDX 9y6m F
124705 144 GSD 7ylm M
CDRM1 146 GSD lOy M
CDRM2 147 GSD 10y9m M
124625 160 GSD 10y6m FN
125570 163 GSD 9ylm MN
126131 164 GSD 7ylm M
127150 167 GSDX lOylOm MN
129481 180 GSD 9y F
Table 25. Details of CDRM cases for which routine pathology was completed 
on spinal cord and brain. (* see Table 1, page 33-44).
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Case
number
Dog ID 
Number*
Breed Age Sex
126586 3 GSD 8y3m FN
129769 11 GSD 10y3m F
129800 14 GSD 9y3m M
129966 31 GSD 9y4m M
130541 33 GSD 8y7m F
129057 50 GSDX 12y7m M
131167 129 GSD 7y M
Table 26. Details of CDRM cases for which routine pathology was completed 
on the spinal cord. (* see Table 1, page 33-44)
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Dog ID 
Number*
Sex Breed Age
(years)
Reason for 
euthanasia
182 M GSD 3 Anal
furunculosis
183 F BMD 6.5 Transitional
cell
carcinoma
184 M Doberman 9 Colorectal
neoplasia
185 FN Flat coat 
retriever
8 Malignant
histiocytosis
186+ M Labrador
Retriever
9 Mast cell 
tumour
187 M GSD 5.5 Testicular
neoplasia
+There was no spinal cord pathology completed for this dog.
Table 27. Dogs with no neurological abnormalities. (* see Table 1, pages 33- 
44)
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Dog ID 
Number*
Sex Breed Age
(years)
Site/Nature of 
spinal cord 
lesion
Age of lesion 
at post 
mortem
169 FN Dachshund 7 T 12/13 Hansen 
type I disc 
extrusion
5 days
170 M Labrador 7 T3 spinal cord 
compression due 
to a ventral bony 
mass
1 week
171 F Anatolian
karabash
8 Brachial nerve 
root avulsion
7 days
172 F Great Dane 0.58 Cervical
Spondylomyelo-
pathy
C3, C4, C6/7
2 weeks
Table 28. Dogs with a focal spinal cord lesion, pathology completed on brain 
and spinal cord. (* see Table 1, pages 33-44).
Dog ID 
Number*
Sex Breed Age
(years)
Site/Nature of 
spinal cord 
lesion
Age of lesion 
at post 
mortem
118 FN crossbreed 11 T13 disc 
extrusion
4 days
173 M Scottish
terrier
2 Fibro­
cartilaginous 
embolism (C2/3)
3 days
Table 29. Dogs with a focal spinal cord lesion, pathology completed on spinal 
cord only. (* see Table 1, pages 33-44)
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Dog ID 
Number*
Sex Breed Age
(years)
Site/Nature of 
spinal cord lesion
Age of 
lesion at 
post 
mortem
174 M Border
terrier
6 Tl/2
F ibrocartilaginous 
embolism
4 days
175 M English
pointer
5 C6/7 traumatic disc 
extrusion
3 weeks
176 M Labrador 9.5 T3/4 Schwannoma 3 weeks
177 M Border
collie
5 T 13/Ll disc prolapse 2  days
178 F Great
Dane
0 . 6 6 Cervical
spondylomyelopathy
C2/3-C6/7
9 days
179 FN DobX 7 T12/13 disc prolapse 2  weeks
111 M German
pointer
4.5 T7 meningioma 2  weeks
Table 30. Dogs with a focal neurological lesion, pathology completed on brain 
only. (*see Table 1, pages 33-44)
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5.2.2 Processing of tissue for paraffin wax sections
A one cm length of every second spinal cord segment was removed and processed 
in a Shandon Elliot 24 hour automatic tissue processor (Histokinette) as described in
8 .1.2.2 Paraffin wax processing, page 204. A one cm2 piece of each of the body 
tissues listed below was removed and processed in the same automatic processor.
The brain was cut into transverse slices. All slices caudal to the level o f the optic 
chiasma were processed in the Shandon Elliot seven day automatic tissue processor 
(Histokinette) (for details 8 .1.2.2 Paraffin wax processing, page 204).
Paraffin-embedded tissue sections were cut on a Biocut 2035 microtome (Leica) and 
mounted onto APES-coated microscope slides (for details see 2.7.3.2 Preparation of 
APES coated slides, page 50).
Paraffin wax sections were routinely stained with Haematoxylin and eosin (H&E) 
and Cresyl violet (CV) (for details see 2.7.4.1.1 Routine stains, page 50).
Paraffin wax sections of the red nucleus from affected and control dogs were stained 
with Congo Red (for details see 2.7.4.1.1.4 Congo Red, page 51).
5.2.3 Processing of tissue for resin embedding
5.2.3.1 Spinal cord
At the time of post mortem a 2mm slice of one cervical, one thoracic and one 
lumbar spinal cord segment was taken, cut into quarters and immersed in 
Karnovsky's modified fixative (paraformaldehyde/glutaraldehyde 4%/5%) (page 
202). These samples were then processed using a Lynx el microscopy tissue 
processor (Leica) for araldite resin embedding (8 .1.2.1 Resin processing, page 203).
5.2.3.2 Brain
Red nucleus tissue for resin embedding was collected from cases perfusion-fixed 
with Karnovsky's modified fixative (paraformaldehyde/glutaraldehyde 4%/5%) (as 
above). On removal from the perfused dog, the brain was immersed in the same 
fixative until complete fixation had occurred. The red nucleus was dissected out 
and sliced at 2mm, then processed using a Lynx el microscopy tissue processor 
(Leica) for araldite embedding (as above).
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5.2.4 Immunocytochemistry
A number of antisera were used in an attempt to define more accurately the nature 
of the lesions. Dogs with identified focal spinal cord lesions were investigated in 
parallel, to determine if the changes occurring in the CDRM dogs were specific to 
the disease.
Immunostaining was carried out by three basic techniques; (i) the PAP technique; 
(ii) the ABC technique which was similar, but employed a biotinylated secondary 
antibody and a preformed avidin and biotinylated horseradish peroxidase 
macromolecular complex (iii) double indirect immunofluorescence. These 
techniques are all described in detail in 2.7.4.1.2 Immunocytochemistry, page 51. 
Complete lists of the antisera used for immunostaining are given in Table 3 (page 
54, PAP techniques), Table 4 (page 55, ABC technique) and Table 5 (page 56, 
immunofluorescent techniques).
The PAP technique was employed for SMI 31, RT-97, RM017, RM024 using 
mouse PAP complex (Sigma) at 1/1250 and a goat a-mouse link Sigma) at 1/10. 
The PAP technique was also used for a-GFAP, a-PLP 226, Affmiti NA 1297, a- 
ubiquitin and a-MBP. This group used a rabbit PAP complex (ICN 
Immunobiologicals) at 1/40 and a goat a-rabbit link (Sigma) at 1/10.
5.3 Results
5.3.1 Histology of spinal cord of dogs with CDRM
5.3.2 White Matter
Pathological changes in the white matter involved axonal degeneration with a 
concomitant loss of myelin in affected areas, often with an accompanying gliosis. 
The glial reaction consisted predominantly of microglia, with some increase in 
astrocytes (Figure 6 , page 122). The allocation of cell types, in sections stained 
with H&E, was based on the nuclear appearance. Microglia have an elongated, rod­
like nucleus, astrocytes have a more rounded, paler nucleus due to less chromatin. 
Some degenerating fibres had associated macrophages. The patterns of 
degeneration are shown in Figure 7, page 123-125.
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(a)
(b)
Figure 6 . Resin sections (1pm) from a dog with CDRM (a) dorsal columns 
showing loss of axons and myelin sheaths in the fasciculus gracilis (b) the 
dorsolateral column at higher magnification to show fibre degeneration (large 
arrows) and the presence of astrocyte processes (small arrows). ( a ) x l 5 0 ( b ) x l 0 0 0
(a) and (b)C4
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5.3.2.1 Dorsal funiculus
White matter changes in the dorsal funiculus varied widely from dog to dog both in 
severity and distribution. The severity ranged from occasional scattered fibre 
degeneration to areas of fibre loss with an associated gliosis. These changes were 
found exclusively in the fasciculus gracilis. Dogs could be grouped according to the 
distribution of degeneration through the length of the dorsal funiculi. The two most 
common patterns were changes throughout cervical, thoracic and lumbar regions of 
the spinal cord, although not necessarily in every segment in each case (9/25), or 
degeneration in the lumbar segments only (5/25). Other variations were 
involvement of the cervical and lumbar segments with sparing of the thoracic cord 
(3/25); thoracic and lumbar involvement only (5/25); thoracic segments only (1/25) 
and finally cervical and thoracic regions only (1/25). Only one of the dogs (Dog 55) 
had no dorsal funiculus changes at all. There were varying degrees of asymmetry 
seen in the dorsal funiculi at all levels.
5.3.2.2 Lateral funiculus
The lateral funiculus consistently showed lesions. In all cases, at least a few 
scattered degenerate fibres were present around the periphery of the cord, not 
always including the ascending dorsal spinocerebellar tracts. Most of the cases 
(16/25) had occasional fibre degeneration around the periphery with a greater 
number o f degenerated fibres in the region of the corticospinal and rubrospinal 
tracts (Figure 8 , page 127). All of these had an associated gliosis in the region of 
the descending tracts.
5.3.2.3 Ventral funiculus
Consideration of the ventral funiculus showed that most o f the degeneration was in 
the descending tracts which surrounded the ventromedian fissure. Degeneration 
tended to involve all the descending tracts in this region, namely the MLF, medial 
vestibulospinal tract, ventral corticospinal tract and the tectospinal tract. Four cases 
showed an associated gliosis in the tectospinal tract; this was a localised occurrence 
in each case and occurred in one spinal cord segment only.
Considering the patterns of degeneration in the lateral and ventral funiculi together, 
three cases showed degeneration in the regions of the corticorubrospinal tracts and 
around the ventromedian fissure only, with sparing of the rest of the white matter.
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(b)
Figure 8 . Spinal cord segments stained with H&E (a) from a normal dog 
showing unaffected dorsolateral (DL) column and dorsal column (D) and (b) 
from a CDRM case to show the degeneration (upper edge outlined by arrows) 
in the dorsolateral columns with sparing of the dorsal columns. Magnification 
xl05. (a) and (b)C8
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5.3.3 Grey Matter
Pathological changes in the grey matter were less consistent. The dogs fell into 
three groups; those that had no grey matter changes (5/25); those having occasional 
chromatolytic neurones (9/25); and the largest group, which had gliosis in the grey 
matter (16/25), often with chromatolytic neurones (6/25). Grey matter gliosis in 
most cases extended throughout the intermediate hom (Figure 9, page 129). In all 
but two cases, the gliosis was bilateral. In the first of these two cases (Dog 160) the 
gliosis was asymmetric in spinal cord segment L2 but was symmetrical by L4. In 
the second case (Dog 3), spinal cord segment T8 showed a slight gliosis in the right 
hom of the grey matter, which was symmetrical by L2. As a general rule, the grey 
matter gliosis occurred only in the lumbar segments. Two cases (Dogs 14 and 47) 
varied from this and had a slight gliosis in the grey matter of spinal cord segment 
C8 . This was an isolated finding in both, as there was no further gliosis in Dog 14 
cranial to T12 and no gliosis in any of the thoracic or lumbar spinal cord segments 
o f Dog 47. Occasional chromatolytic neurones were seen, most commonly in the 
intermediate grey matter of the lumbar spinal cord segments.
5.3.4 Histology of spinal cord of dogs with focal spinal cord lesions
Details of the spinal cords of six dogs with focal spinal cord lesions are given in 
Table 28 (page 118) and Table 29 (page 118). The first of these was a seven year 
old Dachshund with a T12/13 disc extrusion of five days duration. Cranial to the 
lesion there was a mild gliosis in the fasciculi gracili. Caudal to the lesion there 
were a very small number of degenerating axons around the periphery of the ventral 
and lateral columns of the white matter. One chromatolytic neurone was found in a 
SpG from the lumbar enlargement.
The second case was a seven year old Labrador with spinal cord compression at T3 
due to the presence of a ventral bony mass. The clinical signs were of seven days 
duration. Cranial to the lesion the only evidence of degeneration was a mild gliosis 
in one fasciculus gracilis. Caudal to T3 there was loss of axons around the 
periphery of the ventral and lateral columns of the white matter, which involved all 
descending tracts.
The third case was an 11 year old crossbreed with a disc extrusion at T13 of four 
days duration. Cranial to the lesion, the white matter was normal but the grey 
matter was atrophied with an associated greatly enlarged central canal. Caudal to 
the lesion the white matter was again unaffected but there was gliosis in the grey 
matter. The spinal nerve roots throughout the length of the spinal cord showed 
vacuolation. The glia limitans appeared thickened throughout the length of the 
spinal cord.
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Figure 9. Sections of the lum bar spinal cord grey m atter to show density of 
glial cell population (a) from a normal dog and (b) from a dog with CDRM 
showing an increased num ber of glial cells in the intermediate grey m atter. 
Magnification \210. (a) and (b) L2
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The fourth case was a seven month old Great Dane with a two week history of signs 
associated with cervical spondylomyelopathy. The most severely affected region 
was C6/7. Cranial to the lesion, degenerated axons were found in the fasciculus 
gracilis and the fasciculus cuneatus. The dorsal spinocerebellar tracts had a mild 
gliosis. Caudal to the lesion, there were degenerate axons in the area of the 
corticospinal tracts and in the ventral columns.
The fifth case was a two year old Scottish terrier with fibrocartilaginous embolism 
of three days duration. Cranial to C6  the only evidence of degeneration was a 
chromatolytic neurone in the grey matter. Spinal cord segment C6  had many 
degenerate axons in the lateral columns with complete tract degeneration in the 
ventral columns and an associated cellular infiltration. The degeneration was much 
less severe in spinal cord segment C7 and affected only the grey matter and lateral 
column of one side.
The last case was an eight year old Anatolian karabash with a brachial plexus 
avulsion of seven days duration. As the injury occurred in the peripheral nervous 
system it was not exactly comparable to damage which occurs to neurones 
contained entirely within the CNS. It was included, however, to evaluate retrograde 
axonal reaction of defined duration. At the level o f the cervical enlargement the 
population of neurones in the ventral hom ipsilateral to the avulsion were all 
chromatolytic; there was no associated gliosis. Caudal to this lesion the population 
of ventral hom neurones were normal.
5.3.5 Histology of spinal cord of neurologically normal dogs
Examination of the spinal cords o f age-matched dogs with no neurological deficits 
showed very occasional isolated degenerated fibres with no associated gliosis. The 
only consistent lesion was an occasional vacuolation of myelin sheaths in the spinal 
nerve roots, that occurred in the older control dogs.
5.3.6 Histology of brain of dogs with CDRM
Brains from 18 dogs affected by CDRM were examined, these are listed in Table 
; 25, page 115. Pathological changes in the brain were found in both brain nuclei and
white matter structures; the changes in the brain nuclei occurred more consistently.
i
5.3.6.1 Brain nuclei
Affected neurone populations were the red nucleus, the LVN and the lateral 
(dentate) nucleus. A number of changes were seen: mild gliosis with no associated 
neurone changes; neurones with eccentric nuclei and chromatolytic neurones with,
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or without, an associated gliosis (see Figure 10, page 133). In some severely 
affected dogs the number of neurones appeared to be reduced compared with the 
equivalent neuronal population in unaffected dogs suggesting that an actual loss of 
neurones had occurred.
The red nucleus was affected in all dogs examined and was the most severely 
affected nucleus. Gliosis was present in each dog. In 17 cases this was uniform 
throughout the nucleus, although the severity varied between cases. In one case 
(Dog 144) the gliosis was limited to the dorsolateral portion of the nucleus. Fifteen 
cases had evidence of chromatolytic neurones, two of these also had neurones with 
eccentric nuclei. One of the remaining three cases had several neurones with 
eccentric nuclei. Neurone numbers appeared to be reduced in three of the cases, in 
comparison with the neurologically normal control group.
The LVN was affected in all cases but the changes were less severe than those in the 
red nucleus. All cases had evidence of gliosis, the severity varying from mild to 
severe. Gliosis, if present, was uniform throughout the nucleus. Twelve cases had 
chromatolytic neurones, and of these, two also had neurones with eccentric nuclei. 
Only one case had evidence of neuronal loss.
The lateral nucleus was less consistently affected, only eight dogs had evidence of 
degeneration. Most of these had a mild gliosis only, while two had an occasional 
chromatolytic neurone. One case had evidence of a neuronal loss.
5.3.6.2 W hite m atter
White matter changes consisted of gliosis of varying severity and occasional 
degenerate fibres or axonal spheroids. Evidence of degeneration was found in two 
regions, the ventral tegmental decussation and the tract into the nodulus.
The ventral tegmental decussation had evidence of degeneration in 16/18 cases 
(Figure 11, page 134). The most common change was gliosis, this varied from mild 
(12/18) to severe (4/18). Macrophages were seen in association with degenerating 
fibres in six cases.
The tract into the nodulus was affected in 10/18 cases, of which nine exhibited a 
mild gliosis and one a severe gliosis. In only one case was an axonal spheroid seen.
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5.3.7 Histology of brain of neurologically normal dogs
Brains from six dogs with no neurological abnormalities were examined. The only 
changes were occasional lipofuscin granules in the neurones of the red nucleus.
5.3.8 Histology of brain of dogs with focal spinal cord lesions of 
known duration
Brains from 11 dogs with focal spinal cord lesions of known duration were 
examined. The most prolonged of these had had a three week duration of clinical 
signs, so these were all of much shorter duration than CDRM. In the majority of 
cases there was an adequate number of neurones and no evidence of a gliosis 
(Figure 12, page 135). However, a small number of red nuclei (3/11) showed 
occasional changes. One of these cases (Dog 175) had chromatolytic neurones in 
the red nucleus although there was no associated gliosis and no evidence of a loss of 
neurones. One of the Great Danes with cervical spondylomyelopathy (Dog 172) 
had one neurone with a slightly eccentric nucleus. The only other case with obvious 
changes in the red nucleus was the dog with the brachial nerve root avulsion (Dog 
171); this dog had two chromatolytic neurones in one red nucleus.
The LVN showed changes in three of the cases. One dog had chromatolytic 
neurones with no associated gliosis (Dog 169) while two (Dogs 176 and 175) had 
chromatolytic neurones with an associated gliosis.
The lateral nucleus was unaffected in this group of dogs.
White matter changes were not observed in this group of dogs.
5.3.9 Histology of body tissues from affected dogs
No significant abnormalities were found in any of the body tissues examined.
5.3.10 Histology of the peripheral nervous system
Stellate ganglia, cranial mesenteric ganglia, optic nerve and sciatic nerve showed no 
abnormalities in any of the affected dogs.
5.3.11 Histology of the spinal ganglia (SpG)
Several of the affected dogs had occasional chromatolytic neurones in the SpG 
associated with both the cervical and lumbar enlargements. A number o f dogs with 
focal spinal cord lesions also had an occasional chromatolytic neurone in the SpG. 
A chromatolytic neurone was observed in the SpG of only one of the neurologically 
normal dogs (Dog 183).
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(b)
Figure 10. Sections of red nucleus stained with H&E (a) from a dog with a 
C6/7 traum atic disc extrusion of 3 weeks duration to show the normal num ber 
of neurones. Many neurones are chromatolytic (arrows), some of which have 
eccentric nuclei, (b) from a dog with CDRM showing a chromatolytic neurone 
(arrow), a marked reduction in the number of neurones and an increase in glial 
cell numbers. Magnification xl()5.
133
Figure 11. Sections from the ventral tegmental decussation stained with H & 
E. (a) from a dog with CDRM showing a gliosis. Magnification x95. (b) from 
the same dog at higher magnification showing a myeloclast (arrow). 
Magnification xl90. (c) from a dog with a C6/7 lesion of three weeks duration. 
Magnification x95.
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(a)
(b)
Figure 12. Section of red nucleus front a dog with a spinal cord lesion (Tl/2 
Fibrocartilaginous embolism) of four days duration (a) at low power to show 
the relatively high num ber of neurones compared with CDRM cases. 
Magnification xl05. (b) at higher power to show the absence of a gliosis. 
Magnification x230.
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5.3.12 Ultrastructural analysis of spinal cord and red nucleus of 
dogs with CDRM
5.3.12.1 Spinal cord
The electron microscopy study o f the spinal cord was undertaken to confirm that 
both the axon and myelin sheath were affected in CDRM and to determine if the 
early axonal changes might suggest a specific nature for the disease.
Both degenerated axons and myelin sheaths were found in all spinal cord segments 
examined, within the abnormal areas defined by light microscopy. Astrocyte 
processes were prominent within the degenerated regions (Figure 13, pages 137- 
138). Vacuolated macrophages were found in association with a number of the 
degenerated axons. The appearance was typical of Wallerian-type degeneration.
5.3.12.2 Brain nuclei
Changes were found in the two nuclei examined, the red nucleus and the LVN. The 
abnormalities were identical and the majority of information was gathered from the 
red nucleus. Many neurones appeared normal with well defined Nissl bodies and 
Golgi apparatus; lipofuscin granules were often prominent (Figure 14, pages 139- 
140). Affected neurones and dendrites showed loss of the Nissl granules and 
dispersion of the rough endoplasmic reticulum (RER). Ribosomes tended to be 
present as monosomes or polysomes rather than associated with cistemae of 
endoplasmic reticulum. Neurofilaments were often increased (Figure 15, pages 
141-143). Commonly, enmeshed within the neurofilaments, were collections of 
mitochondria and vesicles of various sizes, the origin of which were not determined. 
Occasional myelinated axons were also enlarged by accumulated neurofilaments 
and/or membranous organelles (Figure 16, pages 144-145).
136
An investigation into the pathology associated with CDRM
Figure 13a. Electronmicrograph from the dorsal quadran t of spinal cord 
segment T12 from a dog with CDRM (a) this m icrograph shows two degenerate 
Fibres (arrows), but no evidence of demyelinated axons. There is an increased 
num ber of astrocyte processes (AS). Magnification approxim ately x5000.
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Figure 13b. Electronmicrograph from the dorsal quadran t of spinal cord 
segment T12 from a dog with CDRM (b) Region of longstanding degeneration 
as shown by loss of fibres and a marked increase in astrocyte processes. 
Magnification approximately x8000.
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Figure 14a. Electronmicrographs of normal neurones from the red nucleus of 
a dog with CDRM. (a) The nucleus (N) and associated nuclear pores (small 
arrows) is present. Nissl granules (NS) are well-defined and interspersed with 
clearer areas containing neurofilaments, microtubules and Golgi apparatus 
(G). Magnification approximately x5000.
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Figure 14b. Electronmicrographs of normal neurones from the red nucleus of 
a dog with CDRM. (b) This higher magnification shows numerous lipofuscin 
granules (arrows). Magnification approximately x8000.
140
An investigation into the pathology associated with CDRM
f TfTfeV
Figure 15a. Electronmicrographs of a neurone from the red nucleus of a dog 
with CDRM (a) this micrograph shows a dendrite, recognisable due to the 
presence of synapses (arrow). There is an increase in neurofilaments and 
accumulation of organelles in the centre of the process. Magnification 
approximately x6000.
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Figure 15b. Electronmicrograph of the neurone from Figure 15 (a) showing 
the synapse illustrated in Figure (a) (arrow). Magnification approximately 
xl9000.
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Figure 15c. Electronmicrograph of a neurone from the red nucleus of a dog 
with CDRM (c) the central portion of the dendrite shown in Figure 15 (a) to 
illustrate the accumulation of organelles. There are m itochondria, vesicles and 
vacuoles. Magnification approximately x20000.
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Figure 16a. Electronmicrograph of an axon from the red nucleus of a dog with 
CDRM (a) The axon, which is surrounded by an attenuated myelin sheath, 
contains disorganised neurofilaments. Magnification approxim ately xl4000.
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Figure 16b. Electronm icrograph of an axon from the red nucleus of a dog with 
CDRM (b) shows an axon containing many m em branous organelles, mainly 
dense bodies (arrow) and mitochondria (M). Magnification approximately 
xl4500.
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5.3.13 Immunocytochemistry of the spinal cord of dogs with CDRM
Six of the spinal cords from severely affected dogs (Dogs 144, 5, 164, 163, 12, 49) 
were examined using a number of antibodies detailed in Table 3 (page 54, PAP 
technique), Table 4 (page 55, ABC technique) and Table 5 (page 56, double 
immunofluorescence).
5.3.13.1.1 White matter
As described above, the spinal cord white matter contained degenerating myelinated 
fibres with a concurrent gliosis. In general, the immunostaining profile supported 
this finding. Staining for axons using SMI 31 (Figure 17, page 147), RM024 or RT- 
97, or for myelin using a-PLP, showed varying severities of loss of myelinated 
axons. GFAP immunostaining was somewhat increased in the more severely 
affected regions (Figure 18, page 148).
5.3.13.1.2 Grey matter
Occasional swollen axons were seen using the SMI 31 and RM024 antibodies. Very 
rare examples of immunostained neuronal perikarya were present in all dogs.
5.3.14 Immunocytochemistry of the spinal cords of dogs with focal 
spinal cord lesions
A group of five dogs with focal spinal cord lesions were selected for 
immunocytochemistry (175, 172, 169, 177 and 179). These dogs had all shown 
some evidence, on routine histology, of secondary ascending and descending 
degeneration. The reduced immunostaining with SMI 31 and RM024 antibodies 
reflected the degree of axonal loss.
One case (Dog 171) had a brachial plexus avulsion of 7 days duration with typical 
chromatolytic changes in the ventral horn neurones o f the cervical enlargement. The 
majority o f neuronal somata in this region showed very prominent immunostaining 
with SMI 31 and RM024 antibodies.
5.3.15 Immunocytochemistry of the spinal cords of neurologically 
normal dogs
Very occasional SMI 31-positive swollen axons were detected in the white matter 
and/or grey matter of spinal cords from neurologically normal dogs.
146
An investigation into the pathology associated with CDRM
p»23iTJvfc**
m m
(a)
(b)
Figure 17. Section of lum bar spinal cord from a CDRM case immunostained 
with SMI 31 to show asymmetrical axon loss in the dorsal columns (arrow) (a) 
Magnification \43 and (b) Magnification xl()5. (a) and (b) L2
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(b)
Figure 18. Confocal  images o f  spinal cord immunostained for neurof i laments  
(red) and G F A P  (green) (a) normal dog (b) a CDRIM case to show the dorsal  
spinocerebel lar tract (D) and underlying corticospinal  tracts (C).  The  
spinocerebel lar tract has normal relationship between axons and astrocytes  
while there is axonal loss and astrocytosis  in the corticospinal  tract.
(a) and (b) T12 (a) x250 (b) x600
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5.3.16 Immunocytochemistry and histochemistry of the red nucleus 
of dogs with CDRM
As the red nucleus was the most consistently and severely affected of the brain 
nuclei on histologic examination, it was examined using a number of the antibodies 
listed in Table 3 (page 54).
SMI 31 (Figure 19c, page 150) and RM024 antibodies revealed axonal swellings 
within the red nucleus of three cases (144, 49 and 12). Again using SMI 31, 
RM024, and RT-97, dog 5 had positively stained neurones which suggested an 
increase in phosphorylated neurofilaments throughout the neuronal perikarya. Dog 
49 had positive staining with these antibodies which involved only the neuronal 
nuclei, which suggested a more localised increase in phosphorylated neurofilaments. 
In no case was there evidence of a dramatic astrogliosis or astrocytosis when GFAP 
was used.
Ubiquitin (Dako) immunocytochemistry was applied to the red nucleus of five 
affected cases (Dogs 2, 163, 19, 4 and 14) to determine whether the red nucleus of 
dogs with CDRM had evidence of filamentous intraneuronal inclusions, since these 
had been found in a number of chronic neurodegenerative diseases in man (Perry et 
al., 1987; Mayer et a l , 1991). Two cases had positive staining of occasional 
neuronal nuclei (Dogs 2 and 4) while one (Dog 19) had staining of the nucleus only 
in some neurones and entire neuronal perikarya in others. The final two cases had 
generalised staining of several neuronal perikarya (Dogs 163 and 12). All cases 
examined had a random arrangement of small brown positively stained structures 
throughout the red nucleus. However, these changes were also found in the 
oculomotor nucleus.
A preliminary study of staining of red nucleus sections with Congo Red suggested 
that there was no amyloid deposition, which has been found in patients with 
Huntington's disease (Scherzinger et a l, 1997).
5.3.17 Immunocytochemistry of the red nucleus of neurologically 
normal dogs
No abnormalities were found.
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Figure 19. Sections immunostained with SMI 31. (a) red nucleus of a dog with 
a C6/7 lesion of three weeks duration showing that the majority of neuronal 
cell bodies contain phosphorylated neurofilaments. Occasional neuronal cell 
bodies show eccentric nuclei, (b) oculomotor nucleus from the same dog 
showing a neurone population with no immunostaining of the cell bodies. xl20.
(c) red nucleus from a dog with CDRM showing occasional immunopositive 
neurones. xl20.
Facing page 150
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5.3.18 Immunocytochemistry of the red nucleus of dogs with focal 
spinal cord lesions
Six cases were stained with SMI 31, RM024 and RT-97; one case showed no 
abnormalities (Dog 169), another had immunostaining in several neuronal nuclei 
(Dog 179). The most common finding was staining of the neuronal perikarya o f one 
neurone (Dog 172) or several neurones (Dogs 174, 175 and 177) within the red 
nucleus; this was especially marked in dogs 175 (Figure 19a and b, page 150) and 
177 where all the ventrolateral neurones in both red nuclei were positively stained 
with SMI 31. In addition, dog 177 also had evidence o f axonal swellings when 
stained with SMI 31. Staining with GFAP showed no obvious astrocytosis in any of 
these dogs.
The case with the brachial plexus avulsion showed occasional staining of 
phosphorylated neurofilaments in neuronal nuclei with SMI 31. However similar 
changes were also seen in the oculomotor nucleus.
Ubiquitin staining was carried out on four dogs in this group (Dogs 169, 176, 170 
and 174). One case (Dog 170) had no visible staining. The remaining three had 
some neurones with staining in the nucleus only, other neurones with staining 
throughout the perikarya while many neurones remained unstained. As with the 
CDRM cases, small brown structures were seen throughout the section and changes 
seen in the red nucleus were also seen in the oculomotor nucleus.
Histological staining with Congo Red showed the occasional orange stained area in 
the neuronal perikarya (Dog 169) which suggested possible amyloid deposition.
5.4 Discussion
In the present study spinal cord white matter changes which comprised degenerating 
axons with an associated loss of myelin, often with gliosis, were found in the dorsal, 
lateral and ventral funiculi of affected dogs. The numbers of degenerate fibres in 
specific tracts varied both throughout the length of each cord and between cases. 
Both ascending and descending tracts were affected, which correlated with the 
clinical finding of both sensory and motor deficits. The most consistently affected 
regions of the white matter were the corticospinal tract and rubrospinal tract in the 
lateral funiculus. As previously discussed (see 1.3.3.6 Rubrospinal tract, page 17), 
the rubrospinal tract is an important motor tract while the lateral corticospinal tract 
is of much less functional significance in dogs than in man. These two tracts were 
difficult to distinguish as the fibres intermingle to some extent, and are often 
considered together as the corticorubrospinal tract. Degeneration in the rubrospinal
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tract would result in difficulties with coordination and possibly locomotion. 
Regions with the greatest area of involvement were the caudal thoracic and lumbar 
segments which agreed with previous reports (Averill, 1973; Griffiths and Duncan, 
1975a; Braund and Vandevelde, 1978). This study did not confirm the occurrence 
of small vascular elements of increased density which had been reported by 
Clemmons (1989).
The distribution of the degeneration in the dorsal funiculi was less consistent than 
that in the lateral funiculi. The majority of cases showed degenerating fibres in the 
deeper regions of the dorsal funiculus of the caudal lumbar segments. At the level 
of the mid to caudal thoracic segments very little change was observed in the dorsal 
funiculi. One possible explanation is that the degenerating fibres in lumbar and 
caudal thoracic segments represent the central projections of primary sensory 
neurones whose cell bodies lie in the lumbar SpG. The majority of such fibres 
terminate in the base of the dorsal horn of the grey matter within a few segments of 
entering the spinal cord (King, 1993). Thus it is the distal portions of such axons 
which degenerate. The other region of dorsal funiculus involvement was the 
fasciculus gracilis of the cervical cord, although this was an inconsistent finding. 
These fibres probably represent the long projections of neurones whose cell bodies 
also lie in the lumbar SpG. Thus both regions o f degeneration in the dorsal funiculi 
may represent the distal portions of axons whose cell bodies lie in the lumbar SpG.
Gliosis in the grey matter of the spinal cord of cases of CDRM has been reported 
previously (Averill, 1973; Braund and Vandevelde, 1978). In the present study, the 
distribution of gliosis varied between cases but most commonly affected the 
intermediate horn of the grey matter. It was striking that only the middle and caudal 
lumbar segments were consistently affected by the gliosis in the intermediate grey 
matter. One possible explanation for this distribution of gliosis is that it is related to 
the terminations o f the fasciculus gracilis and the descending tracts which were 
affected by the degeneration. Both the corticospinal and vestibulospinal tracts have 
been reported to terminate on intemeurones found within this region (Jenkins, 
1978). There was no gliosis in the substantia gelatinosa which agreed with the 
clinical finding that pain and temperature detection were unaffected in cases of 
CDRM. Occasional chromatolytic neurones were found in the grey matter of 
affected dogs, most commonly in the intermediate horn.
The finding of occasional chromatolytic neurones in the SpG of some affected cases 
agreed with a previous report (Griffiths and Duncan, 1975a). Occasional 
chromatolytic neurones were also seen in a number of the dogs with focal spinal 
cord lesions. O f the normal dog SpG examined, only one had a single chromatolytic
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neurone. These findings suggest that such degeneration in the SpG was not 
exclusively a change seen with CDRM but was indicative of spinal cord pathology. 
Vacuolation seen in the nerve roots of some of the affected dogs and a number of 
the control dogs could be an age-related change as discussed by Griffiths and 
Duncan (1975b).
Clemmons (1989) is the only author who has previously mentioned changes in the 
brain of affected dogs. He reported occasional lesions in unspecified areas of the 
white matter o f the brain, consisting of demyelination and axon loss, with an 
associated increase in astrocyte numbers and increase in density of small vascular 
elements. In the present study, serial sectioning of the brain o f affected dogs 
revealed changes in a number o f specific brain nuclei and white matter tracts. Brain 
nuclei affected were the red nucleus, LVN and lateral nucleus. The severity of 
changes varied with each affected dog but in all cases the red nucleus was most 
consistently and severely affected. Evidence of degeneration included neurones 
with eccentric nuclei and chromatolytic neurones, sometimes with an associated 
gliosis. The red nucleus also had a variable loss of neurones in the more severely 
affected dogs, suggesting that the chromatolytic neurones in milder cases were 
degenerating and would subsequently be lost. Evidence of degeneration was also 
found in the ventral tegmental decussation, consisting of gliosis and occasional 
degenerating fibres. Involvement o f the red nucleus was consistent with the clinical 
signs since it functions as an important motor centre and as a relay station for 
proprioceptive impulses from the cerebellum to the cerebral cortex.
Although an extensive immunostaining profile was performed, it added relatively 
little to the knowledge gained from paraffin sections stained with H&E or Cresyl 
violet. Any changes found, such as presence of phosphorylated neurofilaments in 
neuronal cell bodies of the brain nuclei, or ubiquitin staining of these cells, tended to 
be inconsistent and involved only a small number o f neurones The ultrastructural 
examination supported the light microscopic analysis. The loss o f Nissl granules 
and dispersion of the RER would account for the chromatolytic appearance of 
neurones. The ultrastructural studies also showed that a small proportion of axons 
in the red nucleus were abnormal with accumulation of neurofilaments and 
organelles. Although the association of such axons with neurones of the red nucleus 
could not be confirmed, it seemed most probable that this was their origin.
Changes in the red nucleus could result from one of two basic mechanisms (i) the 
primary abnormality affected the neuronal cell body with consequent degeneration 
of the axonal projections to the spinal cord or (ii) the primary changes occurred 
within the spinal cord and the findings in the red nucleus represented a retrograde
153
An investigation into the pathology associated with CDRM
axonal response. It was also possible that a combination of these events might have 
occurred such that a derangement of metabolism in the neuronal cell body 
compromised the transport o f material into the spinal axon which consequently 
degenerated, leading in turn to a retrograde axonal response in the parent cell body. 
In order to try and distinguish these possibilities the red nucleus was studied from 
dogs with focal spinal cord lesions of known duration. In this group of dogs the red 
nucleus was much less consistently and much less severely affected. Two of the 
cases with spinal cord lesions per se had changes, one had occasional chromatolytic 
neurones with no associated gliosis while the other had one neurone with an 
eccentric nucleus. The only other dog in this group with changes in the red nucleus 
had a brachial plexus avulsion. There were two chromatolytic neurones in the red 
nucleus o f this dog. None of these dogs had any obvious evidence of neuronal loss. 
In the group of dogs with focal spinal cord lesions there was very little degeneration 
in the red nucleus. Additionally there was no evidence of degeneration in the 
ventral tegmental decussation. These findings suggested that a primary spinal cord 
lesion alone would not result in the degree of degeneration seen in the red nucleus 
o f dogs with CDRM.
Ideally, the control tissue would have been obtained from age-matched dogs of large 
breeds which had had chronic thoracolumbar spinal cord lesions of a similar time 
course to CDRM. Due to the constraints imposed by using clinical cases, such 
material was not available. Thus the material collected was from those dogs with 
focal spinal cord lesions of longest duration that were euthanased at GUVS during 
the course of this project. The most longstanding lesion had resulted in clinical 
signs of three weeks duration. This discrepancy of duration was taken into 
consideration when comparing the two groups.
Since extensive neuropathology has been carried out on the spinal cords of humans 
with chronic spinal cord lesions, a literature search was completed for further 
comparisons with the CDRM cases. Following traumatic damage to the spinal cord 
in man (Kakulas, 1987; Fishman, 1987) retrograde axonal damage was limited to a 
certain distance such that patients with low or mid-thoracic lesions had apparently 
normal corticospinal tracts by the mid-cervical level, while patients with a high 
thoracic to low cervical lesion had apparently normal corticospinal tracts by the 
upper cervical level. The medullary pyramids were unaffected in all cases 
examined, which suggested that retrograde damage, even from a severe traumatic 
lesion, did not extend into the brain itself. The extent of axonal damage in the 
corticospinal tract cranial to the lesion in patients with spinal cord injury decreased 
with increasing distance from the lesion. If retrograde damage followed a similar 
pattern in the dog it was unlikely that such damage to axons in the caudal thoracic
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segments would extend as far cranially as the ventral tegmental decussation. Since 
evidence of degeneration was found in this structure in a number of the CDRM 
cases it was possible that the primary lesion was in fact the neuronal damage in the 
red nucleus. However, on the basis of the pathology it was not possible to 
unequivocally identify the primary site o f the defect.
Selective damage to the thoracic spinal cord had been reported in vitamin B 12 
deficiency in humans and dogs. Vitamin B \2 deficiency in humans (Metz, 1992) 
resulted in a degenerative lesion characterised by swelling of myelin sheaths and 
breakdown of myelin with disruption of the axon, leading to a spongy, vacuolated 
cord. Changes were most severe in the dorsal funiculi o f the thoracic cord, although 
the lateral funiculi did become affected later (subacute combined degeneration). In 
addition to the spinal cord lesions, foci of demyelination were also found in 
unspecified areas of the white matter in the brain. This condition also affected the 
peripheral nerves which showed a decreased number of myelin sheaths. An 
inherited B 12 deficiency had been reported in the Giant Schnauzer dog (Fyfe et a l , 
1991) which had a simple autosomal recessive inheritance, and closely resembled 
the human condition in clinical presentation and pathology. The underlying 
mechanism for this disease was not properly understood but was thought to be a 
failure of ileal enterocytes to mediate transcytosis of cobalamin. There were 
significant differences between the pathology associated with vitamin B 12 
deficiency and that seen in CDRM. The pathology seen in the thoracic cord was 
originally perivenular in the vitamin B 12 deficiencies and was usually multifocal 
whereas the lesions in CDRM were topographically continuous in all tracts in most 
cases (an exception being the dorsal funiculi in a small number of affected dogs). In 
addition, the peripheral nervous system (PNS) remained unaffected in CDRM. The 
available evidence would suggest that CDRM is not the result o f a deficiency of 
vitamin B 12.
Vitamin E has been tentatively linked with the aetiopathogenesis o f CDRM. 
Deficiency of this vitamin has been associated with neurological disease in a 
number of naturally occurring and experimentally induced conditions in several 
species. Following two years on a vitamin E deficient diet a group of rhesus 
monkeys (Nelson et al., 1981) had a concomitant loss o f axons and myelin sheaths 
in the dorsal columns accompanied by mild fibrillary astrocytosis. Prolonged 
deficiency in rats (Pentschew and Schwarz, 1962; Southam et al., 1991) resulted in 
systemic axonal dystrophy in rostral parts of the dorsal columns and in the gracile 
and cuneate nuclei with secondary loss of myelin and accompanying Wallerian-type
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fibre degeneration (changes which were typical of a central-peripheral distal 
axonopathy).
Vitamin E deficiency in man is very uncommon but does occasionally result from 
chronic fat malabsorption. This occurs in atresia o f the bile ducts and other severe 
forms of chronic cholestasis in children or secondary to genetic disorders, for 
example, abetalipoproteinaemia which is the most severe naturally occurring form 
of vitamin E deficiency. The resulting multisystemic disorder has a neurological 
component. One distinct clinical and genetic entity which has led specifically to 
spinocerebellar degeneration was called ataxia with vitamin E deficiency (AVED). 
In this condition, the pathology was the result o f impaired hepatic secretion of a- 
tocopherol into blood, which resulted in plasma vitamin E levels which were 
approximately 10% of normal. The resulting neurological deficit was a peripheral 
neuropathy caused by the dying back of large diameter fibres. The precise 
neuropathology associated with this condition had not been characterised but there 
did appear to be greater involvement of the central sensory pathways than the 
peripheral nerves (Ouahchi et al., 1995; Arita et al., 1995).
The neuropathology associated with vitamin E deficiency has been reported in much 
more detail in a number of conditions in the horse. Equine degenerative 
myeloencephalopathy (EDM) (for details see 1.5.2 Equine, page 24) resulted in 
widespread neuroaxonal dystrophy in brain stem nuclei, lateral cervical and thoracic 
nuclei and lumbosacral and cervical intermediate grey columns. In addition, 
lipofuscin pigment accumulation and astrogliosis were seen in these areas while the 
ventral and dorsal spinocerebellar tracts and ventromedial funiculi o f the cervical 
and thoracic spinal cord segments showed degeneration of axons and myelin with 
some gliosis (Mayhew et al., 1987). A form of neuroaxonal dystrophy had also 
been described in the Morgan horse which had pathologic changes only in the 
accessory cuneate nucleus. A spinal ataxia had been described in the zebra (Montali 
et al., 1974) which was characterised by symmetrical degeneration in the ventral 
(descending tracts adjacent to the ventro-median fissure) and lateral (ascending and 
descending tracts) funiculi. Both the axons and myelin sheaths were affected and 
the degenerate tracts were topographically continuous. In this condition the dorsal 
columns and grey matter were unaffected and no changes were found in the brain 
rostral to the medulla oblongata. These conditions had some similarities with the 
pathology of CDRM, in that both the axons and myelin sheaths were degenerate in 
affected tracts and many of the same tracts were affected. However, the most 
severely affected white matter tracts in EDM were the dorsal and ventral 
spinocerebellar tracts while the corticospinal and rubrospinal tracts were the most 
severely affected in CDRM. Axonal swellings were a prominent feature in these
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equine conditions while they occurred infrequently in CDRM. Although there were 
some similarities in pathology between the conditions caused by vitamin E 
deficiency and CDRM, on balance it was unlikely that vitamin E deficiency was a 
significant factor in the development of CDRM in the GSD.
Previous studies (Waxman et al., 1980a; Waxman et al., 1980b; Barclay and 
Haines, 1994) implicated a cell-mediated autoimmunity as a possible cause of 
CDRM (page 5 Introduction). In this study there was no evidence of perivascular 
cuffing nor o f lymphocyte infiltration in the spinal cord in either paraffin or resin 
sections. As there was no other evidence from the pathology to suggest an immune- 
mediated mechanism this aspect was not pursued any further. An obvious way to 
definitively rule out the presence of inflammatory cells would be to use antibodies 
specific to each cell type e.g. T lymphocytes, B lymphocytes and macrophages.
Recent reports on the pathology of a group of human neurodegenerative diseases 
which have marked clinical and pathological similarities with CDRM suggested that 
ubiquitin positive fibrillar inclusions (Davies et al., 1997; Scherzinger et al., 1997; 
DiFiglia et a l,  1997) were found in the nuclei of specific neurones in both affected 
patients and in mice transgenic for the Huntington's disease mutation. Equivalent 
inclusions were not found in any of the CDRM cases examined. Amyloid had also 
been found (Scherzinger et al., 1997) in the cytoplasm of affected neurones in 
Huntington's disease; to date this has not been found in the CDRM cases. The 
above changes had been reported in the areas of brain known to be the primary 
lesion. At this stage the red nucleus might well be the primary site of damage in 
CDRM, however this has not been established definitively which could explain the 
lack of such inclusions in the CDRM cases.
Examination of Figure 7 indicated that there was some correlation between the gait 
score at time of death with the extent of degeneration found. However, dogs with 
the same gait score did not consistently have the same pattern of degeneration on 
examination of the spinal cord. The pattern of pathological change was not 
consistent with the clinical signs.
In summary, CDRM is a neurodegenerative disorder which affects selected areas of 
the spinal cord and brain stem. The changes in the white matter were those of 
Wallerian-type degeneration which have a tendency to affect the more distal regions 
of certain motor and sensory tracts. In this sense CDRM had some features of a 
distal axonopathy ("dying back" disease). However, the abnormalities in brain 
nuclei such as the red nucleus, may indicate a primary problem in the neuronal 
somata as a result of which degeneration may occur in the distal regions of the
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associated axons. Defining the primary site of the pathology i.e. neuronal cell body 
versus distal axon would require examination at the very earliest time point of the 
disease. The pathology identifies lesions in the red nucleus which could be 
consistent with change in the descending tracts. However there is no consistent 
obvious pathological change in the neuronal somata supplying the ascending tracts. 
This dichotomy may represent a useful area for further study. With the constraints 
imposed through the use of clinical cases such material would be very difficult to 
obtain. It is also probable that such changes could be subtle and resolvable only in 
material preserved by intravascular perfusion, again imposing considerable 
difficulties in collection.
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6.1 Background
The identification of CDRM as a neurodegenerative disorder prompted a search for 
similar diseases in other species, particularly man, in which an aetiology was 
known. Several unrelated human neurodegenerative disorders have late-onset and 
were associated with degeneration of specific neuronal populations, as occurred in 
CDRM. Many of these disorders were caused by expanded trinucleotide repeats, 
particularly the CAG repeat.
This section briefly reviewed aspects relevant to trinucleotide repeats and the 
neurodegenerative disorders which have been associated with expanded repeats.
6.2 Trinucleotide repeats in the mammalian genome
Classical studies based on reassociation kinetics have shown that the haploid 
mammalian genome contained a number of repeating nucleotide sequences. The 
size o f these repeats varied from complex complete genes (such as the ribosomal 
RNA genes) down to simple sequences of one or two base pairs. Organisation of 
these repeat sequences varied from widely dispersed copies of a relatively long, 
complex sequence to tandem arrays of simple sequence composition. Arrays of up 
to five to six nucleotides were called simple tandem repeats (STRs). Within this 
group dinucleotide repeats were the most common, most notably AC.
Of particular interest were the expanded trinucleotide repeats, which could occur at 
various loci throughout the transcription unit. Increase in the length of these repeats 
had arisen in a number of human disorders. The first genetic disease reported in 
association with a trinucleotide repeat was Fragile X Syndrome which was the result 
of the dynamic mutation of the sequence CCG in the 5^  untranslated region (UTR) 
of the FMR1 gene and was the most common form of familial mental retardation 
(Sutherland and Richards, 1995). Since then a number of other diseases have been 
linked to expanded repeats and are presented in Table 31 (page 161).
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Disease Expanded Repeat
various human cancers minisatellite, di-,tri- & tetra-nucleotides
Hereditary Non-polyposis Colon Cancer mono-,di- and tri-nucleotide
Fragile X CCG
FRAXE CCG
Spinal and bulbar muscular atrophy CAG
Myotonic dystrophy CTG
Huntington's disease CAG
Spinocerebellar ataxia 1-7 CAG
Machado-Joseph disease CAG
Haw river syndrome CAG
Dentatorubral-pallidoluysian atrophy CAG
Friedreich's ataxia GAA
Table 31. Human diseases which have been associated with expanded repeats. 
6.2.1.1 Trinucleotide repeats
Trinucleotide repeats have been found in all regions of the transcription unit viz. the 
5 / non-coding region, exons, introns or the 3  ^ non-coding region. Diseases caused 
by trinucleotide repeat expansions fell into two major groups. The first group, 
which have been classified as Type I disorders (Stuart and Leipold, 1983; La Spada 
et al., 1994; Perutz, 1996; Sanjeeva Reddy and Housman, 1997), included the 
progressive neurodegenerative disorders; X-linked spinal and bulbar muscular 
atrophy (SBMA), Huntington's disease, Dentatorubral-pallidoluysian atrophy 
(DRPLA), Machado-Joseph disease (MJD) and the Spinocerebellar ataxias (SCA1- 
7). These disorders were characterised by neuronal loss in specific brain nuclei and 
essentially affected only the nervous system, with the exception of SBMA, which 
also had systemic hormonal effects. They were caused by small, limited CAG 
repeat expansions, normal individuals had up to 37 repeats while those with disease 
always had more than 41 repeats, which encoded poly glutamine (Figure 20, page 
163). These mutations altered properties of the affected protein which resulted in a
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gain of function which was particularly deleterious to neurones. The second group 
called Type II disorders included Fragile X syndrome (FRAXA), FRAXE mental 
retardation and Myotonic dystrophy (DM). These were all multi-system disorders 
which were associated with much larger expansions of repeats located in the 5^  
(FRAXA, FRAXE) or 3  ^ UTR (DM) of the gene. Diseases in the second group 
were not progressive neurodegenerative disorders but may caused abnormal brain 
and neuromuscular development. In addition, this group exhibited marked somatic 
mosaicism, with repeat sizes which varied widely throughout the somatic tissues of 
affected individuals.
For both these groups, when an expansion resulted in disease, the disorder 
transmitted as a dominant trait subject to genetic anticipation. This feature was 
thought to be due to the inherent instability of the expanded trinucleotide repeat, 
which could alter in size in successive generations (Sutherland and Richards, 1995). 
The length of repeats could contract, but much more commonly would increase in 
unit length as it passes through the germline, which resulted in an earlier age of 
onset and a more severe phenotype in successive generations. In many of these 
diseases, although not in DM, the paternal line was more unstable than the maternal, 
presumably due to the larger number of cell divisions which occurred per generation 
(Jennings, 1995; Paulson and Fischbeck, 1996). Recent studies of individual sperm 
from males with Huntington’s disease had demonstrated a significant increase in 
sperm trinucleotide repeat lengths compared with the repeat lengths of the father 
(Sanjeeva Reddy and Housman, 1997). In addition, repeat length increased as a 
function of paternal age. These findings suggested that replication of DNA in 
primary male germ cells may either favour repeat expansion or select for germ cells 
or mature sperm which carry longer repeat expansions. Expansions arose from 
CAG triplet repeats, which were polymorphic in the normal population (Warren, 
1996; Paulson and Fischbeck, 1996), but once a critical threshold was reached, 
which varied according to the condition, hairpin structures could form which would 
result in replication errors and increased repeat size. The number o f repeats 
correlated more closely with age of onset than severity of clinical signs (Richards 
and Sutherland, 1994).
Another neurodegenerative disease was Friedreich's ataxia (Stumpf et a l , 1987; 
Ben Hamida et a l , 1993; Campuzano et a l , 1996; Carvajal et a l , 1996). This 
condition was most often manifest from adolescence although occasionally onset in 
middle age or later occurs. The molecular lesion was a GAA repeat expansion 
within intron 1 of the X25 gene which coded for the protein frataxin. Unusually the 
mode of inheritance was autosomal recessive, meaning that anticipation could not 
be seen as one generation only was affected (Mandel, 1997).
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CGG
_ _ _  3 7UTR
Normal Affected
11-34 SBMA 40-62
19-36 SCA I 43-81
6-34 HD 36-121
7-25 DRPLA 49-88
3-13 HRS 63-68
12-37 MJD 61-84
Figure 20. Schematic representation of an archetypal Pol II gene depicting the 
loci of the lesions for a number of the human conditions associated with 
expanded trinucleotide repeats.
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6.2.2 Neurodegenerative conditions resulting from CAG repeat 
expansions
The spinocerebellar ataxias and DRPLA had several similarities to CDRM in terms 
of pathology and were probably the most relevant conditions. Huntington’s disease 
and SBMA were described for completeness but appear to had few pathological 
similarities with CDRM.
6.2.2.1 Huntington's disease
Huntington's disease, the most commonly occurring Type I disease (Paulson and 
Fischbeck, 1996), was an autosomal dominant neurodegenerative disorder 
characterised by involuntary movements (chorea), behavioural disturbance and 
cognitive impairment. Early in the disease there was selective degeneration of 
striatal projection neurones which progressed to widespread neuronal loss in 
advanced cases. The genetic defect, an expanded (CAG)n repeat within the coding 
region of the large IT-15 gene, was identified in 1993 by the Huntington's Disease 
Collaborative Group. The product was huntingtin, the CAG expansion encoded a 
poly glutamine tract six to 34 amino acids long in normal individuals and 36 to 121 
in Huntington’s disease patients (MacDonald and Gusella, 1996).
6.2.2.2 X-linked spinal and bulbar muscular atrophy (SBMA)
X-linked spinal and bulbar muscular atrophy or Kennedy's Disease was a rare 
progressive adult-onset motor neuronopathy which was characterised by proximal 
muscle weakness, atrophy and fasciculations. Pathological changes seen were 
degeneration of the anterior horn cells, sensory neurones in the SpG and brain stem 
motor nuclei (Brooks and Fischbeck, 1995). The trinucleotide repeat (CAG)n in the 
first exon of the androgen receptor (AR) gene was expanded from the normal range 
of 11 to 34 residues to 40 to 62 in SBMA patients.
6.2.2.3 Spinocerebellar ataxias 1-7
These late-onset progressive neurodegenerative diseases were dominant 
spinocerebellar ataxias, which represented a phenotypically heterogeneous group of 
disorders, with a prevalence of familial cases of approximately 1 in 100,000. They 
were all characterised by varying abnormalities of balance attributed to dysfunction 
or pathology of the cerebellum and cerebellar pathways. In many of these 
conditions dysfunction extended beyond the cerebellum to involve basal ganglia 
function, oculomotor disorders and neuropathy.
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6.2.2.4 Spinocerebellar ataxia 1 (SCA1)
Spinocerebellar ataxia 1 was characterised by ataxia, ophthalmoparesis and 
weakness, sometimes with spasticity, which typically began in the third to fifth 
decade and progressed over 10 to 20 years. Anticipation could result in a much 
earlier onset and more rapid progression, childhood cases most often resulted from 
paternal transmission. The disease usually began with cerebellar signs such as 
clumsiness and ataxia but progressed to include dysarthria, bulbar dysfunction, 
oculomotor disturbance and pyramidal tract signs. Neuropathological changes 
included loss o f Purkinje cells and the neurones in the inferior olive, with 
degeneration of the spinocerebellar tracts. The molecular lesion was in the protein- 
coding region of the SCA1 gene which encoded the protein ataxin-1. The variation 
in ataxin-1 poly glutamine tract length was from 19 to 36 repeats in normal 
individuals to 43 to 81 repeats in affected individuals. The expanded repeat was 
invariably an uninterrupted sequence of CAG repeats. In contrast to the normal­
sized CAG alleles which were almost always interrupted by one to three CAT 
repeats (La Spada et al., 1994). It was suggested that this difference may contribute 
to the stability o f the normal allele.
6.2.2.5 Spinocerebellar ataxia 2 (SCA2)
Patients with SCA2 were often clinically indistinguishable from those with SCA1. 
Additional clinical signs seen in some SCA2 patients included dementia and 
neuropathy. The brain regions most affected by pathology were the cerebellum, 
pontine nuclei, inferior olives and substantia nigra (Imbert et a l , 1996). In this 
disorder the molecular lesion was an expanded CAG repeat in the spinocerebellar 
ataxia 2 (SCA2) gene on chromosome 12 which encoded ataxin-2. Normal 
individuals had 15 to 24 repeats while affected individuals had 35 to 59 repeats.
6.2.2.6 Spinocerebellar ataxia 3 (SCA3)
Despite having a phenotype which was distinct from that of Machado-Joseph 
disease, the genotype in the two diseases was identical, both having an expanded 
CAG repeat in the gene variously called SCA3 (Zoghbi, 1996) and MJD1 
(Haberhausen et a l , 1995). Clinically these patients showed severe cerebellar 
dysarthria and supranuclear ophthalmoplegia with ataxia of limbs and gait. 
Neurodegeneration involved the cerebellar peduncles, dorsal columns and basal 
ganglia predominantly although some affected families also demonstrated loss of 
Purkinje cells. Normal individuals had 13 to 36 repeats while SCA3 patients had 66 
to 79 (Matilla et a l , 1995).
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6.2.2.7 Spinocerebellar ataxias 4, 5 and 7 (SCA4, 5, and 7)
These conditions were clinically indistinguishable and characterised by ataxia, 
dysarthria, dysmetria, intention tremor and macular degeneration leading to 
blindness. On neuropathological investigation, degeneration of the pathways 
associated with the cerebellum was found. The exact position of the CAG 
expansion remained to be defined for these conditions although the chromosomal 
locus in SCA4 and SCA5 had already been identified: SCA4; 16q24 and SCA5;
1 lcen.
6.2.2.8 Spinocerebellar ataxia 6
SCA6 was characterised by ataxia, dysarthria, nystagmus and vibratory sense loss. 
Cerebellar and mild brain stem atrophy were seen. The affected gene encoded 
ataxin-6 (a calcium channel subunit, a ^ ) -  This condition was unusual in that 
normal individuals had 4 to 16 repeats while affected patients had a relatively small 
expansion with only 21 to 27 repeats.
6.2.2.9 M achado-Joseph disease (MJD)
MJD could be separated into three distinct subtypes on the basis o f age at onset and 
clinical presentation (DeStefano et a l , 1996). Type II was the most frequent 
presentation with progressive ataxia, pyramidal signs and ophthalmoplegia. The 
mean age of onset for this group was approximately 40 years of age. Type I was 
characterised by early onset and had marked pyramidal and extra-pyramidal signs in 
addition to the signs seen in type II. Type III was also associated with marked distal 
atrophy and sensory loss and tended to develop between 40 and 60 years o f age. 
The molecular lesion was an expanded CAG trinucleotide repeat sequence in the 
Machado-Joseph disease 1 (MJD1) gene on chromosome 14 which encoded ataxin- 
3. Normal individuals had 12 to 37 repeats while affected patients had between 61 
and 84 repeats (Paulson et a l , 1997).
6.2.2.10 Dentatorubral-Pallidoluysian atrophy (DRPLA)
DRPLA was a rare neurodegenerative disease characterised by ataxia, 
choreoathetosis, myoclonus, epilepsy and dementia. Clinically, this condition had 
been divided into three subtypes; myoclonic-epilepsy, pseudo-Huntington's and 
ataxic-choreoathetoid forms. However, the distinctions between these types were 
not precise and more than one form could be seen within the same family. DRPLA 
showed anticipation, the most severe cases usually resulted from paternal 
transmission. Patients which exhibited early onset usually progressed more rapidly 
and had myoclonic epilepsy. Neuronal degeneration was frequently widespread and
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particularly severe in the globus pallidus, dentato-rubral system and subthalamic 
nucleus (Luys body). The CAG repeat in the CTG-B37 gene encoded a 
poly glutamine tract in a protein predicted to be 124kDa. This gene was one of a 
family which were expressed specifically in the CNS. Paulson and Fischbeck 
(1996) reported that normal individuals had 7 to 25 copies of the repeat compared 
with 49 to 88 copies in affected patients.
6.2.2.11 Haw river syndrome (HRS)
A condition with marked clinical and pathological similarities with DRPLA, Haw 
river syndrome, was an autosomal dominant neurodegenerative disease 
characterised by ataxia, chorea, seizures and dementia. There was a marked 
neuronal loss in the dentate nucleus, microcalcification of the globus pallidus, 
demyelination of the centrum semiovale and marked neuroaxonal dystrophy of the 
posterior columns (Burke et al., 1995). This specific condition had been seen in 
only one African-American family where it started between 15 and 30 years of age 
and progressed to death within 15 to 25 years. The molecular lesion involved a 
CAG expansion of the CTG-B37 gene. Burke et al. (1995) found three to 13 repeats 
in normal individuals with patients having 63 to 68 repeats (these figures varied 
from those given for normal individuals quoted in the previous paragraph, however 
both ranges were well below the threshold for disease). Due to the geographical 
distance between the Japanese families with DRPLA and this HRS family it was 
likely that HRS had occurred as a spontaneous mutation.
Despite a number of neurodegenerative diseases being reported which shared 
extended polyglutamine stretches in the altered proteins, the pathogenesis of the 
neuropathology was still controversial. Based on the phenotypic similarities 
between these diseases there appeared to be a common mechanism at work. In 
addition, recent work had led to the identification of proteins which interacted with 
polyglutamine peptides, irrespective of the specific flanking amino acids (Pulst et 
a l , 1996). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was bound by a 
poly glutamine peptide, both huntingtin and atrophin-1 (the DRPLA gene product) 
bind to GAPDH in vitro. A binding protein had been identified which appeared to 
interact specifically with huntingtin and not with atrophin-1. Although huntingtin 
was widely expressed, this huntingtin-associated protein showed a pattern of 
expression restricted to cell types involved in Huntington’s disease and may have 
explained the cell-type specific degeneration seen in the disease.
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6.3 Perspective
A number o f late onset neurodegenerative diseases in humans bore resemblances to 
CDRM. Several o f these autosomal dominant diseases viz. SCA I, DRPLA, MJD 
and Huntingtons Disease correlated with the presence of a CAG trinucleotide repeat 
expansion which encoded a poly glutamine tract. To date, all diseases which 
corresponded to a trinucleotide repeat expansion had been restricted to humans. All 
were late-onset disorders characterised by degeneration of specific (though different 
in each case) neuronal populations. In addition, there was considerable 
heterogeneity even within a single disease. It was remarkable that so many late- 
onset neurodegenerations were caused by the same basic mutation viz. a CAG 
expansion. Based on a combination of the high incidence of CDRM in the GSD 
population and the clinical and pathological similarities between CDRM and the 
human disorders an investigation into whether CDRM in the dog was also 
associated with a CAG trinucleotide repeat expansion was begun. It must be 
emphasised that although CDRM affected specific neuronal populations, the 
distribution of the neurodegeneration in CDRM was not identical to any of the 
aforementioned human neurodegenerative disorders.
Such a search raised two main factors which merit close attention. One inherent 
difficulty was the late age of onset of CDRM as compared to the expected life span. 
Dogs can develop clinical signs at any time from six years up to 14 years o f age, life 
expectancy for the GSD is 12 to 14 years. Thus it was anticipated that the 
establishment of a strong control population would be extremely difficult. In 
addition, limited reports had occurred (Rubinsztein et al., 1996) o f individuals in 
old-age who had remained without clinical signs of Huntington's disease despite 
having CAG repeat expansions in the disease size range. Another difficulty was the 
significant variation in normal and diseased size ranges of trinucleotide repeat 
expansions which had been found between laboratories.
6.3.1 Experimental Programme
A series o f parallel, but distinct, approaches were instigated. The initial 
investigation involved the specific technique of PCR of GSD gDNA to determine 
the existence of the canine orthologue to SCAI, CTG-B37 (DRPLA) and MJD I 
genes. This was followed by Repeat Expansion Detection (RED) analysis of CAG 
repeat elements per se, a technique which would detect trinucleotide repeat 
expansions without prior knowledge of the chromosomal location. At the same time 
Southern blotting analysis was used for the attempted identification o f a specific 
restriction enzyme fragment harbouring the CAG expansion. As an adjunct to these
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genomic manipulations, western blot analysis using the 1C2 antibody raised against 
the TATA-binding protein (TBP), which has specifically identified expanded 
polyglutamine tracts in a number of the human neurodegenerative diseases, was 
employed.
6.4 Canine orthologues of human genes associated with 
late onset progressive neurodegenerative disorders
6.4.1 Perspective
At the time of commencement of this study the molecular basis for a number of the 
human progressive neurodegenerative disorders had been characterised. Primer 
pairs, for use in PCR were available for three of the conditions, namely SCA1, 
DRPLA and MJD. As part of a study w3hich investigated the characterisation of 
the gene causing SCA1 and identification of its murine orthologue, sequence 
analysis had been carried out on a 3kb segment of the murine Seal gene. Results 
indicated that Seal encodes a predicted protein of 792 amino acids which showed 
89% amino acid identity with the human protein. In addition, preliminary analysis 
of the murine locus suggested that it was similar to the human locus and had two 
large exons which contained the coding region and a very long 3/UTR with 
sequence homology which extended into the 5/UTR (85%) and 3/UTR (63%) 
regions (Banfi et a l,  1994). These findings suggested the existence of a reasonable 
degree of cross-species homology between the human and canine Seal genes.
Could a canine orthologue to any of these three genes, namely SCA1, CTG-B37 or 
MJD1, be identified by PCR ? (see Figure 21, page 171). The first step in this 
investigation was the random testing of the available human primers by PCR. The 
initial aim being to ensure that the primer pairs were not species-specific. Once it 
was established that the primers would amplify canine gDNA, they were tested 
against a number of affected dogs and an age-matched control group in an attempt 
to ascertain if a product similar to that produced in affected humans was seen in the 
dogs with CDRM.
6.4.2 Primers
Sequences for the primer pairs used to amplify genomic fragments of SCA1 (SCA1) 
and CTG-B37 (DRPLA) genes in addition to the control PCR product lengths are 
detailed in Table 6, page 61. The partial cDNA clone for ataxin-1 was kindly 
donated by Dr H. Zoghbi, Departments of Paediatrics and Molecular and Human 
Genetics, Baylor College of Medicine, Houston. The primer pairs available for
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MJD1 (MJD) were pulled out following a data base search, but although the two 
available reverse primers were exonic, the only forward primer was entirely intronic 
(Kawaguchi et a l , 1994). This essentially ruled them out for use in cross-specific 
amplification of the canine orthologue of the MJD1 gene.
6.4.3 Results
6.4.3.1 Rep-l/Rep-2
RT-PCR of pAx which harbours a partial cDNA ataxin-1 human clone confirmed a 
band around 200bp corresponding to the predicted PCR product of 214bp (Chong et 
a l , 1995). Figure 22 (page 172) indicates that this product is present in both 
affected and unaffected dogs but it does not occur in the mouse. A total o f nine 
affected and two control dogs were investigated. Despite altering the Mg 
concentration, the addition of 2 % formamide and alteration of the annealing 
temperature, the presence of spurious bands was invariant.
6.4.3.2 DRPLA-l/DRPLA-2
A band corresponding to the predicted PCR product size of 140bp was readily 
resolvable against human gDNA. PCR product obtained from mouse had no 
corresponding signal at 140bp, however there was a band corresponding to 
approximately 130bp. A total of two affected and two control dogs were tested with 
these primers, there was no evidence of the band of interest in any of the dogs tested 
Figure 23, page 173.
6.4.4 Discussion
These studies were equivocal regarding the presence of a canine orthologue to either 
SCA1 or CTG-B37. This issue could be resolved by performing a Southern blot 
analysis and probing with the isolated SCA1 or CTG-B37 fragment respectively. 
This would (a) identify if a canine orthologue was present and (b) whether there was 
any size difference between dogs with CDRM and unaffected dogs, in each case.
170
Investigation of potential molecular lesions
initiation stop
codon codon
2080br
5 UTR— Q ] 0 S [ l ] S f f l B ] [ 3'UTR
-H.CAG) —  
n
PCR product
| (CAClt |  C o n t r o l
(CAG)
n+m l C D R M
Figure 21. A schematic representation of the SCA1 transcriptional unit 
illustrating the anticipated differences in PCR product profile that would be 
between CDRM and control dogs if there was an expansion similar to that found 
in SCA1 in man.
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Figure 22. Products of PCR reaction using primers Rep-1 and Rep-2. Lanes 1 
and 10 lOObp DNA ladder, lanes 2 and 3 gDNA from two unaffected GSDs 
(Dogs 6 6  and 77), lanes 4 and 5 gDNA from two GSDs with CDRM (Dogs 49 
and 3), lane 6  gDNA from normal mouse, lane 7 human gDNA, lane 8  pAx 
(positive control), lane 9 SDW (negative control).
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140bp
Figure 23. Products of PCR reaction using primers DRPLA-1 and DRPLA-2. 
Lanes 1 and 9 lOObp DNA ladder, lanes 2 and 3 gDNA from two unaffected 
GSDs (Dogs 6 6  and 77), lanes 4 and 5 gDNA from two GSDs with CDRM (Dogs 
3and 49), lane 6  gDNA from normal mouse, lane 7 human gDNA (positive 
control) and lane 8 SDW (negative control).
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6.5 Southern blot analysis
6.5.1 Perspective
A preliminary data base search (data not presented) confirmed as in other 
mammalian genomes, CAG elements of varying unit length were well represented 
throughout the canine genome. The basic aim of this Southern blotting analysis 
study was to detect and identify small restriction enzyme fragments harbouring 
CAG repeats. The experimental design, as depicted in Figure 24 (page 175), 
involved enzymatic digestion of affected and control canine gDNA with a cocktail 
o f four cutter restriction enzymes (Figure 25, page 176) which did not contain CAG 
or its complement within their recognition sequence. The high predicted frequency 
of four base recognition i.e. 1 :4 4 in combination with other four cutters, formed the 
basis of expectation that size differences due to variation in the CAG content within 
small restriction enzyme fragments would be resolvable at the level of Southern 
detection.
As detailed in Figure 24 (page 175) such an approach may have led to the 
identification of a “footprint” i.e. restriction fragment hybridisation profile which 
would distinguish affected from unaffected dogs. If  such a “footprint” could be 
obtained, in addition to providing a preliminary diagnostic test, it would lead to a 
gene isolation programme.
Digests were performed as discussed in 2.8 .5.3 Restriction enzyme digestions (page 
62).
A number of restriction digestion enzymes were employed (Table 7, page 62). 
Three groups of CDRM dogs were selected for Southern blotting analysis on the 
basis of their classification of (a) clinical diagnosis of CDRM (Dogs 33, 32, 56, 57,
30) (b) diagnosis of CDRM confirmed at post mortem (Dogs 14, 2, 31) (c) diagnosis 
of CDRM confirmed at post mortem and had shown a possible expansion with the 
RED technique (6.6.1 Perspective, page 180) (Dogs 18, 17, 3). In addition, two 
groups of control dogs were selected, three non-GSDs (Dogs 101, 103, 104) and 
seven GSDs with no clinical signs of CDRM (Dogs 62, 74, 61, 60, 82, 6 8  and 69).
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Figure 24 Overall strategy in relation to the Southern analysis if  constant 
differences between CDRM cases and unaffected dogs were identified.
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Figure 25. Schematic outline of the experimental strategy employed to size 
fractionate restriction enzyme fragments harbouring putative CAG expanded 
repeats associated with CDRM and control dogs.
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6 .5 .2  R esu lts
The integrity o f the high molecular weight (MW) gDNA used throughout the study 
which remained intact following prolonged incubation at 37°C and sequential 
reduction in the size of the digested gDNA population following digestion with 
various restriction enzyme cocktails o f four and six cutters is illustrated in Figure 26 
(page 178).
Autoradiograph of Southern blot showing differences in hybridisation profiles using 
random primed 32P labelled DNA probe generated from DM 200 cloned PCR 
product for seven affected dogs and three unaffected dogs is illustrated in Figure 27 
(page 179). Other combinations of enzymes were tested (data not presented) but, as 
is depicted in Figure 27 differences in hybridisation profiles could not be equated 
with dogs affected and those unaffected by CDRM.
6.5 .3  D iscu ssion
The ambition of the Southern analysis was to determine whether it was possible to 
produce a diagnostic “footprint” for dogs affected with CDRM. The results 
obtained suggested that there were different hybridisation profiles but these could 
not be resolved into affected and non-affected groups. It was decided that although 
a more concentrated and detailed study may indeed have resolved the problem, the 
effort and the time could not be justified. There were several other possibilities for 
investigating the problem which could potentially provide a more direct route to the 
answers.
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23kb
Figure 26. Example of canine gDNA undigested and digested with a range of 
four cutter and six cutter restriction digestion enzymes run out on a 0.7% 
agarose gel. The two m arkers used are X H in d lll (lane 1) and lOObp ladder 
(lane 9). Lane 2 undigested gDNA, lane 3 undigested gDNA incubated at 37°C, 
lane 4 gDNA digested with Bam HI, lane 5 gDNA digested with Bam  HI and 
Hind  III, lane 6  gDNA digested with Hae III, lane 7 gDNA digested with Hae 
III and Hha  I, lane 8  gDNA digested with Hae III, Hha  I and San  3AI.
178
Investigation o f potential molecular lesions
Figure 27. Autoradiograph of Southern blot showing differences in 
hybridisation profdes, using random primed 32p labelled DNA probe generated 
from DM 200 cloned PCR product. The gDNA had been digested with BamYLl 
and Hae III. Lanes 1, 5, 6 , 7, 8 , 9 and 10 are GSDs with CDRM (Dogs 14, 
33,32, 39, 31, 57 and 42), lanes 2, 3, and 4 are normal non-GSDs (Dogs 101, 104 
and 33).
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6.6 Repeat expansion detection (RED)
6.6.1 Perspective
Repeat expansion detection was a technique first developed by Schalling in 1993 
(Schalling et al., 1993). The RED technique was a genome-wide screening method 
and represented a shortcut in identifying a subtype of mutations, compared to 
linkage and positional cloning (Lindblad et a l, 1996). It therefore had the potential 
for identification of a pathological repeat expansion in a genetically uncharacterised 
disease without any knowledge of the chromosomal location of the mutation or 
candidate disease gene. Genomic DNA was used as template for a two-step cycling 
process which generated oligonucleotide multimers when expanded trinucleotide 
sequences were present in large numbers.
The aim was to utilise the RED technique to look for a potentially pathological 
repeat expansion in GSDs.
The basis of this technique was the ability of a single oligonucleotide to hybridise to 
its complementary strand in gDNA. A thermostable ligase was used to covalently 
link adjacent oligonucleotides which formed a larger single-stranded fragment. 
Repeated cycles o f denaturation and annealing followed by ligation resulted in the 
formation of detectable levels of fragments which represented multimers of the 
oligonucleotide. The accumulation of ligation products was strongly dependent on 
the amount of substrate DNA, active enzyme and the cycle number used. Use of a 
high molar excess of oligonucleotide, ensured that any previously ligated products 
would be unable to further ligate, thus the maximum fragment size generated would 
correspond closely to the actual size o f the longest repeat with a particular sequence 
motif in the genome. This technique is illustrated in Figure 28 (page 181). Details 
o f the mouse gDNA which was used as an internal control are given in 2.8 .6 .3 
Ligation (page 64).
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Figure 28. A schematic representation of the repeat expansion detection (RED) 
technique outlining the key steps. Mo mouse control, C. control dog, CDRM 
affected dog.
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Two oligonucleotides were selected, a 51mer comprising 17 CTG repeats 
(Cruachem) and a 30mer comprising 10 CTG copies (Oligonucleotide Synthesis, 
Yale Medical School), these were within a suitable size range for the anticipated 
expansions and had shown consistent results when used in other laboratories. A 
total o f 120 dogs were tested. Twenty one of the CDRM cases (including three 
GSDXs) had been confirmed at post mortem while 36 (including one GSDX) were 
clinically affected. The control group included a large number of neurologically 
normal dogs in addition to a smaller group of dogs with well-defined focal spinal 
cord lesions. In the control group there were 22 GSDs, three GSDXs, 26 non-GSDs 
and 12 dogs with focal spinal cord lesions. A complete list of all dogs tested is in 
Table 1 (pages 33-44). The ideal control group would have been equal numbers of 
age-matched unaffected GSDs, this was operationally difficult to achieve, thus the 
average age of the unaffected GSDs was less than that of the affected group. 
However, one of the control GSDs was 13 years old (Dog 66).
6.6.2 Results
Each individual run had to be considered on its own merits, direct comparisons were 
possible only if the conditions resulted in an identical mouse profile. A series of 
experiments which utilised the 51mer are illustrated in Figure 29 (page 184), the 
mouse ladder is shown in each and the number of bands is presented. In the first 
experiment (a) one affected dog had product at 102bp, 153bp, 204bp and 255bp 
(Dog 5), Figure 30 (page 185), while 11 other affected dogs had a maximum 
product size of 153bp. The control group had signal at 102bp (Dogs 92, 89, 91, 
100, 94, 86) and 153bp (Dogs 104, 78, 87, 88, 105, 84, 106, 85). In the second 
experiment (b) two affected dogs had evidence of product at 102bp, 153bp and 
204bp (Dogs 3 and 4), Dog 3 also had a faint product band at 255bp (Figure 31, 
page 186), while three affected dogs had product at 102bp only (Dogs 1, 2 and 49). 
The remaining four gDNAs were from control animals all of which had product at 
102bp only. At this stage a number of experiments were conducted using the 
30mer. Results from these suggested that two affected dogs had an expansion (Dog 
18 had signal up to and including 210bp while dog 17 had signal up to and including 
240bp) while 26 affected dogs had no signal greater than 120bp. All control dogs 
had signal no greater than 90bp or 120bp. The 51mer was then used for a final 
group of experiments aimed at establishing whether or not a CAG expansion was 
involved in CDRM.
In (c) all dog gDNAs tested had a maximum signal size of 102bp, this included four 
affected (Dogs 40, 6, 15, 33) and four unaffected GSDs (Dogs 66, 67, 68, 69). In 
(d) three affected dogs (Dogs 35, 53, 54), two old unaffected GSDs (Dogs 66 and 
68) and two control dogs which were non-GSDs were tested, all had a maximum
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signal of 204bp. Considering (e), (f) and (g) as a group, all dogs tested had a 
maximum signal o f 153bp (Figure 32, page 187). This group included 12 affected 
dogs (Dogs 41, 42, 4, 51, 43, 44, 31, 32, 45, 48, 46, and 47), two o f which were run 
twice on separate occasions (Dogs 4 and 45), the remainder were from GSDs of 
eight years and older with no clinical signs of CDRM at the time of collection of the 
blood sample.
gDNA was extracted from the brain (not the red nucleus as this was being collected 
to make a cDNA library) of eight post mortem cases, because this somatic tissue 
might have had a greater number of expansions than blood, so sensitivity would 
have been improved. Five of the dogs were CDRM cases (Dogs 28, 50, 31, 33 and 
3) and three were dogs with focal spinal cord lesions (Dogs 118, 119 and 120). The 
aims were to examine the signal obtained with gDNA extracted from brain for these 
dogs, the results were then compared with those obtained from blood for the same 
group of dogs. Initially all eight brain gDNA samples were tested. Under these 
conditions the mouse control had a maximum signal of 357bp. In this run two of 
the affected dogs (Dogs 50 and 31) had a maximum product size of 153bp. The 
remaining gDNAs gave no signal above 51 bp (the 51 bp product had run off the 
bottom of the gel). This experiment was repeated, on this occasion the mouse 
control gave a maximum product size of 306bp, the same two dogs (Dogs 50 and
31) had a maximum signal of 102bp while two more CDRM cases (Dogs 3 and 28) 
had signal at 51 bp. As before, none of the controls had any visible signal. A 
comparison between gDNA extracted from blood and brain was run for four dogs. 
Three affected (Dogs 28, 50 and 33) and one control (Dog 120) were tested. The 
mouse control had a maximum signal size of 255bp. All four gDNAs from blood 
samples had bands at 51 bp and 102bp, while that from one of the CDRM cases 
(Dog 28) also had a band at 153bp. O f the four samples of gDNA from brain, one 
of the affected dogs (Dog 50) had a visible band at 51 bp while none of the control 
dogs had any visible band (Figure 33, page 188).
6.6.3 Discussion
O f the 57 affected dogs tested, five were RED positive. O f the 63 control dogs 
tested there was no evidence for an expansion, this included the twelve animals with 
focal spinal cord lesions. It was technically difficult to reproduce the sensitivity of 
the technique, however the extent of separation of the mouse positive control was a 
useful guide to sensitivity in each run. Overall, the results suggest that there may be 
an expansion involved in a number of dogs with CDRM. There were a number of 
possible reasons why the results were equivocal. It may be that the technique was 
not sensitive enough to pick up what may be a relatively small expansion. An 
obvious modification would be to reduce the length of the oligonucleotides.
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Figure 30. Autoradiograph of the RED technique using 32P-labelled (CAG)iq. 
Lanes 1, 2, 4 and 8 normal non-GSDs (Dogs 104, 78, 87 and 88 respectively), 
lanes 3, 5, 6 and 7 GSDs with CDRM (Dogs 5, 6, 7 and 8 respectively). Dog 5 
has product up to and including 204bp and 255bp (arrows). (Perform ed by Dr. 
Bonnie King).
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255bp
204bp
153 bp
102 bp
P S R
Figure 31. Autoradiograph of the RED technique using 32p_iabelled (CAG)jo- 
In all cases the gDNA was derived from blood. Lane 1 mouse ladder, lanes 2, 6, 
7, 8 and 9 are from dogs with CDRM (Dogs 49, 7, 4, 3 and 1 respectively), lanes 
3, 4 and 5 are from control dogs (Dogs 83, 103 and 102 respectively). Dogs 4 
and 3 have product up to and including 204bp while Dog 3 had a faint band at 
255bp (arrows). (Performed by Dr. Bonnie King).
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Figure 32. Autoradiograph of the RED technique using 32p_iabened (CAG)io- 
In all cases the gDNA was derived from blood. Lane 1 mouse ladder, lanes 2, 4, 
5, 6 and 7 are from dogs with CDRM (Dogs 47, 46, 4, 48 and 45 respectively), 
lanes 3, 8 and 9 are from control dogs (Dogs 77, 76 and 75 respectively).
187
Investigation of potential molecular lesions
3 0 6 b p
2 5 5 b p
: 2 0 4 b p  
1 5 3 b p
1 0 2 b p
5 1  b p
1 2  3 4 5 6 7  8 9
Figure 33. Autoradiograph of the RED technique using 32p_ia belled (CAG)iq. 
The gDNA is derived from two sources; blood and brain, for each dog. Lane 1 
Dog 120 (control) gDNA from blood, lane 2 Dog 120 gDNA from brain, lane 3
Dog 28 (CDRM) gDNA from blood, lane 4 Dog 28 gDNA from brain, lane 5
Dog 50 (CDRM) gDNA from blood, lane 6 Dog 50 gDNA from brain, lane 7
Dog 33 (CDRM) gDNA from blood, lane 8 Dog 33 gDNA from brain, lane 9
mouse ladder. Dog 28 (gDNA from blood) gave a 153bp product (arrow).
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6.7 Western blot analysis
6.7.1 Perspective
A monoclonal antibody named 1C2, had been raised against TATA-binding protein 
(TBP), which had a stretch of 38 poly glutamines (Trottier et a l ,  1995). This 
monoclonal antibody specifically recognised peptides overlapping the 
polyglutamine stretch. It had been used successfully to detect expanded 
poly glutamine repeats in Huntington's disease, SCA1 and SC A3, when applied to 
lymphoblastoid cell lines (LCLs) in patients affected by these diseases. As all the 
dogs to be tested were to be euthanased and an abundance of suitable tissue could be 
collected there was no need to develop LCLs. The MOBP antibody was used as a 
qualitative and quantitative control (Figure 34b, page 190).
The aim was to use the 1C2 monoclonal antibody to look for pathogenically 
expanded polyglutamine tracts in dogs with CDRM.
In this study the western blot analysis was carried out on protein lysates from whole 
brain which had been collected within 40 minutes of death and stored in liquid 
nitrogen, details of the preparation are given in 2.8.7.1 Sample preparation, page 66. 
A total of eight samples were tested, three from dogs with focal spinal cord lesions 
(Dogs 118, 119 and 120) and five from dogs with CDRM (Dogs 3, 28, 31, 33 and 
50). The positive control was the protein extract from a SCA1 cell line (Coriell Cell 
Repositories, Bar Harbor), (Figure 35, page 191). Full details o f the technique are 
given in 2.8.7 Western blot analysis (pages 66-68).
6.7.2 Results
The first run indicated a band corresponding to 71kDa for six o f the dogs tested 
(Dogs 120, 119, 118, 28, 31,33), the remaining two dogs (Dogs 3 and 50) had no 
band (Figure 35, page 191). A second run with the same samples resulted in a 
71kDa product in a different group of six dogs (Dogs 120, 118, 28, 50, 31, and 3) 
and no product in two of the dogs (Dogs 119 and 33), (Figure 34, page 190).
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F igure 34. F luorographs o f  w estern analysis on protein  lysates o f  w h o le  brain  
using the E C L  technique. Lanes 1, 2 and 3 dogs w ith focal sp inal cord  lesions  
(D ogs 120, 118 and 119 respectively), lanes 4, 5, 6, 7 and 8 dogs w ith  C D R M  
(D ogs 28, 50, 31, 3 and 33 respectively), (a) 1C2 antibody (b) M O B P  antibody . 
(P erform ed  by D ouglas K irkham )
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71kDa
68kDa
Figure 35. Fluorograph of western analysis of protein lysates from whole brain 
using the ECL technique. Lanes 1 and 6  SCA1 cell line (positive control) lanes 
2, 3, 4, 7 and 8 dogs with CDRM (Dogs 33, 31, 28, 3 and 50 respectively), lanes 
5, 9 and 10 dogs with focal spinal cord lesions (Dogs 118, 119 and 120 
respectively). (Performed by Dr. Bonnie King).
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6.7.3 Discussion
This preliminary set of results suggested that the 1C2 monoclonal antibody could be 
successfully applied to canine tissue, it also suggested that protein lysates were a 
suitable medium for western blot analysis with this monoclonal antibody (Figure 34, 
page 190). However, there was no clear distinction of western profiles between 
CDRM cases and control dogs. The technique requires improvement and 
application to a tighter control population i.e. aged GSDs with no clinical signs of 
CDRM. The dogs tested to date were cases euthanased and post-mortemed at 
GUVS during the course of the project.
The ability of the 1C2 monoclonal antibody to detect altered proteins depended on 
the length of the poly glutamine stretch. In the human disease situation, patients 
proteins which contained a long poly glutamine stretch (60-85 glutamines) gave a 
much stronger signal intensity than those with fewer polyglutamines (~40) which 
suggested that this was a quantitative technique (Trottier et al., 1995). It may be 
that the length of any polyglutamine stretch in the CDRM dogs would be too short 
to result in an obvious difference when compared with unaffected dogs.
6.8 General Discussion
At the start of this project neurodegenerative diseases associated with a CAG 
trinucleotide repeat expansion had been identified in man and investigated using a 
number of molecular biological techniques. Amplification of specific genomic 
regions harbouring the CAG repeats, by PCR, involved the application of human 
primers directly to canine tissue, in the expectation that there would be sufficient 
cross-species homology to imply a canine orthologue. Results obtained, suggested 
that in the case o f the SCA1 primers, there was cross-species homology but there 
was no distinction between affected and unaffected dogs tested. Application of the 
DRPLA primers was less successful, none of the dogs tested had the expected 
product. The only other primer pairs available at this stage were those for MJD. 
These were not tested as the forward primer was entirely intron sequence. Intronic 
sequences were not well conserved between species. Accordingly there was a high 
probability that intronic primers would vary considerably between species thus the 
likelihood of detecting a canine orthologue to a human gene was very low.
Southern blot analysis was employed initially to try and find a “footprint” for 
affected dogs, which differed from unaffected dogs. If  a “footprint” could be 
established it would be a starting point for gene isolation as it would provide a probe 
to screen appropriate libraries. In addition, isolation of the specific fragment would
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allow the sequence to be determined. This in turn would allow primers flanking the 
repeated region to be designed, such that gDNA from dogs could be screened by 
PCR for size differences between affected and unaffected dogs. This approach 
would still be applicable if the other techniques currently being tried proved 
unsuccessful.
Application of the RED technique to gDNA samples from a group of affected and 
unaffected dogs confirmed that there were a number of products of varying size 
which could be identified in both the CDRM and control dog populations. This 
technique was applied to gDNA obtained from blood and brain, that obtained from 
blood proved more useful. Profound differences in the distributions of longest 
(CAG)n repeat lengths have been found in different human populations (Sirugo et 
a l, 1997). This suggested that it was important to have accurate information on the 
normal variation of trinucleotide repeats of interest within the species population 
being studied in order to minimise population stratification artefacts. In man, such 
variations were best explained by random genetic drift of alleles at (CAG)n- 
containing loci. The mutation rate at such loci must be low, as a high mutation rate 
would homogenise allele frequencies within a short evolutionary period, thus any 
evidence of random genetic drift among populations would be obscured. Thus, 
gross instability events were, in all probability, a rare phenomenon.
In any investigation which involved a late-onset disease in an inbred population 
such as the GSD, the optimal control population would be old unaffected dogs of 
the same breed. This was operationally difficult as GSDs could develop clinical 
signs of CDRM over a wide age range. To compensate for this possible problem, a 
large number of non-GSDs of widely varying ages (three to thirteen years old) were 
tested alongside the GSDs with CDRM. Results o f this study would suggest that, 
depending on specific experimental conditions, dogs unaffected by CDRM can have 
repeat lengths corresponding to ligation of up to four (CTG) 17 oligonucleotides 
which was equivalent to genome lengths of (CAGj^g to (CA G )^. However, dogs 
in the unaffected group most commonly had ligation of up to three (CTG) 17 
oligonucleotides. Dogs with CDRM can have repeat lengths corresponding to five 
(CTG) 17 which was equivalent to genome lengths of (CAG)s5 to (CAG)ioi- Using 
the lOmer, the control dogs had a maximum of four ligated (CTG) 10 while the two 
CDRM cases which had evidence of an expansion had seven and eight ligated 
(CTG) 10 oligonucleotides. Taking the results as a whole, but ignoring RED run (d) 
in Figure 29 (page 184) which varied in sensitivity compared to other runs in the 
group, the maximum number of repeats found in the unaffected dogs was 51 while 
the affected dogs with “expansions” had a minimum of 70 trinucleotide repeats. Of 
the affected dogs tested by the RED technique only a very small proportion (9.4%)
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had evidence for a possible trinucleotide expansion. However, none of the 
unaffected dogs either GSDs or other breeds had any evidence of expansion. This 
fact alone suggested that a trinucleotide repeat expansion cannot be excluded as a 
possible factor in the development of CDRM.
These findings suggested that either CDRM was caused by a trinucleotide repeat 
expansion in combination with other factors, or the expansion was too small to be 
detected by the size of oligonucleotides used. The use of smaller oligonucleotides 
would improve the sensitivity o f the technique and so address this question. One 
problem was the lack of consistency in the results. One case (Dog 4) had a product 
corresponding to ligation of five (CTG) 17 in one run only, despite there being better 
separation of the mouse ladder on subsequent runs where the maximum product for 
the same dog was three (CTG) 17. Recent work by Sirugo et al (1997) established 
the consistency of results with the RED technique when it was applied to both 
humans and non-human primates. The inconsistencies found in this study may have 
been another reflection of the need for more sensitive techniques in the dog 
compared with humans and non-human primates.
The preliminary work carried out so far on Western blot analysis using the 1C2 
antibody suggested that the technique may still be useful but some fine-tuning was 
required. The target proteins which were defective in the human neurodegenerative 
diseases were dissimilar, but for the presence of polyglutamine stretches. In 
addition, the proteins probably had different, but as yet unknown, functions. SBMA 
was the only condition where the protein function was known, this protein was an 
androgen receptor. The 1C2 antibody had a strong length affinity, which suggested 
that a unique conformation was recognised which required a minimum length of 
polyglutamine, this conformation was then stabilised by any further increase in size 
(Trottier etal., 1995).
In summary, the results from the above experiments provided some evidence that 
CDRM may be caused by a trinucleotide repeat expansion. However further work 
would be required to definitively prove whether or not this was the case.
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The material presented in this thesis concerned the clinical presentation, 
neuropathology and the assessment of potential aetiologies of chronic degenerative 
radiculomyelopathy in the German shepherd dog. The clinical study confirmed 
most of the previous findings (Averill, 1973; Griffiths and Duncan, 1975a; Braund 
and Vandevelde, 1978; Clemmons, 1989). The only notable difference found was a 
clinical course of six to 18 months rather than the six to 12  months previously 
reported (Clemmons, 1992). This clinical course related to the time period from 
onset of clinical signs to loss of effective pelvic limb function. Only two cases 
developed thoracic limb signs which were manifested as stumbling. Thoracic limb 
involvement occurred approximately two years after the onset o f pelvic limb signs, 
which had necessitated the use of “dog carts” to maintain some mobility. 
Clemmons had suggested, without indicating a time scale, that dogs may eventually 
progress to develop brain stem signs (1992). There was no indication of brain stem 
signs occurring in any of the dogs in the present study, even in the two cases 
maintained for over two years. It was unlikely that any of the cases seen in this 
study could have meaningfully been maintained any longer as they were very 
severely debilitated. Further findings from the clinical study suggested that 
although CDRM did occur in other large breeds o f dog, it was predominantly a 
disease of the GSD. The finding of several pairs of affected littermates, and 
evidence of cases in several generations in the same pedigree lineage within the 
GSD breed strongly suggested that the disease had a genetic basis. A molecular 
investigation of this aspect of the aetiology of CDRM was instigated, and pedigree 
collection to allow the establishment of a GSD pedigree database is currently 
underway.
The neuropathology study confirmed earlier descriptions of spinal cord pathology. 
Lesions in the spinal cord white matter were indicative of breakdown of both axons 
and associated myelin sheaths, often with a concurrent microglial and/or 
macrophage response and astrocytosis. These changes, typical of Wallerian-type 
degeneration, were found in both ascending and descending tracts. The 
corticorubrospinal tracts {i.e. the overlapping corticospinal and rubrospinal tracts in 
the lateral funiculi) were the most severely affected, particularly from the mid- 
thoracic to mid-lumbar segments. There may be some evidence to suggest that the 
disease affects the distal portions of certain long tracts such as the 
corticorubrospinal tract and the fasciculus gracilis. As the rubrospinal tract is a very 
important motor tract in the dog, this finding was consistent with the motor deficits 
found on clinical examination. Comparison of gait score at death with the pattern of 
degeneration on histopathological examination of the spinal cord for the 25 dogs 
included in the pathology study suggested that there was some correlation between
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the clinical signs and extent of degeneration. However, the exact pattern of 
degeneration could not be predicted by gait score alone. The proprioceptive deficits 
which occur would be consistent with the pathology seen in the major 
proprioceptive tracts of the spinal cord such as the fasciculus gracilis, with some 
involvement of the degenerated spinocerebellar tracts.
Changes were also found in specific nuclei and white matter structures of the brain. 
The red nucleus was the most severely and consistently affected structure. Changes 
in this nucleus were degenerating neurones, manifested as both neurones with 
eccentric nuclei and chromatolytic neurones. In addition, there was evidence of a 
neuronal dropout in the most severely affected dogs. The red nucleus is o f great 
importance both as the major motor centre in animals and as a relay point for 
proprioceptive impulses from cerebellum to cerebral cortex (Jenkins, 1978). Thus, 
some of the major clinical signs seen in cases of CDRM i.e. ataxia and paresis were 
consistent with degeneration in this nucleus. The associated degeneration found in 
the ventral tegmental decussation and in the rubrospinal tracts provide further 
evidence that the changes within the red nucleus were likely to be of significance. 
Though the neuropathology study did not suggest a specific aetiology it has allowed 
some of the previously-suggested causes to be excluded. Several authors had 
suggested that CDRM was a chronic demyelinating disorder (Waxman et a l ,  1980a; 
Waxman et al., 1980b). However, both light microscopy and electron microscopy 
studies completed in this project strongly suggested that both axons and the myelin 
sheaths were involved in the degeneration thus CDRM was a neurodegeneration 
rather than a demyelinating disorder.
Despite the finding of previously unreported degeneration in specific nuclei and 
white matter areas in the brains of dogs affected by CDRM, the primary site of 
degeneration i.e. neuronal cell body versus distal axon has not been established. 
Examination of tissue from very early cases of CDRM would help answer this 
question but such material is very difficult to obtain within the boundaries of a 
project based on clinical cases.
There had been suggestions that vitamin E deficiency may have been involved in 
the aetiology of CDRM (Williams et al., 1984; Williams et al., 1985); however, this 
was highly unlikely for the dogs included in this study. Measurements o f serum 
vitamin E indicated that normal GSDs have levels comparable with other breeds. 
Also, although GSDs with CDRM showed a wide fluctuation in vitamin E 
concentrations there was no indication of a reduction compared with either 
unaffected GSDs or unaffected dogs of other breeds. In this study, CDRM seemed 
to be concurrent with, if anything, a slightly elevated serum vitamin E
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concentration. Additional evidence that affected dogs do not have a vitamin E 
deficiency was provided by visual comparison o f the rates of degeneration for those 
CDRM cases given oral supplementation with vitamin E (along with vitamin B and 
EPO) with those given no therapy, where no obvious difference was found.
The results obtained from the various molecular techniques, which addressed the 
issue of whether or not CDRM was the result o f a CAG trinucleotide repeat 
expansion, were equivocal. There were a number of possible explanations for this. 
The most likely explanation was that if CDRM was caused by a trinucleotide repeat 
expansion, then the expansion could be relatively small. The expansion may well 
be small in affected dogs for a number of reasons. Firstly, in other species e.g. the 
human neurodegenerative conditions caused by expanded CAG repeats, the severity 
of disease increased and the age of onset decreased with increasing length of 
expansion as often occurred between generations. Evidence from related affected 
dogs with CDRM does not indicate a dramatically more severe phenotype nor a 
significantly younger age of onset in subsequent generations. Secondly, in the 
human neurodegenerative diseases signs of systemic disease outwith the CNS were 
occasionally seen, whereas dogs with CDRM had a phenotype which appeared to 
affect only the CNS, which suggested that the underlying lesion may be less severe 
in the affected dogs. In addition, the techniques used to detect the expansions in 
human neurodegenerative disorders may not have been sensitive enough to pick up 
a small expansion in the dog genome. This does not rule out trinucleotide repeat 
expansion as a possible cause for CDRM, nor does it rule out the possibility that 
CDRM is caused by a CAG repeat expansion.
Until recently it had been assumed that greater than 40 CAG repeats represented a 
pathological expansion. Recent work which involved the RED technique suggested 
that this premise may be incorrect (Nakamoto et al., 1997). In the populations 
tested (75 normal, healthy Japanese students and 30 randomly chosen healthy 
Caucasians) the incidence of more than 51 CAG/CTG repeats in normal Japanese 
was 42.7% while in the Caucasians it was 13.3%. In both these normal populations, 
CAG/CTG repeats o f up to 91 were found. Work by Sirugo et al (1997) using the 
RED technique to do total genome scans, found a wide range in the size of 
maximum CAG/CTG repeats in the normal population, with the greatest variation 
found in East Asian individuals (up to 92 repeats in normal individuals). In 
addition, these repeat lengths at the loci being detected were relatively stable so 
could not be described as “expansions” with any sense of abnormality or dynamic 
change in length. These authors suggested that the intensity of signal may reflect 
the number of copies per genome, of sequences of the various longer lengths e.g. a 
locus with a (C T G )n5 should more often allow the final ligations of six (CTG) 17
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than would a locus with a (CTG) 102- This suggested that if CDRM was the result of 
a small CAG expansion then the intensity of signal could be faint, or even not 
visible, dependent on the maximum CAG length present.
7.1.1 In summary
CDRM is a chronic progressive neurodegenerative disease which affects large breed 
dogs, with a marked predilection for the GSD. Overt clinical signs and pathology 
are limited to the CNS, the neuronal population of the red nucleus is specifically 
affected. There is some, inconclusive, evidence that a trinucleotide repeat 
expansion may be involved.
7.2 Future aims
A more detailed pathological description of CDRM has been established. The 
classification of CDRM as a chronic, progressive neurodegenerative condition has 
been confirmed. Future work on the pathology would involve the use of new 
antibodies to specific cell structures of interest, as they become available. A more 
detailed electron microscopy study of the red nucleus in dogs with CDRM is 
justified; in particular, a specific examination of the nuclei o f the neurones within 
the red nucleus. This would be of interest as neuronal intranuclear inclusions have 
recently been reported in Huntington's disease, one of the chronic progressive 
neurodegenerative diseases in man which is characterised by a CAG trinucleotide 
expansion (Scherzinger et al., 1997).
The construction of a data base to provide a more detailed evaluation of pedigrees to 
allow conventional genetic analysis of the disease is currently at the planning stages. 
This approach is of particular relevance due to the finding, in the course of this 
project, of several groups of closely-related affected GSDs.
A more direct approach to the molecular genetic background to the disease should 
determine whether or not expanded CAG repeats are involved in CDRM. The PCR 
work carried out so far was addressing the direct questions; are there canine 
orthologues for SCA1 and CTG-B37 respectively and are either of them expanded in 
cases of CDRM ? The results to date are equivocal so the approach would be to 
employ Southern transfer of the PCR products from primers used to amplify canine 
orthologues, followed by probing with human ataxin-1 and human atrophin-1 for 
which sequences have been determined. On the basis that cross hybridisation would 
occur, as would be expected from the degree of species homology present, this 
would confidently identify if canine orthologues of these genes existed. These
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genes could then be compared in affected and unaffected dogs and any differences 
assessed.
A gene hunt would involve the construction of cDNA libraries from RNA extracted 
from the brain nuclei of affected and age-matched control dogs. These could be 
probed for the presence of expressed sequence tags (ESTs) harbouring CAG repeats. 
Candidate ESTs would then be isolated, sequenced and compared to data in 
appropriate gene banks. In parallel, given the possibility that the lesion is not a 
CAG expansion, a more general gene hunt would also be activated. This would 
involve subtractive hybridisation using the cDNA libraries already constructed. 
Differential display would also be employed. Upon verification by northern 
analysis, clones would be sequenced and compared to databanks. This technique 
has the advantage that it would lead directly to gene cloning. Both subtractive 
hybridisation and differential display technologies would determine which clones, if 
any, are disproportionately represented in the samples from dogs with CDRM 
compared with control dogs. Any clones disproportionately represented in the 
disease tissue could then be sequenced and compared to data banks. In addition, 
preparing a cDNA clone from a spinal cord injury dog as a control would confirm 
the specificity of any clones identified. The identification of cDNA clones, whether 
CAG expansions or not, would allow the preparation of genomic clones. The 
genomic clones in turn, would identify the molecular anatomy of the genetic lesion 
causing CDRM.
In conclusion, location of the affected gene in CDRM would result in the production 
of a diagnostic test. If a trinucleotide repeat expansion was confirmed then a 
straight-forward PCR based diagnostic test would be developed. If  a gene was 
identified which did not fall into the category of a trinucleotide repeat expansion 
then a more complex sequence-based diagnostic test would be performed. For 
example, a Southern-based assay. In turn, there would be the possibility of 
developing a rational therapy to treat affected animals. A further advantage of 
cloning the putative causal gene would be to use the information gained in CDRM 
research to further knowledge of any similar human disorders.
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8.1 Tissue fixation and processing
8.1.1 Fixatives
8.1.1.1 Buffered neutral formaldehyde, 4% (BNF)
To prepare 1 litre of fixative:
40% formaldehyde* lOOmls
tap water 900mls
sodium dihydrogen orthophosphate 4g
dipotassium hydrogenortho phosphate 8 g
*40g paraformaldehyde in lOOmls water, heat to between 60°C and 70°C add 1M 
sodium hydroxide drop by drop until the precipitate has cleared. Cool to 4°C.
8.1.1.2 Karnovsky's modified fixative (paraformaldehyde/glutaraldehyde
4%/5%)
To prepare 1 litre of “strong fix” :
8 % paraformaldehyde* 500ml
25% glutaraldehyde (EM grade) 2 0 0 ml
0.08M isotonic cacodylate buffer** to total volume 1 litre
calcium chloride 500mg
Filter. Store for a maximum of 14 days at 4°C.
*8 % paraformaldehyde:
40g paraformaldehyde in 500ml distilled water, heat to 65°C and clear with 1M 
NaOH, cool to 4°C.
**0.08M sodium cacodylate buffer:
17.1224g sodium cacodylate made up to litre with distilled water. Use 1M HC1 to 
adjust pH to 7.2.
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8.1.2 Tissue processing protocols
8.1.2.1 Resin processing
Samples were processed for araldite resin embedding using a Lynx el microscopy 
tissue processor (Leica). Processing involved the following solutions:
1) isotonic cacodylate 
buffer
4°C 50 mins
2 ) 1% osmium tetroxide in 
cacodylate buffer
room temperature 2  hrs
3) isotonic cacodylate 
buffer
room temperature 30 mins
4) 50% ethanol 4°C 5 mins
5) 50% ethanol 4°C 10  mins
6 ) 70% ethanol 4*C 5 mins
7) 70% ethanol 4°C 10  mins
8 ) 80% ethanol 4°C 5 mins
9) 80% ethanol 4°C 10  mins
1 0 ) 90% ethanol 4°C 5 mins
1 1 ) 90% ethanol 4°C 10  mins
1 2 ) ethanol 4°C 2 0  mins
13) ethanol 4°C 2 0  mins
14) propylene oxide room temperature 15 mins
15) propylene oxide room temperature 15 mins
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16) 1:3 resin* :propylene 
oxide
room temperature 13 hrs
17) 1 :2 resin:propylene 
oxide
room temperature 6  hrs
18) 1 :2 resin:propylene 
oxide
room temperature 18 hrs
19) resin 30°C 4 hrs
* resin composition see page 205.
Processed samples were embedded in resin filled silicone moulds and left to 
polymerise overnight at 60°C.
8 .1.2.2 Paraffin wax processing
Solutions used in the Shandon Elliot 24 hour automatic tissue processor 
(Histokinette) to prepare spinal cords and body tissues for paraffin blocks:
i) 70% methylated spirit / 5% phenol 2  hrs
2 ) 90% methylated spirit / 5% phenol 2  hrs
3) methylated spirit 2  hrs
4) ethanol / 5% phenol 2  hrs
5) ethanol / 5% phenol 1 hr
6 ) ethanol / 5% phenol 1 hr
7) 1% celloidin in methyl benzoate* 4 hrs
8 ) xylene 1 hr(x3)
9) paraffin wax 4-6 hrs
1 0 ) paraffin wax 7 hrs
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Solutions used in the Shandon Elliot 7 day automatic tissue processor (Histokinette) 
to prepare brains for paraffin blocks:
1) 70% methylated spirit/5% phenol 6  hrs
2 ) methylated spirit 10  hrs
3) absolute alcohol/5% phenol 6  hrs
4) absolute alcohol/5% phenol 6  hrs
5) absolute alcohol/amyl acetate 4 hrs
6 ) amyl acetate I 10  hrs
7) amyl acetate II 10  hrs
8 ) 1% celloidin in methyl benzoate* 2 0  hrs
9) 1% celloidin in methyl benzoate 2 0  hrs
1 0 ) xylene 4 hrs
1 1 ) paraffin wax 14 hrs
1 2 ) paraffin wax 1 0 - 2 0  hrs
* celloidin was obtained as Necoloidine (Merck) as an 8 % solution which following 
dilution with methyl benzoate was considered as a 1% solution.
8.1.3 Mounting media 
8 .1.3.1 Araldite Resin
araldite CY212 (resin) 30g
dodecanyl succinic (hardener) 25.2g
anhydride(DDSA)
2,4,6-tri-dimethylamino- (accelerator) 1 .2 ml
methylphenol(DMP 30)
di-butyl phthalate (plasticiser) 1 .0 ml
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8.2 Staining protocols and stains
8.2.1 Staining of tissues for light microscopy
8.2.1.1 Haematoxylin and eosin
Sections were passed through the following solutions:
1) xylene 2  min
2 ) absolute alcohol 2  min
3) methylated spirit 2  min
4) water 2  min
5) Lugols iodine (page 209) 1 min
6 ) water 1 min
7) 5% sodium thiosulphate 
(Hypo)
1 min
8 ) water
9) Mayer's haematoxylin 
(page 2 1 0 )
10
mins
1 0 ) 1% acid alcohol (page 2 1 0 ) 3 dips
1 1 ) water 2  mins
1 2 ) Scots tap water substitute 
(page 2 1 0 )
1 min
13) water 2  mins
14) methylated spirit 10  secs
15 saturated alcoholic eosin 2  mins
16) methylated spirit 2  mins
17) absolute alcohol 2  mins
18) histoclear 2  mins
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19) xylene 5 mins
Sections were mounted in DPX permanent mounting media.
8.2.1.2 Haematoxylin
Immunocytochemistry sections were counterstained as appropriate:
1) water 2  mins
2 ) Mayer's haematoxylin 50 secs
3) water wash off excess 
haematoxylin
4) Scots tap water substitute 30 secs
Sections were dehydrated as above.
8.2.1.3 Cresyl Violet
Sections were passed through the following solutions:
i) xylene 2  min
2 ) absolute alcohol 2  min
3) methylated spirit 2  min
4) water 2  min
5) 0 .1% acidified cresyl violet* 6  min
6 ) acetic acid acidified meth. 
spirit to differentiate
1 min
7) methylated spirit briefly
8 ) absolute alcohol 2  min
9) histoclear 2  min
1 0 ) xylene 5 min
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*cresyl violet is acidified by the addition of 5 drops of 10% acetic acid for every 30 
mis o f stain, it is then pre-heated to 56°C before use.
8.2.1.4 Congo Red
1) xylene 2 min
2 ) absolute alcohol 2 min
3) methylated spirit 2 min
4) water 2 min
5) haemalum 5min
6 ) water lmin
7) 1% acid alcohol (page 2 1 0 ) 3 dips
8 ) congo red 2 0 min
9) lithium carbonate 15sec
1 0 ) methylated spirit 2 min
1 1 ) absolute alcohol 2 min
1 2 ) histoclear 2 min
13) xylene 5 min
8.2.1.5 3,4,3'4' tetraaminobiphenylhydrochloride (DAB)
50mg DAB
50ml distilled water
40ml 0 .2 M N a2 HPO4
add until pH is 7.3 0.2M KH2 PO4
Filter. Use soon after preparing as light sensitive.
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8.2.1.6  Vectastain Elite ABC reagent
5 mis PBS
2  drops reagent A
2  drops reagent B
Mix well, stand for 30 minutes before use.
8.2.1.7 M ountant for immunofluorescence
Citifluor (Chemlab, University of Kent)
8.2.2 Staining of tissues for electron microscopy
i) saturated uranyl acetate in 
50% ethanol
5-15
mins
2 ) 50% ethanol rinse
3) 50% ethanol rinse
4) distilled water rinse x 2
5) air dry
6 ) Reynold's lead citrate* 
(Sodium hydroxide 
moistened chamber)
5-10
mins
7) 1M sodium hydroxide rinse x 3
8 ) distilled water rinse x 5
*details 8.2.2.1.6 Reynold's lead citrate, page 210. 
8.2.2.1.1 Lugols Iodine
lg Iodine
2 g Potassium iodide
Made up to lOOmls with distilled water.
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8.2.2.1.2 Mayer's Haematoxylin
l.Og haematoxylin
lO.Og potassium alum
0 .2 g sodium iodate
Made up to 1 litre with distilled water. Bring to boiling point, allow to cool 
overnight then add:
l.Og citric acid
50g chloral hydrate
8.2.2.1.3 1% Acid Alcohol
1% HC1 in methylated spirit
8.2.2.1.4 Scots tap water substitute:
3.5g sodium bicarbonate
2 0 .0 g magnesium sulphate
Made up to 1 litre with distilled water 
8.2.2.1.5 Methylene blue/azur II:
1% methylene blue
1% azur II
1% borax
In distilled water
8.2.2.1.6 Reynold's lead citrate
1.33g lead nitrate
1.76g sodium citrate
Dissolve each in 15ml distilled water, mix the two together and shake vigorously for 
1 minute followed by occasional shaking for the next 30 minutes. Clear with 8.0ml
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1M sodium hydroxide, make up to final volume with 50ml distilled water (final 
pH 12).
8.3 Buffers
8.3.1 General buffers
8.3.1.1 Phosphate buffer
~80% Na2PO4
-20%  KH2 PO4  added to pH 7.4
8.3.1.2 Phosphate buffered saline (PBS)
8.006g NaCl
0 .2 0 1 2 g KC1
0.2042g KH2 P 0 4
1.1356g Na2P04 (pH 7.3)
In 1 litre distilled, deionized water. Sterilise by autoclaving.
8.3.1.3 Tris buffered saline (TBS)
25mM Tris pH 7.5
136mM sodium chloride 
2.6mM potassium chloride
8.3.1.4 Tris EDTA (TE) buffer
lOmM tris pH 8 , ImM EDTA
500pl 1M tris pH 8
1 0 0  pi 0.5M EDTA
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8.3.2 Agarose gel running buffer
8.3.2.1 Tris acetate EDTA buffer (TAE)xlO
0.04M Tris acetate, 0.001M EDTA
48.4g tris base
11.4ml glacial acetic acid
2 0 ml 0.5M EDTA (pH 8 )
made up to 1 litre in distilled water, final pH 7.6
8.3.3 SDS-Page gel buffers for RED 
8.3.3.1 Tris borate EDTA buffer (TBE)xlO
108g Tris base
55g boric acid
40ml 0.5M EDTA (pH 8 )
made up to 1 litre in distilled water, final pH 8 .2-8.4 
8.3.4 SDS-Page gel buffers for westerns
8.3.4.1 Stacking gel buffer
0.5M Tris HC1 pH 6 .8
6 g Tris pH 6 .8
40ml distilled water
48ml 1MHC1
Made up to lOOmls with distilled water.
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8.3.4.2 Resolving gel buffer
3.0M Tris HC1 pH 8 .8
36.3g Tris
48ml HC1 1M
Made up to 100ml with distilled water. 
8.3.4.3 Reservoir bufferxlO
30.3g Tris
144g glycine
1 0 g SDS
Made up to 1 litre with distilled water.
8.3.5 Tris buffered saline (TBS)
2.4g Trizma base
8 .0 g sodium chloride
made up to 1 litre with distilled water, adjust pH to 7.6 with hydrochloric acid. 
Store at 4°C.
8.3.6 Tris buffered saline-Tween (TBS-T)
Dilute required volume of Tween™-20 in TBS (see above) to give a 0.1%(v/v) 
solution. Store at 4°C.
8.3.7 Sodium chloride/sodium citrate (SSC) x 20
3M sodium chloride/0.3M sodium citrate
1753g sodium chloride
882g sodium citrate
made up to 10  litres with distilled water
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8.4 Loading dyes
8.4.1 6 x buffer for TAE conditions
30% glycerol (Sigma)
0.25% bromophenol blue 
0.25% xylene cyanol FF (Sigma)
8.4.2 5 x stop solution for TBE conditions (RED)
95% formamide
20mM EDTA 
0.05% bromophenol blue 
0.05% xylene cyanol
8.4.3 SDS-Page loading buffer for westerns
0.0625M Tris HC1 pH 6 .8
2% SDS 
1 0% glycerol
Only add the following as buffer is being added to samples: 
0 .0 0 2 % bromophenol blue 
5% mercaptoethanol/40mM DTT (dithiothreitol)
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8.5 Reagents for genomic DNA isolation
8.5.1 RNase A
To prepare a DNase-free stock solution:
1) Dissolve RNase A to the required concentration in lOmM Tris-HCl pH 7.5, 
15mMNaCl.
2) Heat to 100°C for 15 minutes.
3) Allow to cool to room temperature. Store in aliquots at -20°C.
8.5.2 Proteinase K
Proteinase K was supplied lyophilised with the QUIAmp® kit. It was reconstituted 
in SDW at 18mg/ml and stored at -20°C in small aliquots which were discarded 
after use.
8.5.3 Nucleon II cell lysis solution
lOmM Tris-HCl, 320mM sucrose, 5mM MgCl2 , 1% Triton X-100
109.54g sucrose
1 .0 2 g MgCl2
lOmls 1M Tris (pH 8 )
lOmls Triton X (add after autoclaving)
Made up to 1 litre in distilled water.
8.5.4 Nucleon II washing solution
400mM Tris-HCl, 60mM EDTA, 150mM NaCl, 1% SDS
2.19g NaCl
lOOmls 1M Tris (pH 8 )
30mls 0.5MEDTA
25mls 10% SDS (add after autoclaving)
Made up to 250mls in distilled water.
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8.5.5 Digestion buffer for large scale gDNA extraction from brain
lOmM Tris pH 8, 25mM EDTA pH 8, lOOmM NaCl, 0.5%SDS
0.42g NaCl
1ml 1M Tris (pH 8)
5ml 0.5M EDTA (pH 8)
5ml 10% SDS (add after autoclaving)
8.6 Isolation and manipulation of proteins
8.6.1 Pierce Protein Assay
Reagent A sodium carbonate
sodium bicarbonate
BCA detection reagent
sodium tartarate in 0 .1M NaOH
Reagent B 4% copper sulphate.5 H2 O
The standard protocol was employed, this measured protein in the range of 100 to 
1200 pg/ml and used BCA(bicinchoninic acid) protein assay reagent
Reagent A 2ml
Reagent B 40 pi
Protein Sample lOOpl
The above were incubated at 37°C for 30 minutes and the optical density measured 
at 562nm.
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8.6.2 Polyacrylamide gel compositions
8.6.2.1 Stock Solution: 40% acrylamide-bisacrylamide
380g acrylamide (DNA sequencing grade)
20g N,N' -methylenebisacry lamide
To 600ml distilled water
Heat the solution to 37°C to dissolve the chemicals. Adjust the volume to 1 litre 
with distilled water. Filter the solution through a nitrocellulose filter (Nalge, 0.45- 
micron pore size). Store in dark bottles at 4°C.
8.6.2.2 4% resolving gel
4.0ml acrylamide-bisacrylamide (30:0.8)
3.75ml resolving gel buffer stock
(3M Tris-HCl (pH8 .8 ))
0.3ml 10% SDS
0.7ml 
21.25ml 
15pl
8.6.2.3 10% resolving gel
1 0 ml acrylamide-bisacrylamide
3.75ml resolving gel buffer stock
(3M Tris-HCl (pH 8 .8 ))
0.3ml 10% SDS
0.7ml 1.5% ammonium persulphate
12.75ml distilled water
15 pi TEMED (just before pouring gel)
1.5% ammonium persulphate 
distilled water
TEMED (just before pouring gel)
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8.6.2.4 2.5% stacking gel
2.5ml acrylamide-bisacrylamide (30:0.8)
5.0 ml stacking gel buffer stock
(0.125M Tris-HCl (pH 6 .8 ))
0.2ml SDS
I .0ml 1.5% ammonium persulphate
I I .3ml water
0.015ml TEMED
8.7 Bacteriological media
8.7.1 Luria-Bertani medium
lOg tryptone (Oxid)
5g yeast extract (Oxid)
lOg sodium chloride
Make up to 1 litre in distilled water, adjust to pH 7 using ~0.2ml 5N sodium
hydroxide. Sterilise by autoclaving for 20 minutes at 15 lb/in2. Store at 4°C.
8.7.2 SOC medium
20g tryptone (Oxid)
5g yeast extract (Oxid)
0.5g sodium chloride
Made up to 970ml in distilled water, add 10ml 250mM potassium chloride, adjust 
pH to 7.0 using 5N sodium hydroxide (~0.2ml). Autoclave for 20 minutes at 
151b/in2. Cool to <60°C then add 20ml of filter sterilised 1M glucose solution. 
Store at 4°C.
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9. Abbreviations
APES 3 -aminopropy ltriethoxy-silane
APS Ammonium persulphate
ATP Adenosine triphosphate
a-TTP a-tocopherol transfer protein
AVED Ataxia with vitamin E deficiency
BNF Buffered neutral formaldehyde
bp Base pairs
°C Degrees centigrade
cDNA Complementary DNA
CDRM Chronic degenerative radiculomyelopathy
cm Centimetre
CNS Central nervous system
Con A Concanavalin A
cpm Counts per minute
CV Cresyl violet
DAB 3,4,3 ',4 '-tetraminobiphenyl hydrochloride
DM Myotonic dystrophy
DMSO Dimethyl sulphoxide
DNA Deoxyribonucleic acid
DRPLA Dentatorubral-pallidoluysian atrophy
DTT Dithiothrietol
DW Distilled water
EACA Epsilon aminocaproic acid
EDM Equine degenerative myeloencephalopathy
EDTA (Ethylenedinitrilo)tetraacetic acid
EM Electron microscopy
EMG Electromyograph
EMND Equine motor neurone disease
EPO Evening primrose oil
EST Expressed sequence tag
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Abbreviations
FCE Fibrocartilaginous embolism
FeLV Feline leukaemia virus
FRAXA Fragile X syndrome
FRAXE A sub-group of fragile X syndrome
g Gram
gDNA Genomic DNA
GFAP Glial fibrillary acidic protein
GSD German shepherd dog
GUVS Glasgow University Veterinary School
H&E Haematoxylin and eosin
HD Hip dysplasia
HPLC High performance liquid chromatography
HRS Haw river syndrome
i.d. internal diameter
in. Hg inches of mercury
kb Kilobase
kDa Kilo Dalton
K2 HPO4  Potassium hydrogen phosphate
L Litre
lb Pound
LB Luria Bertani
LCL Lymphoblastoid cell line
LiCL Lithium chloride
LVN Lateral vestibular nucleus
M Molar
Mb Megabase
mg Milligram
MgCl2  Magnesium chloride
MgSC>4 Magnesium sulphate
min Minute
ml Millilitre
mM Millimolar
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Abbreviations
MJD Machado-Joseph disease
MW Molecular weight
NaAc" Sodium acetate
NaCl Sodium chloride
NaH2 P0 4 Sodium hydrogen phosphate
NaOH Sodium hydroxide
ng Nanogram
NGS Normal goat serum
NSAID Non-steroidal anti-inflammatory drug
OA Osteoarthritis
PAP Peroxidase anti-peroxidase
PBS Phosphate buffered saline
PCR Polymerase chain reaction
PHA Phytohaemagglutinin P
PNS Peripheral nervous system
PUFA Polyunsaturated fatty acid
RBC Red blood cell
RER Rough endoplasmic reticulum
RNA Ribonucleic acid
RNAse A Ribonuclease A
rpm Revolutions per minute
RT-PCR Reverse transcriptase-polymerase chain reaction
SBMA Spinal and bulbar muscular atrophy (Kennedy's Disease)
SCA1-7 Spinocerebellar ataxia 1-7
SCD Subacute combined degeneration
SDS-PAGE Sodium dodecyl sulphate polyacrylamide gel electrophoresis
SDW Sterile distilled water
sec Second
SpG Spinal ganglion
sq. in. Square inch
SSC Standard sodium citrate
STR Simple tandem repeat
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TU Transcription unit
TAE Tris acetate EDTA
TBE Tris borate EDTA
TBP Tocopherol-binding protein
TE Tris EDTA
TEMED N,N,N' ,N' ,-tetramethylethylenediamine
TLCK Na-p-tosyl-l-lysine chloro-methyl ketone
U Unit
juiCi Microcurie
Pg Microgram
Pi Microlitre
pm Micrometre
jam 1"! Micromoles per litre
UTP Uridine-5' -triphosphate
UV Ultraviolet
VLDL Very low density lipoprotein
w/v Weight in volume
X-phos 5-bromo-4-chloro-3-indoy 1-phosphate
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